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ABSTRACT 
 
Postpartum haemorrhage is the leading cause of maternal death in the 
developing world accounting for 30% of such deaths in areas where 
maternal mortality is high. Current literature supports active 
management of the third stage of labour to decrease the incidence of 
postpartum haemorrhage, but which uterotonic drugs is preferable for 
prophylactic use is still being debated. This study was carried out in 
the maternity department of the ‘’Hospital Général de Reference 
Nationale’’ of N’ Djamena, Chad to compare the efficacy of oral and 
rectal misoprostol to that of syntometrine in the active management of 
third stage of labour. The study was a large prospective, three arms 
randomized controlled trial, which included 2400 women. The women 
were randomly distributed in three groups of 800 each for misoprostol 
oral 400 µg, misoprostol rectal 400µg and syntometrine (oxytocin 5 IU 
+ ergometrine 0.5 mg) 1 vial IM.  
The primary outcomes were the mean blood loss, incidence 
postpartum haemorrhage, need of additional oxytocics, mean change 
in haemoglobin and hematocrit. Secondary outcome included duration 
of the third stage, manual removal of placenta, blood transfusion, 
adverse effects (fever, shivering, nausea, headache, vomiting and 
diarrhoea) and incidence of hypertension.  
The mean blood loss w as estimated to be 223 ± 142 mL, 232  ± 146 mL, 
233 ± 144 mL for syntometrine, misoprostol rectal and oral 
respectively.   
Postpartum haemorrhage had occurred in 4.62%, 4.75% and 4.75% of 
subjects treated with syntometrine, misoprostol rectal and oral 
respectively.  
Blood loss > 1000 ml was recorded in 0.75%, 0.75% and 0.87% of 
subjects treated with syntometrine, misoprostol rectal and oral 
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respectively. The mean (±SD) change in haemoglobin level was not 
significantly different between treatment groups (0.59±0.49 g/dl for 
misoprostol oral, 0.60±0.33 g/dl for misoprostol rectal and 0.55±0.38 
g/dl for syntometrine).  
There was no significant difference between groups in the duration in 
third stage of labour, the proportion that required manual removal of 
placenta or additional oxytocics. Shivering had occurred mainly in the 
group of oral misoprostol 14.75% and rectal misoprostol 8.75% 
compared to syntometrine 4%. Meanwhile, more subjects who received 
misoprostol oral and rectal had experienced pyrexia compared to 
syntometrine: 7.87% versus 6.56% versus 1.25%. Nausea, vomiting, 
headache and hypertension were more frequently in the group of 
syntometrine. 
The women and the midwives and doctors in their majority were 
satisfied with the use of misoprostol (oral or rectal) compared to 
syntometrine. 
Misoprostol was less costly than parenteral oxytocics, taken in 
consideration that it is stable and is not affected by degradation in 
tropical climates as preparations that contain oxytocin or ergometrine. 
In conclusion, this comparative study of misoprostol oral and rectal 
had provided evidences that it is as efficacious as syntometrine in 
reducing postpartum blood loss and incidence of postpartum 
haemorrhage, and without the side effects of drugs that contain 
ergometrine.  
Our results could have important applications in other areas, such as 
rural areas and home birthing were access to the immediate 
management of complications of the third stage of labour might not be 
readily available.  
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 ﺒﺴﻡ ﺍﷲ ﺍﻟﺭﺤﻤﻥ ﺍﻟﺭﺤﻴﻡ 
 
  ﺨﻼﺼﺔ
% 03ﺇﻥ ﺍﻟﻨﺯﻴﻑ ﺒﻌﺩ ﺍﻟﻭﻻﺩﺓ ﻫﻭ ﺍﻟﺴﺒﺏ ﺍﻟﺫﻯ ﻴﺅﺩﻱ ﺇﻟﻰ ﻭﻓﺎﺓ ﺍﻷﻤﻬﺎﺕ ﻓﻲ ﺍﻟﺩﻭل ﺍﻟﻨﺎﻤﻴﺔ ﺇﺫ ﺃﻥ ﻨﺴﺒﺔ 
ﻤﺎﻜﺘﺏ ﺤﺎﻟﻴﺎ ﻓﻲ . ﻤﻥ ﻫﺫﻩ ﺍﻟﻭﻓﻴﺎﺕ ﺘﺤﺩﺙ ﻓﻲ ﺍﻟﻤﻨﺎﻁﻕ ﺍﻟﺘﻲ ﻴﻜﻭﻥ ﻓﻴﻬﺎ ﻤﻌﺩل ﻭﻓﻴﺎﺕ ﺍﻷﻤﻬﺎﺕ ﻋﺎﻟﻴﺎﹰ
ﺯﻴﻑ ﻤﺎ ﺒﻌﺩ ﺍﻟﻭﻻﺩﺓ ﻭﻟﻜﻥ ﺩﻋﻡ ﺍﻟﺘﺩﺨل ﺍﻟﻔﺎﻋل ﻓﻲ ﺍﻟﻤﺭﺤﻠﺔ ﺍﻟﺜﺎﻟﺜﺔ ﻟﻠﻭﻻﺩﺓ ﻟﺘﻘﻠﻴل ﺤﺩﻭﺙ ﺍﻟﻨﻴﻫﺫﺍ ﺍﻟﻤﺠﺎل 
. ﺒﺤﺙﺍﻟﻌﻘﺎﻗﻴﺭ ﺍﻟﻤﻭﺘﺭﺓ ﻟﻌﻀﻼﺕ ﺍﻟﺭﺤﻡ ﺘﻜﻭﻥ ﻤﻔﻀﻠﺔ ﻟﻼﺴﺘﺨﺩﺍﻡ ﺍﻟﻭﻗﺎﺌﻰ ﺇﻻ ﺃﻨﻬﺎ ﻤﺎﺯﺍﻟﺕ ﻤﻭﻀﻊ 
ﻟﻤﻘﺎﺭﻨﺔ ﻜﻔﺎﺀﺓ ﻋﻘﺎﺭ "  ﺘﺸﺎﺩ-ﺍﻟﻤﺴﺘﺸﻔﻲ ﺍﻟﻌﺎﻡ ﺍﻟﻘﻭﻤﻲ ﺒﺎﻨﺠﻤﻴﻨﺎ " ﺃﺠﺭﻴﺕ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﻓﻲ 
ﺩﺨل ﺍﻟﻔﺎﻋل ﻓﻲ ﺍﻟﻤﺭﺤﻠﺔ ﻤﻴﺴﻭﺭﺒﺭﻭﺴﺘﻭل ﺍﻟﺫﻱ ﻴﺅﺨﺫ ﺒﺎﻟﻔﻡ ﺃﻭ ﺒﺎﻟﻤﺴﺘﻘﻴﻡ ﻤﻊ ﻋﻘﺎﺭ ﺴﻨﺘﻭﻤﺘﺭﻴﻥ ﻓﻲ ﺍﻟﺘ
ﻜﺎﻨﺕ ﺍﻟﺩﺭﺍﺴﺔ ﻤﺠﺎﻻﹰ ﻭﺍﺴﻌﺎﹰ ﻭﻫﻲ ﺘﺠﺭﺒﺔ ﻋﺸﻭﺍﺌﻴﺔ ﻤﻘﺎﺭﻨﺔ ﺫﺍﺕ ﺜﻼﺙ ﻓﺌﺎﺕ ﻭﺍﻟﺘﻲ . ﺍﻟﺜﺎﻟﺜﺔ ﻟﻠﻭﻻﺩﺓ
 ﺍﻤﺭﺃﺓ ﻟﻜٍل 008 ﺍﻤﺭﺃﺓ ﺘﻡ ﺘﻭﺯﻴﻊ ﺍﻟﻨﺴﺎﺀ ﻋﺸﻭﺍﺌﻴﺎﹰ ﻓﻲ ﺜﻼﺙ ﻤﺠﻤﻭﻋﺎﺕ، ﺒﻜل ﻤﺠﻤﻭﻋﺔ 0042ﻀﻤﺕ 
 ﻤﺎﻴﻜﺭﻭﺠﺭﺍﻡ 004ﻘﻴﻡ  ﻤﺎﻴﻜﺭﻭﺠﺭﺍﻡ ﻭﻤﻴﺴﻭﺒﺭﻭﺴﺘﻭل ﺒﺎﻟﻤﺴﺘ004ﻤﻥ ﻤﻴﺴﻭﺒﺭﻭﺴﺘﻭل ﻋﻥ ﻁﺭﻴﻕ ﺍﻟﻔﻡ 
  .ﻭﺴﻨﺘﻭﻤﺘﺭﻴﻥ ﺤﻘﻨﺔ ﻭﺍﺤﺩﺓ ﺒﺎﻟﻌﻀل
ﺍﻷﻭﻟﻴﺔ ﻫﻲ ﻓﻘﺩﺍﻥ ﻤﺘﻭﺴﻁ ﻟﻠﺩﻡ ﻭﺤﺩﻭﺙ ﻨﺯﻴﻑ ﺒﻌﺩ ﺍﻟﻭﻻﺩﺓ ﻭﺍﻟﺤﻭﺠﺔ ﺇﻟﻰ ﻋﻘﺎﺭ ﺇﻀﺎﻓﻲ ﺍﻟﻤﻌﺎﻴﻴﺭﻜﺎﻨﺕ 
ﺍﻟﻨﺴﺒﺔ ﺍﻟﻤﺌﻭﻴﺔ ﺍﻟﺤﺠﻤﻴﺔ )ﻤﻭﺘﺭ ﻟﻌﻀﻼﺕ ﺍﻟﺭﺤﻡ ﻭﺘﻐﻴﻴﺭ ﻤﺘﻭﺴﻁ ﻓﻲ ﺍﻟﻬﻴﻤﻭﻗﻠﻭﺒﻴﻥ ﻭﺍﻟﺭﺍﺴﺏ ﺍﻟﺩﻤﻭﻱ 
  (.ﻟﻜﺭﻴﺎﺕ ﺍﻟﺩﻡ ﺍﻟﺤﻤﺭﺍﺀ
 ﺍﻟﺜﺎﻨﻭﻴﺔ ﻤﺩﺓ ﺍﻟﻤﺭﺤﻠﺔ ﺍﻟﺜﺎﻟﺜﺔ ﻭﺍﻹﺯﺍﻟﺔ ﺍﻟﻴﺩﻭﻴﺔ ﻟﻠﻤﺸﻴﻤﺔ ﻭﻨﻘل ﺍﻟﺩﻡ ﻭﺍﻷﻋﺭﺍﺽ ﺍﻟﺠﺎﻨﺒﻴﺔ ﻴﺭ ﺍﻟﻤﻌﺎﻴﺘﻀﻤﻨﺕ
  .ﻭﺤﺩﻭﺙ ﺍﺭﺘﻔﺎﻉ ﻓﻲ ﻀﻐﻁ ﺍﻟﺩﻡ( ﺤﻤﻲ ﻭﺍﺭﺘﻌﺎﺵ ﻭﻏﻴﺜﺎﻥ ﻭﺼﺩﺍﻉ ﻭﻗﺊ ﻭﺍﺴﻬﺎل)
 441 ±- 332  ﻤﻠﻴﻠﺘﺭ ، 641 ±232،  241ﻤﻠﻴﻠﺘﺭ   ± 322ﺘﻡ ﺘﻘﺩﻴﺭ ﺍﻟﻔﻘﺩﺍﻥ ﺍﻟﻤﺘﻭﺴﻁ ﻟﻠﺩﻡ ﺏ 
  .ﺒﺭﻭﺴﺘﻭل ﺒﺎﻟﻔﻡ ﻭﻋﻥ ﻁﺭﻴﻕ ﺍﻟﻤﺴﺘﻘﻴﻡ ﻋﻠﻰ ﺍﻟﺘﻭﺍﻟﻲﻤﻠﻴﻠﺘﺭ ﻟﻠﺴﻨﺘﻭﻤﺘﺭﻴﻥ ﻭﺍﻟﻤﻴﺴﻭ
ﻋﻨﺩ ﺘﻨﺎﻭل ﺴﻨﺘﻭﻤﺘﺭﻴﻥ %57.4ﻭ% 57.4ﻭ % 26.4ﺤﺩﺙ ﺍﻟﻨﺯﻴﻑ ﻤﺎ ﺒﻌﺩ ﺍﻟﻭﻻﺩﺓ ﺒﻨﺴﺒﺔ 
  .ﻭﻤﻴﺴﻭﺒﺭﻭﺴﺘﻭل ﻋﻥ ﻁﺭﻴﻕ ﺍﻟﻔﻡ ﻭﻋﻥ ﻁﺭﻴﻕ ﺍﻟﻤﺴﺘﻘﻴﻡ ﻋﻠﻰ ﺍﻟﺘﻭﺍﻟﻲ
ﻤﻥ ﺍﻟﻤﺭﻴﻀﺎﺕ ﺍﻟﻼﺌﻲ % 78.0ﻭ% 57.0ﻭ% 57.0 ﻤﻠﻴﻠﺘﺭ ﺒﻨﺴﺒﺔ 0001ﻤﻥ ﺃﻜﺜﺭ ﺴﺠل ﻓﻘﺩﺍﻥ ﺍﻟﺩﻡ 
ﺇﻥ .  ﻋﻼﺠﻬﻥ ﺒﺎﻟﺴﻨﺘﻭﻤﺘﺭﻴﻥ ﻭﺍﻟﻤﻴﺴﻭﺒﺭﻭﺴﺘﻭل ﻋﻥ ﻁﺭﻴﻕ ﺍﻟﻤﺴﺘﻘﻴﻡ ﻭﻋﻥ ﻁﺭﻴﻕ ﺍﻟﻔﻡ ﻋﻠﻰ ﺍﻟﺘﻭﺍﻟﻲﺘﻡ
 ﺤﻴﺙ ﻭﺠﺩ ﺃﻨﻪﻤﺘﻭﺴﻁ ﺍﻹﻨﺤﺭﺍﻑ ﺍﻟﻤﻌﻴﺎﺭﻱ ﻟﻤﺴﺘﻭﻱ ﺍﻟﻬﻴﻤﻭﻗﻠﻭﺒﻴﻥ ﻟﻡ ﻴﺨﺘﻠﻑ ﻜﺘﻴﺭﺍﹰ ﺒﻴﻥ ﺍﻟﻤﺠﻤﻭﻋﺎﺕ 
% 33.0± % 06.0ﺩﻴﺴﻴﻠﺘﺭ ﻟﻠﻤﻴﺴﻭﺒﺭﻭﺴﺘﻭل ﻋﻥ ﻁﺭﻴﻕ ﺍﻟﻔﻡ، ﻭ/ﺠﺭﺍﻡ% 94.0± % 95.0ﺘﻨﺎﻭﻟﺕ 
ﺩﻴﺴﻴﻠﺘﺭ / ﺠﺭﺍﻡ% 83.0 ± 55.0ﻠﺘﺭ ﻟﻠﻤﻴﺴﻭﺒﺭﻭﺴﺘﻭل ﻋﻥ ﻁﺭﻴﻕ ﺍﻟﻤﺴﺘﻘﻴﻡ ﻭﺩﻴﺴﻴ/ ﺠﺭﺍﻡ
  .ﻟﻠﺴﻨﺘﻭﻤﺘﺭﻴﻥ
 ﺒﻴﻥ ﺍﻟﻤﺠﻤﻭﻋﺎﺕ ﺒﺎﻟﻨﺴﺒﺔ ﻟﻤﺩﺓ ﺍﻟﻤﺭﺤﻠﺔ ﺍﻟﺜﺎﻟﺜﺔ ﻟﻠﻭﻻﺩﺓ ﻭﺍﻟﻨﺴﺒﺔ ﺍﻟﺘﻲ ﺍﻗﺘﻀﺕ ﺭﺍﹰﻜﺒﻴﺎﹰ ﻟﻡ ﻴﻜﻥ ﻫﻨﺎﻟﻙ ﺍﺨﺘﻼﻓ
 ﻅﻬﺭﺕ ﺭﻋﺸﺔ ﺒﺼﻭﺭﺓ ﺭﺌﻴﺴﻴﺔ ﻓﻲ.  ﺇﺯﺍﻟﺔ ﺍﻟﻤﺸﻴﻤﺔ ﻴﺩﻭﻴﺎﹰ ﺃﻭ ﺇﻀﺎﻓﺔ ﻋﻘﺎﺭ ﻤﻭﺘﺭ ﻟﻌﻀﻼﺕ ﺍﻟﺭﺤﻡ 
ﻭﻤﻴﺴﻭﺒﺭﻭﺴﺘﻭل ﻋﻥ % 57.41ﺍﻟﻤﺠﻤﻭﻋﺔ ﺍﻟﺘﻲ ﺘﻨﺎﻭﻟﺕ ﻤﻴﺴﻭﺒﺭﻭﺴﺘﻭل ﻋﻥ ﻁﺭﻴﻕ ﺍﻟﻔﻡ ﻜﺎﻨﺕ ﺒﻨﺴﺒﺔ 
iv 
ﻓﻲ %. 4ﻤﻘﺎﺭﻨﺔ ﺒﺎﻟﻤﺠﻤﻭﻋﺔ ﺍﻟﺘﻲ ﺘﻨﺎﻭﻟﺕ ﺴﻨﺘﻭﻤﺘﺭﻴﻥ ﺒﻨﺴﺒﺔ % 57.8ﻁﺭﻴﻕ ﺍﻟﻤﺴﺘﻘﻴﻡ ﻜﺎﻨﺕ ﺒﻨﺴﺒﺔ 
ﺫﺍﺕ ﺍﻟﻭﻗﺕ، ﺸﻌﺭ ﻋﺩﺩ ﻜﺒﻴﺭ ﻤﻥ ﺍﻟﻤﺭﻴﻀﺎﺕ ﺍﻟﻼﺘﻲ ﺘﻨﺎﻭﻟﻥ ﺩﻭﺍﺀ ﻤﻴﺴﻭﺒﺭﻭﺴﺘﻭل ﺒﺎﻟﻔﻡ ﻭﺒﺎﻟﻤﺴﺘﻘﻴﻡ 
ﻜﻤﺎ ﺘﻤﺕ %. 52.1ﻤﻘﺎﺒل % 65.6ﻤﻘﺎﺒل % 78.7ﺩﺭﺠﺔ ﺍﻟﺤﺭﺍﺭﺓ ﻤﻘﺎﺭﻨﺔ ﺒﺎﻟﺴﻨﺘﻭﻤﺘﺭﻴﻥ ﺒﺎﺭﺘﻔﺎﻉ 
ﻤﻼﺤﻅﺔ ﻏﺜﻴﺎﻥ ﻭﻗﺊ ﻭﺼﺩﺍﻉ ﻭﺍﺭﺘﻔﺎﻉ ﻀﻐﻁ ﺍﻟﺩﻡ ﺒﻁﺭﻴﻘﺔ ﻤﺘﻜﺭﺭﺓ ﻋﻨﺩ ﺍﻟﻤﺠﻤﻭﻋﺔ ﺍﻟﺘﻲ ﺘﻨﺎﻭﻟﺕ 
  .ﺴﻨﺘﻭﻤﺘﺭﻴﻥ
ﻤﻘﺎﺭﻨﺔ ( ﺒﺎﻟﻔﻡ ﺃﻭ ﺒﺎﻟﻤﺴﺘﻘﻴﻡ)ﺍﻗﺘﻨﻊ ﺃﻏﻠﺏ ﺍﻟﻨﺴﺎﺀ ﻭﻤﻘﺩﻤﻭ ﺍﻟﺭﻋﺎﻴﺔ ﺍﻟﺼﺤﻴﺔ ﺒﺎﺴﺘﺨﺩﺍﻡ ﻤﻴﺴﻭﺒﺭﻭﺴﺘﻭل 
  . ﺘﻭﻤﺘﺭﻴﻥﺒﺎﻟﺴﻨ
ﺇﻥ ﻋﻘﺎﺭ ﺍﻟﻤﺎﻴﺴﻭﺒﺭﻭﺴﺘﻭل ﻫﻭ ﺃﻗل ﺘﻜﻠﻔﺔ ﻤﻥ ﺍﻟﻌﻘﺎﻗﻴﺭ ﺍﻟﻤﻭﺘﺭﺓ ﻟﻌﻀﻼﺕ ﺍﻟﺭﺤﻡ ﺍﻟﺘﻲ ﺘﺅﺨﺫ ﻋﻥ ﻁﺭﻴﻕ 
ﺍﻟﺤﻘﻥ، ﻤﻊ ﺍﻷﺨﺫ ﻓﻲ ﺍﻻﻋﺘﺒﺎﺭ ﺃﻥ ﺍﻟﻤﺎﻴﺴﻭﺒﺭﻭﺴﺘﻭل ﻫﻭ ﺜﺎﺒﺕ ﻭﻻ ﻴﺘﺄﺜﺭ ﺒﺎﻟﺘﻠﻑ ﻓﻲ ﺍﻟﻤﻨﺎﺨﺎﺕ ﺍﻟﺤﺎﺭﺓ 
  . ﻜﻤﺎ ﻴﺤﺩﺙ ﻓﻲ ﻜل ﺍﻟﻤﺴﺘﺤﻀﺭﺍﺕ ﺍﻟﺘﻲ ﺘﺤﺘﻭﻯ ﻋﻠﻰ ﺍﻭﻜﺴﻴﺘﻭﺴﻴﻥ ﺃﻭ ﺍﺭﻗﻭﻤﺘﺭﻴﻥ
ﺩﺭﺍﺴﺔ ﺍﻟﻤﻘﺎﺭﻨﺔ ﻟﺩﻭﺍﺀ ﻤﻴﺴﻭﺒﺭﻭﺴﺘﻭل ﺍﻟﺫﻱ ﻴﺅﺨﺫ  ﺒﺎﻟﻔﻡ ﺃﻭ ﺒﺎﻟﻤﺴﺘﻘﻴﻡ ﻗﺩﻤﺕ ﺃﺩﻟﺔ  ﺍﻟﺨﺎﺘﻤﺔ، ﺇﻥ ﻫﺫﻩ ﺍﻟﻓﻲ
ﺒﺄﻨﻪ ﻴﻤﺘﺎﺯ ﺒﻨﻔﺱ ﻜﻔﺎﺀﺓ ﻋﻘﺎﺭ ﺴﻨﺘﻭﻤﺘﺭﻴﻥ ﻓﻲ ﺘﻘﻠﻴل ﻓﻘﺩﺍﻥ ﺍﻟﺩﻡ ﺒﻌﺩ ﺍﻟﻭﻻﺩﺓ ﻭﻓﻲ ﺘﻘﻠﻴل ﺤﺩﻭﺙ ﺍﻟﻨﺯﻴﻑ 
ﺒﻌﺩ ﺍﻟﻭﻻﺩﺓ، ﻭﻟﻴﺴﺕ ﻟﻪ ﺃﻋﺭﺍﺽ ﺠﺎﻨﺒﻴﺔ ﻤﺜل ﻤﺎ ﺘﻭﺠﺩ ﻓﻲ ﺍﻷﺩﻭﻴﺔ ﺍﻟﺘﻲ ﺘﺤﺘﻭﻯ ﻋﻠﻰ ﻋﻘﺎﺭ 
ﻗﺩ ﺘﻜﻭﻥ ﻟﻨﺘﺎﺌﺠﻨﺎ ﻫﺫﻩ ﺘﻁﺒﻴﻘﺎﺕ ﻤﻬﻤﺔ ﻓﻲ ﻤﻨﺎﻁﻕ ﺃﺨﺭﻯ ﻤﺜل ﺍﻟﻤﻨﺎﻁﻕ ﺍﻟﺭﻴﻔﻴﺔ ﺤﻴﺙ ﺘﺘﻡ ﻭ. ﺍﻻﺭﻗﻭﻤﺘﺭﻴﻥ
ﺍﻟﻭﻻﺩﺓ ﻓﻲ ﺍﻟﻤﻨﺯل ﻭﺤﻴﺙ ﻻ ﻴﻭﺠﺩ ﺍﻟﺘﺩﺨل ﺍﻟﺴﺭﻴﻊ ﺍﻟﻤﺒﺎﺸﺭ ﻟﻠﺤﺩ ﻤﻥ ﻤﻀﺎﻋﻔﺎﺕ ﺍﻟﻤﺭﺤﻠﺔ ﺍﻟﺜﺎﻟﺜﺔ 
  . ﻟﻠﻭﻻﺩﺓ
 vii
ABBREVIATION 
 
PPH : Postpartum haemorrhage  
APH :  Antepartum haemorrhage 
LMP : Last menstrual period 
VB:  Vaginal birth 
BP:  Blood pressure 
DSTL: Duration of third stage of labour 
FHR:  Fetal heart rate 
FL:  Fundal level 
CX:  Cervix: 
BG + RH: Blood group and rhesus factor 
M±SD: Mean and standard deviation  
HIV :  Human immunodeficiency  virus 
HVB : Hepatitis B virus 
Hte :  Hematocrit 
Hb :  Haemoglobin 
RCT : Randomized controlled trial 
PG :  Prostaglandins 
RR :   Relative risk 
CI :  Confidence interval 
WHO: World Health Organisation 
µg :  Microgram 
IM:  Intramuscular  
IV:  Intravenous 
mL :  Milliliter 
g/dl :  Gram per deciliter 
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 MATERNITY OF THE H.G.R.N. 
PROTOCOL : PREVENTION OF POSTPARTUM HAEMORRHAGE 
(Misoprostol  versus syntometrine) 
Computer number  
 
 
Date  of admission    
 
Identity of the patient 
Name  Age  
Residence  Marital status   
 
Obstetric history 
Gestity   Parity   VB  Caesarean   PPH   APH  
 
Gynaecological  history  
Menarche    Kata   LMP  Gynaecological operation   
 
Medical history 
Cardiopathy  Asthma  Glaucoma  Chronic diseases   
 
Surgical history :  
 
Clinical examination 
1 – General examination :  
Weight  BP   Pulse    Temperature  
Cardiovascular system   Respiratory system   
 
2 – Obstetrical examination :  
a)Abdominal examination 
FL   Presentation   Engagement    
FHR       Abdominal scar   
 
b) Gynaecological examination 
Dilatation  CX   Vaginal bleeding   Presentation   
 
* Investigations 
BG + RH  HB    HTE   
 
* Echography 
Number of foetus   Placenta localisation     
Foetal viability   Presentation   
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* Intrapartum data 
Spontaneous labour    Induction   Augmentation    
Analgesia   Duration of first stage   Duration of second stage  
Spontaneous delivery    Forceps   Ventouse    
 
* Third stage of labour data 
 
Control group (syntometrine) 
 
Active management  Episiotomy  Perineal tear  
Manual removal of placenta  addition of oxytocin or ergometrine  
 
Measurement of blood loss   DTSL  
 
Maternal side effects   : Headache  Nausea  Vomiting    
BP (30 mn)  Temperature (30 mn)   
Foetal weight    Placental weight  
 
Satisfaction 
a) Patient : very good   Good  Poor    
b) Caregiver : very good   Good  Poor  
 
Group of misoprostol :      Oral  Rectal     
 
Active management  Episiotomy  Perineal tear  
Manual removal of placenta  Addition of oxytocin  
 
Measurement of blood loss   DTSL  
 
Maternal side effects: Headache  Nausea  Vomiting    
Fever      Shivering  BP (30 mn)  Temperature   
Foetal weight      Placental weight          
 
Satisfaction 
Patient : very good  Good   Poor  
Caregiver : very good  Good   Poor  
 
Before treatment  :      Hb 
After treatment (h)  :   Hb 
 Hte 
Hte 
 Difference  :       Hb 
                           Hte 
  
Hospitalisation for severe PPH   
Needs of blood transfusion   
Others complications   
 
v 
  ﺒﺴﻡ ﺍﷲ ﺍﻟﺭﺤﻤﻥ ﺍﻟﺭﺤﻴﻡ 
  
  ﺨﻼﺼﺔ
ﺇﻥ ﺍﻟﻨﺯﻴﻑ ﺒﻌﺩ ﺍﻟﻭﻻﺩﺓ ﻫﻭ ﺍﻟﺴﺒﺏ ﺍﻟﺫﻯ ﻴﺅﺩﻱ ﺇﻟﻰ ﻭﻓﺎﺓ ﺍﻷﻤﻬﺎﺕ ﻓﻲ ﺍﻟﺩﻭل ﺍﻟﻨﺎﻤﻴﺔ ﺇﺫ ﺃﻥ ﻨﺴﺒﺔ 
ﻤﺎﻜﺘﺏ . ﻤﻥ ﻫﺫﻩ ﺍﻟﻭﻓﻴﺎﺕ ﺘﺤﺩﺙ ﻓﻲ ﺍﻟﻤﻨﺎﻁﻕ ﺍﻟﺘﻲ ﻴﻜﻭﻥ ﻓﻴﻬﺎ ﻤﻌﺩل ﻭﻓﻴﺎﺕ ﺍﻷﻤﻬﺎﺕ ﻋﺎﻟﻴﺎﹰ% 03
ﺔ ﻟﻠﻭﻻﺩﺓ ﻟﺘﻘﻠﻴل ﺤﺩﻭﺙ ﺍﻟﻨﺯﻴﻑ ﻤﺎ  ﺘﺩﻋﻡ ﺍﻟﺘﺩﺨل ﺍﻟﻔﺎﻋل ﻓﻲ ﺍﻟﻤﺭﺤﻠﺔ ﺍﻟﺜﺎﻟﺜﺤﺎﻟﻴﺎ ﻓﻲ ﻫﺫﺍ ﺍﻟﻤﺠﺎل
ﺍﻟﻭﻗﺎﺌﻰ ﺇﻻ ﺃﻨﻬﺎ ﺒﻌﺩ ﺍﻟﻭﻻﺩﺓ ﻭﻟﻜﻥ ﺍﻟﻌﻘﺎﻗﻴﺭ ﺍﻟﻤﻭﺘﺭﺓ ﻟﻌﻀﻼﺕ ﺍﻟﺭﺤﻡ ﺘﻜﻭﻥ ﻤﻔﻀﻠﺔ ﻟﻼﺴﺘﺨﺩﺍﻡ 
"  ﺘﺸﺎﺩ-  ﺒﺎﻨﺠﻤﻴﻨﺎ ﺍﻟﻤﺴﺘﺸﻔﻲ ﺍﻟﻌﺎﻡ ﺍﻟﻘﻭﻤﻲ" ﺃﺠﺭﻴﺕ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﻓﻲ . ﻤﺎﺯﺍﻟﺕ ﻤﻭﻀﻊ ﻨﻘﺎﺵ
ﻡ ﻤﻊ ﻋﻘﺎﺭ ﺴﻨﺘﻭﻤﺘﺭﻴﻥ ﻓﻲ ﻟﻤﻘﺎﺭﻨﺔ ﻜﻔﺎﺀﺓ ﻋﻘﺎﺭ ﻤﻴﺴﻭﺭﺒﺭﻭﺴﺘﻭل ﺍﻟﺫﻱ ﻴﺅﺨﺫ ﺒﺎﻟﻔﻡ ﺃﻭ ﺒﺎﻟﻤﺴﺘﻘﻴ
ﻜﺎﻨﺕ ﺍﻟﺩﺭﺍﺴﺔ ﻤﺠﺎﻻﹰ ﻭﺍﺴﻌﺎﹰ ﻭﻫﻲ ﺘﺠﺭﺒﺔ ﻋﺸﻭﺍﺌﻴﺔ . ﺍﻟﺘﺩﺨل ﺍﻟﻔﺎﻋل ﻓﻲ ﺍﻟﻤﺭﺤﻠﺔ ﺍﻟﺜﺎﻟﺜﺔ ﻟﻠﻭﻻﺩﺓ
 ﺍﻤﺭﺃﺓ ﺘﻡ ﺘﻭﺯﻴﻊ ﺍﻟﻨﺴﺎﺀ ﻋﺸﻭﺍﺌﻴﺎﹰ ﻓﻲ ﺜﻼﺙ 0042ﻤﻘﺎﺭﻨﺔ ﺫﺍﺕ ﺜﻼﺙ ﻓﺌﺎﺕ ﻭﺍﻟﺘﻲ ﻀﻤﺕ 
 004 ﺍﻤﺭﺃﺓ ﻟﻜٍل ﻤﻥ ﻤﻴﺴﻭﺒﺭﻭﺴﺘﻭل ﻋﻥ ﻁﺭﻴﻕ ﺍﻟﻔﻡ 008ﻤﺠﻤﻭﻋﺎﺕ، ﺒﻜل ﻤﺠﻤﻭﻋﺔ 
  . ﻤﺎﻴﻜﺭﻭﺠﺭﺍﻡ ﻭﺴﻨﺘﻭﻤﺘﺭﻴﻥ ﺤﻘﻨﺔ ﻭﺍﺤﺩﺓ ﺒﺎﻟﻌﻀل004ﺭﻭﺠﺭﺍﻡ ﻭﻤﻴﺴﻭﺒﺭﻭﺴﺘﻭل ﺒﺎﻟﻤﺴﺘﻘﻴﻡ ﻤﺎﻴﻜ
 ﻋﻘﺎﺭ  ﻭﺤﺩﻭﺙ ﻨﺯﻴﻑ ﺒﻌﺩ ﺍﻟﻭﻻﺩﺓ ﻭﺍﻟﺤﻭﺠﺔ ﺇﻟﻰﺍﻟﺩﻡﻓﻘﺩﺍﻥ  ﻤﺘﻭﺴﻁﻜﺎﻨﺕ ﺍﻟﻨﺘﺎﺌﺞ ﺍﻷﻭﻟﻴﺔ ﻫﻲ 
ﺍﻟﻨﺴﺒﺔ ) ﻓﻲ ﺍﻟﻬﻴﻤﻭﻗﻠﻭﺒﻴﻥ ﻭﺍﻟﺭﺍﺴﺏ ﺍﻟﺩﻤﻭﻱ ﻤﺘﻭﺴﻁﻭﺘﻐﻴﻴﺭ ﺇﻀﺎﻓﻲ ﻤﻭﺘﺭ ﻟﻌﻀﻼﺕ ﺍﻟﺭﺤﻡ 
  .ﻟﺩﻡ ﺍﻟﺤﻤﺭﺍﺀﺍﻟﻤﺌﻭﻴﺔ ﺍﻟﺤﺠﻤﻴﺔ ﻟﻜﺭﻴﺎﺕ ﺍ
ﺘﻀﻤﻨﺕ ﺍﻟﻨﺘﺎﺌﺞ ﺍﻟﺜﺎﻨﻭﻴﺔ ﻤﺩﺓ ﺍﻟﻤﺭﺤﻠﺔ ﺍﻟﺜﺎﻟﺜﺔ ﻭﺍﻹﺯﺍﻟﺔ ﺍﻟﻴﺩﻭﻴﺔ ﻟﻠﻤﺸﻴﻤﺔ ﻭﻨﻘل ﺍﻟﺩﻡ ﻭﺍﻷﻋﺭﺍﺽ 
  .ﻭﺤﺩﻭﺙ ﺍﺭﺘﻔﺎﻉ ﻓﻲ ﻀﻐﻁ ﺍﻟﺩﻡ( ﺎﻥ ﻭﺼﺩﺍﻉ ﻭﻗﺊ ﻭﺍﺴﻬﺎلﻴﺤﻤﻲ ﻭﺍﺭﺘﻌﺎﺵ ﻭﻏﺜ)ﺍﻟﺠﺎﻨﺒﻴﺔ 
 441± - 332،  ﻤﻠﻴﻠﺘﺭ  641 ±232 ، 241ﻤﻠﻴﻠﺘﺭ ±   322 ﻟﻠﺩﻡ ﺏ ﺍﻟﻤﺘﻭﺴﻁﺘﻡ ﺘﻘﺩﻴﺭ ﺍﻟﻔﻘﺩﺍﻥ 
  .ﻴﻠﺘﺭ ﻟﻠﺴﻨﺘﻭﻤﺘﺭﻴﻥ ﻭﺍﻟﻤﻴﺴﻭﺒﺭﻭﺴﺘﻭل ﺒﺎﻟﻔﻡ ﻭﻋﻥ ﻁﺭﻴﻕ ﺍﻟﻤﺴﺘﻘﻴﻡ ﻋﻠﻰ ﺍﻟﺘﻭﺍﻟﻲﻤﻠ
ﻋﻨﺩ ﺘﻨﺎﻭل ﺴﻨﺘﻭﻤﺘﺭﻴﻥ %57.4ﻭ% 57.4ﻭ % 26.4ﺒﻌﺩ ﺍﻟﻭﻻﺩﺓ ﺒﻨﺴﺒﺔ ﺤﺩﺙ ﺍﻟﻨﺯﻴﻑ ﻤﺎ 
  .ﻭﻤﻴﺴﻭﺒﺭﻭﺴﺘﻭل ﻋﻥ ﻁﺭﻴﻕ ﺍﻟﻔﻡ ﻭﻋﻥ ﻁﺭﻴﻕ ﺍﻟﻤﺴﺘﻘﻴﻡ ﻋﻠﻰ ﺍﻟﺘﻭﺍﻟﻲ
ﻥ ﺍﻟﻤﺭﻴﻀﺎﺕ ﺍﻟﻼﺌﻲ ﻤ% 78.0ﻭ% 57.0ﻭ% 57.0 ﻤﻠﻴﻠﺘﺭ ﺒﻨﺴﺒﺔ 0001ﻤﻥ ±ﺴﺠل ﻓﻘﺩﺍﻥ ﺍﻟﺩﻡ 
. ﺘﻡ ﻋﻼﺠﻬﻥ ﺒﺎﻟﺴﻨﺘﻭﻤﺘﺭﻴﻥ ﻭﺍﻟﻤﻴﺴﻭﺒﺭﻭﺴﺘﻭل ﻋﻥ ﻁﺭﻴﻕ ﺍﻟﻤﺴﺘﻘﻴﻡ ﻭﻋﻥ ﻁﺭﻴﻕ ﺍﻟﻔﻡ ﻋﻠﻰ ﺍﻟﺘﻭﺍﻟﻲ
ﻴﺭﺍﹰ ﺒﻴﻥ ﺍﻟﻤﺠﻤﻭﻋﺎﺕ ﺍﻟﺘﻲ ﺘﻑ ﻜﻠﺍﻹﻨﺤﺭﺍﻑ ﺍﻟﻤﻌﻴﺎﺭﻱ ﻟﻤﺴﺘﻭﻱ ﺍﻟﻬﻴﻤﻭﻗﻠﻭﺒﻴﻥ ﻟﻡ ﻴﺨﺘ± ﺇﻥ ﻤﺘﻭﺴﻁ 
± % 06.0 ﻭ ﺩﻴﺴﻴﻠﺘﺭ ﻟﻠﻤﻴﺴﻭﺒﺭﻭﺴﺘﻭل ﻋﻥ ﻁﺭﻴﻕ ﺍﻟﻔﻡ/ﺠﺭﺍﻡ% 94.0± % 95.0 ﺘﺭﻭﺍﺤﺕ ﺒﻴﻥ
/ ﺠﺭﺍﻡ% 83.0 ± 55.0ﺩﻴﺴﻴﻠﺘﺭ ﻟﻠﻤﻴﺴﻭﺒﺭﻭﺴﺘﻭل ﻋﻥ ﻁﺭﻴﻕ ﺍﻟﻤﺴﺘﻘﻴﻡ ﻭ/ ﺠﺭﺍﻡ% 33.0
  .ﺩﻴﺴﻴﻠﺘﺭ ﻟﻠﺴﻨﺘﻭﻤﺘﺭﻴﻥ
 ﻟﻠﻭﻻﺩﺓ ﻭﺍﻟﻨﺴﺒﺔ ﺍﻟﺘﻲ ﺩﻭﺭ ﺍﻟﺨﻼﺹﻟﻡ ﻴﻜﻥ ﻫﻨﺎﻟﻙ ﺍﺨﺘﻼﻑ ﻜﺒﻴﺭ ﺒﻴﻥ ﺍﻟﻤﺠﻤﻭﻋﺎﺕ ﺒﺎﻟﻨﺴﺒﺔ ﻟﻤﺩﺓ 
ﺔ ﺒﺼﻭﺭﺓ   ﻅﻬﺭﺕ ﺭﻋﺸ. ﺇﻀﺎﻓﺔ ﻋﻘﺎﺭ ﻤﻭﺘﺭ ﻟﻌﻀﻼﺕ ﺍﻟﺭﺤﻡ ﺍﻗﺘﻀﺕ ﺇﺯﺍﻟﺔ ﺍﻟﻤﺸﻴﻤﺔ ﻴﺩﻭﻴﺎﹰ ﺃﻭ
iv 
% 57.41 ﺍﻟﺘﻲ ﺘﻨﺎﻭﻟﺕ ﻤﻴﺴﻭﺒﺭﻭﺴﺘﻭل ﻋﻥ ﻁﺭﻴﻕ ﺍﻟﻔﻡ ﻜﺎﻨﺕ ﺒﻨﺴﺒﺔ ﺔﺭﺌﻴﺴﻴﺔ ﻓﻲ ﺍﻟﻤﺠﻤﻭﻋ
ﻤﻘﺎﺭﻨﺔ ﺒﺎﻟﻤﺠﻤﻭﻋﺔ ﺍﻟﺘﻲ ﺘﻨﺎﻭﻟﺕ % 57.8ﻭﻤﻴﺴﻭﺒﺭﻭﺴﺘﻭل ﻋﻥ ﻁﺭﻴﻕ ﺍﻟﻤﺴﺘﻘﻴﻡ ﻜﺎﻨﺕ ﺒﻨﺴﺒﺔ 
ﻓﻲ ﺫﺍﺕ ﺍﻟﻭﻗﺕ، ﺸﻌﺭ ﻋﺩﺩ ﻜﺒﻴﺭ ﻤﻥ ﺍﻟﻤﺭﻴﻀﺎﺕ ﺍﻟﻼﺘﻲ ﺘﻨﺎﻭﻟﻥ ﺩﻭﺍﺀ %. 4ﺴﻨﺘﻭﻤﺘﺭﻴﻥ ﺒﻨﺴﺒﺔ 
ﻤﻘﺎﺒل % 78.7ﺎﻟﻤﺴﺘﻘﻴﻡ ﺒﺎﺭﺘﻔﺎﻉ ﺩﺭﺠﺔ ﺍﻟﺤﺭﺍﺭﺓ ﻤﻘﺎﺭﻨﺔ ﺒﺎﻟﺴﻨﺘﻭﻤﺘﺭﻴﻥ ﻤﻴﺴﻭﺒﺭﻭﺴﺘﻭل ﺒﺎﻟﻔﻡ ﻭﺒ
ﺎﻥ ﻭﻗﺊ ﻭﺼﺩﺍﻉ ﻭﺍﺭﺘﻔﺎﻉ ﻀﻐﻁ ﺍﻟﺩﻡ ﺒﻁﺭﻴﻘﺔ ﺜﻴﻜﻤﺎ ﺘﻤﺕ ﻤﻼﺤﻅﺔ ﻏ%. 52.1ﻤﻘﺎﺒل % 65.6
  .ﻤﺘﻜﺭﺭﺓ ﻋﻨﺩ ﺍﻟﻤﺠﻤﻭﻋﺔ ﺍﻟﺘﻲ ﺘﻨﺎﻭﻟﺕ ﺴﻨﺘﻭﻤﺘﺭﻴﻥ
( ﻘﻴﻡﺒﺎﻟﻔﻡ ﺃﻭ ﺒﺎﻟﻤﺴﺘ)ﺍﻗﺘﻨﻊ ﺃﻏﻠﺏ ﺍﻟﻨﺴﺎﺀ ﻭﻤﻘﺩﻤﻭ ﺍﻟﺭﻋﺎﻴﺔ ﺍﻟﺼﺤﻴﺔ ﺒﺎﺴﺘﺨﺩﺍﻡ ﻤﻴﺴﻭﺒﺭﻭﺴﺘﻭل 
  . ﻤﻘﺎﺭﻨﺔ ﺒﺎﻟﺴﻨﺘﻭﻤﺘﺭﻴﻥ
ﺍﻟﺘﻲ ﺘﺅﺨﺫ ﻋﻥ ﺍﻟﻤﻭﺘﺭﺓ ﻟﻌﻀﻼﺕ ﺍﻟﺭﺤﻡ ﻥ ﻋﻘﺎﺭ ﺍﻟﻤﻴﺴﻭﺒﺭﻭﺴﺘﻭل ﻫﻭ ﺃﻗل ﺘﻜﻠﻔﺔ ﻤﻥ ﺍﻟﻌﻘﺎﻗﻴﺭ ﺁ
ﻫﻭ ﺜﺎﺒﺕ ﻭﻻ ﻴﺘﺄﺜﺭ ﺒﺎﻟﺘﻠﻑ ﻓﻲ ﺍﻟﻤﻴﺴﻭﺒﺭﻭﺴﺘﻭل ﻁﺭﻴﻕ ﺍﻟﺤﻘﻥ، ﻤﻊ ﺍﻷﺨﺫ ﻓﻲ ﺍﻻﻋﺘﺒﺎﺭ ﺃﻥ 
 ﻤﺎ ﻴﺤﺩﺙ ﻓﻲ ﻜل ﺍﻟﻤﺴﺘﺤﻀﺭﺍﺕ ﺍﻟﺘﻲ ﺘﺤﺘﻭﻯ ﻋﻠﻰ ﺍﻭﻜﺴﻴﺘﻭﺴﻴﻥ ﺃﻭﻜﺍﻟﻤﻨﺎﺨﺎﺕ ﺍﻟﺤﺎﺭﺓ 
  . ﺍﺭﻗﻭﻤﺘﺭﻴﻥ
 ﺒﺎﻟﻔﻡ ﺃﻭ ﺒﺎﻟﻤﺴﺘﻘﻴﻡ  ﺍﻟﺫﻱ ﻴﺅﺨﺫ ﻓﻲ ﺍﻟﺨﺎﺘﻤﺔ، ﺇﻥ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﺍﻟﻤﻘﺎﺭﻨﺔ ﻟﺩﻭﺍﺀ ﻤﻴﺴﻭﺒﺭﻭﺴﺘﻭل
ﻓﻲ ﺘﻘﻠﻴل ﻓﻘﺩﺍﻥ ﺍﻟﺩﻡ ﺒﻌﺩ ﺍﻟﻭﻻﺩﺓ ﻭﻓﻲ ﺘﻘﻠﻴل ﺴﻨﺘﻭﻤﺘﺭﻴﻥ   ﻋﻘﺎﺭﻗﺩﻤﺕ ﺃﺩﻟﺔ ﺒﺄﻨﻪ ﻴﻤﺘﺎﺯ ﺒﻨﻔﺱ ﻜﻔﺎﺀﺓ
ﺍﻟﺘﻲ ﺘﺤﺘﻭﻯ ﺤﺩﻭﺙ ﺍﻟﻨﺯﻴﻑ ﺒﻌﺩ ﺍﻟﻭﻻﺩﺓ، ﻭﻟﻴﺴﺕ ﻟﻪ ﺃﻋﺭﺍﺽ ﺠﺎﻨﺒﻴﺔ ﻤﺜل ﻤﺎ ﺘﻭﺠﺩ ﻓﻲ ﺍﻷﺩﻭﻴﺔ 
ﻭﻗﺩ ﺘﻜﻭﻥ ﻟﻨﺘﺎﺌﺠﻨﺎ ﻫﺫﻩ ﺘﻁﺒﻴﻘﺎﺕ ﻤﻬﻤﺔ ﻓﻲ ﻤﻨﺎﻁﻕ ﺃﺨﺭﻯ ﻤﺜل ﺍﻟﻤﻨﺎﻁﻕ . ﻋﻠﻰ ﻋﻘﺎﺭ ﺍﻻﺭﻗﻭﻤﺘﺭﻴﻥ
ﺍﻟﺭﻴﻔﻴﺔ ﺤﻴﺙ ﺘﺘﻡ ﺍﻟﻭﻻﺩﺓ ﻓﻲ ﺍﻟﻤﻨﺯل ﻭﺤﻴﺙ ﻻ ﻴﻭﺠﺩ ﺍﻟﺘﺩﺨل ﺍﻟﺴﺭﻴﻊ ﺍﻟﻤﺒﺎﺸﺭ ﻟﻠﺤﺩ ﻤﻥ ﻤﻀﺎﻋﻔﺎﺕ 
  . ﺍﻟﻤﺭﺤﻠﺔ ﺍﻟﺜﺎﻟﺜﺔ ﻟﻠﻭﻻﺩﺓ
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Chapter One 
1-   INTRODUCTION AND LITERATURE REVIEW 
 
1.1 -  INTRODUCTION: 
  
Postpartum haemorrhage (PPH) is a major cause of morbidity and 
mortality in the non-industrialized countries. As many as 25% of maternal 
deaths in rural areas are due to postpartum haemorrhage (1). A 
community-based investigation of causes of maternal mortality in rural 
Zimbabwe described the leading cause of death as postpartum 
haemorrhage (4o/100.000 births), while in UK between 1991 – 1993 
maternal mortality from postpartum haemorrhage was 1/100.000 births 
(2). The difference in absolute maternal mortality from postpartum 
haemorrhage between non-industrialized and industrialized counties 
under scores the effectiveness of medical care in the reduction of mortality 
from this cause. 
 
In my country Chad, postpartum haemorrhage constitutes a major cause 
of maternal death. The maternal mortality rate is about 800 per 100.000 
births (3). Uterine atony accounts for 85% of PPH, a fact that reflects 
inadequate management of the third stage of labour. We are facing the 
problem of inadequacy of facilities for blood transfusion for the 
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immediate supply of blood for transfusion in case of PPH. Nevertheless, 
the problem of safe blood for transfusion is still a major handicap because 
of the risk of transmission of viral diseases namely HIV and hepatitis B 
virus (HBV). All these facts impose the need to improve the management 
of the third stage of labour. 
 
Active management of the third stage of labour has been the standard care 
in many developed countries. It is usually implemented as a package 
including early oxytocics therapy such as oxytocin and / or Ergometrine, 
cord clamping and controlled cord traction. This policy have been 
beneficial, the incidence of PPH is reduced approximately by 40% (4). 
However, current oxytocics are far from ideal, particularity for routine use 
in developing countries; because they lack stability in tropical conditions. 
When Syntometrine is stored for prolonged period the temperature must 
be maintained between 2°C and 8°C and it must be protected from light 
(5). Studies designed to simulate the storage condition commonly found in 
tropical countries showed that a variety of brands of Ergometrine lost 21% 
to 27% of their potency after one month and over 90% after one year of 
storage exposed to light and at 21°C to 25°C (6). This storage requirement 
are important hurdle to the wide spread use of Oxytocin in the developing 
world. The use of conventional oxytocics requires sterile syringes and 
needles an important consideration in developing countries. These drugs 
are not without side effects and complications.  
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Prostaglandins are known to be useful in the treatment of severe PPH and 
in this situation may be superior to oxytocin and ergometrine (7). 
Prostaglandins do not cause hypertension, which enable them to be used 
in hypertensive women (8). They may therefore be useful in the prevention 
of postpartum haemorrhage (9). Prostaglandins E2 analogue sulprostone is 
effective in the prevention of recurrence of atonic postpartum 
haemorrhage. 
Prostaglandins F2α had been used in the management of postpartum 
haemorrhage (10). These pharmacological agents are expensive and require 
optimal conditions for conservation. 
Recently, Misoprostol, a prostaglandin E1 analogue used for the 
prevention of peptic ulcer disease, has also been reported for the 
prevention of postpartum haemorrhage. Misoprostol is affordable, easily 
stored at room temperature and possesses a shelf life of several years. Its 
safety has been established as uterotonic in obstetrics and gynaecology. 
More recently, it has been shown in several studies to be a potent 
uterotonic agent used in the induction of labour, cervical priming and 
management of intra-uterine foetal death. Its use in the third stage of 
labour has recently been suggested (11).  
 
An uncontrolled study published in the British Journal of Obstetric and 
Gynaecology confirmed the feasibility of its use (12). 
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In April 1998, the WHO commenced recruitment to a large multicentre 
international trial of oral misoprostol compared to oxytocin. This WHO 
study was a hospital based multicentre double blind randomised 
controlled clinical trials conducted during the period April 1998 – May 
1999. It involved the use of oral Misoprostol 600 µg versus 10 unit of 
oxytocin IV. The aim of the study was to test the hypothesis that the use 
of Misoprostol in the active management of the third stage of labour is 
equivalent to that of oxytocin in terms of measured blood loss of 1000 mL 
or more (13).   
 
In the recent years, misoprostol per rectum has been tested in the 
prevention of postpartum haemorrhage in small clinical trials. Such route 
of administration if confirmed effective in the active management of the 
third stage of labour would have several advantages, because side effects 
of oral misoprostol are essentially gastrointestinal and are dose 
dependant. Therefore, gastrointestinal side effects are reduced and 
administration to patients who are vomiting and unable to take orally or 
under anaesthesia during caesarean section would be possible (14). 
 
In most of the developing countries and among them Chad, labour occurs 
usually in health centres lacking facilities and medical personnel. 
Therefore, the choice for suitable pharmacological agents and protocol for 
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utilization is essential with the aim of reducing the incidence of 
postpartum haemorrhage.  
 
Misoprostol may be an alternative and there is a need to undertake a 
research to establish its efficiency, safety, cost and acceptability through 
randomised clinical studies. This is the aim of this MD thesis. 
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1.2 - REVIEW OF LITERATURE 
 
1.2.1 - Physiology of the Third Stage of Labour: 
 
Traditionally, the physiology of the third stage of labour is described as 
contraction of the uterus soon after delivery of the baby followed by 
separation of the placenta from the uterine wall. Then the placenta is 
spontaneously expelled, a process that can take up to half an hour. 
Separation of the placenta is evidenced by a show of blood, lengthening of 
the cord and a firmly contracted uterus, which rises up in the abdomen 
and assumes a more globular shape with greater mobility.  
 
As long ago as 1933, Brandt described the necessity of a uterine 
contraction to cause detachment of the placenta from the decidual bed.  
According to Brandt, uterine contractions prevent blood in the intervillous 
spaces from escaping back into the maternal circulation (15). Then, the 
placenta is squeezed so that blood is forced into decidual sinuses, which 
become compressed and then burst. Extravasated blood under tension 
causes tearing of the very fine septa of the spongiosa, thereby detaching 
the placenta. Dieckman et al, on at other hand, stressed the importance of 
slow delivery of the fetus so that the uterine wall is given time to contract 
and retract, thereby tear in itself from the placenta. This author has stated 
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that retroplacental haematoma is almost non-existent and that it has 
nothing to do with placental separation (16). 
 
Herman et al, using real-time ultrasonographic studies of the third stage of 
labour in patients with normal delivery had contributed to better 
understanding of the physiological phases that occurred in placenta 
separation.  During ultrasonographic imaging of the third stage, the 
authors were able to show that immediately after delivery, the placenta-
free wall became thick and the placenta-site wall remained thin. 
Thereafter the placenta-site wall thickened gradually from < 1 cm to > 2 
cm. At this point, the placenta was already separated, and could be seen 
detached from the uterine wall as it begins a sliding movement toward the 
cervix. No haematoma was observed between the placenta and its 
adjacent uterine wall. Once the placenta begins its movement, the zone of 
separation remained unchanged, and a small amount of blood collected in 
the uterine cavity, indicating that bleeding during placental separation is 
rather a consequence and not a cause. In six normal deliveries, gentle 
traction of the cord was applied before uterine contraction of the placenta-
site wall occurred. This procedure had no effect until all areas of the 
uterine wall thickened, indicting that contraction should occur before 
detachment ensures. On the base of these sequences of events, the authors 
divided the third stage into 4 phases according to the ultrasound 
appearances: latent phase, contraction phase, detachment phase and 
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expulsion phase. In the latent phase that immediately follows delivery of 
the fetus, all the myometrium contracts except for that behind the 
placenta, which remains relaxed. In the contraction phase, the retro-
placental myometrium contracts leading to the detachment phase where 
the placenta is sheared away from the deciduas. In the expulsion phase, 
the placenta is expelled from the uterus by uterine contraction (17).  
 
The ultrasound studies demonstrated that the duration of the third stage 
of labour is dependant on the length of the latent phase and a prolonged 
third stage is due to contractile failure in the retro-placental area. In the 5 
cases of retained placenta in which they conducted serial ultrasonographic 
myometrial thickness measurements, these authors found a universal 
failure of retro-placental contraction (17). 
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1.2.2- Definition of Postpartum Haemorrhage: 
 
Postpartum haemorrhage is defined as excessive bleeding from the genital 
tract following the delivery of the baby. It is further subdivided into 
primary if it occurs immediately after the delivery or secondary if bleeding 
occurs after 24 hours postpartum. Excessive bleeding during the third 
stage of labour is therefore, primary rather than secondary in nature (18). 
Traditionally, 500 mL of blood loss was considered a cut-off point 
between normal and abnormal blood loss after delivery and hence this 
definition of PPH was included in medical textbooks for decades (19).  
 
The World Health Organization (WHO) defines primary postpartum 
haemorrhage as bleeding in excess of 500 mL in the first 24 h following 
delivery, and this definition is generally adopted in the UK. In certain 
countries such as Australia and Zimbabwe, the minimum cut-off for 
defining postpartum haemorrhage is 600 mL (19). 
 
The definition of postpartum haemorrhageas 500 mL remains a useful 
alarm. A fit well-nourished woman of average build should be able to 
cope with this and does not need blood transfusion with its inherent costs 
and dangers. But, this is certainly not the case in countries where severe 
anaemia is common and the circulating red cell mass might be reduced(20).   
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When researching the third stage of labour, a major variable is that of 
estimation of bleeding and diagnosis of postpartum haemorrhage. The 
method of evaluating haemorrhage is well defined in the major trials, 
allowing statistical comparisons to be undertaken between and among 
groups. 
 
1.2.2.1- Determination of Blood Loss: 
Method of measuring blood loss have been summarized by Wilcox et al 
(21). These are: (a) direct collection of blood in pans with or without 
shunting others fluid into separate container; (b) gravimetric methods by 
which sponges are weighed before and after use; (c) determination of 
change in blood volume before and after delivery; and (d) 
spectrophotometric method by which blood and sponges containing blood 
are mixed in a solution which converts haemoglobin to acid haematin or 
cyanmethemoglobin, which in turn can be measured in a colorimeter. 
However, the spectrophotometric method appears to be the most 
accurate.  
 
The average estimated blood loss at a vaginal birth usually is based on 
Pritchard’s word in the mid-1960s. In Pritchard’s research, approximately 
60% of women giving birth vaginally lost less than 500 mL of blood and 
an estimated 5% lost 1.000 mL or more (22). Although 500 mL may be a 
common standard, it has commonly been acknowledged that visual 
estimation of blood loss often is inaccurate and commonly 
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underestimated by 34-50%. Razvi et al investigated the issue of estimated 
blood loss (EBL) by comparing it to measured blood loss (MBL). They 
found that EBL and MBL best correlated when the blood loss was 
between 150 and 300 mL. When the MBL was 150 mL there was a high 
incidence of overestimation. For nine women who had a measured blood 
loss of 500 mL or more, only one was correctly diagnosed according to 
EBL, and three who had an EBL of 500 mL or more actually had an 
MBL that was less (23). Cunninghan et al summarized this controversy by 
acknowledging that visual estimation is ‘‘notoriously inaccurate’’ (22). 
 
In addition to recognizing that estimation of blood loss is less than 
optimal, different parameters to define postpartum haemorrhage have 
been suggested. Combs and Laros suggested using a retrospective 
outcome variable of a decrease in the postpartum haematocrit of 10% or 
more (24). Klapholz theorized that the need for transfusion could be used as 
an objective sign that a postpartum haemorrhage had occurred, but on 
investigation, he found wide variables in the actual administration of 
transfusions. For example, the transfusion rate in one hospital dropped 
from 4.6 to 1.9% between 1976 and 1986, perhaps because of increased 
awareness about blood borne diseases (25).  
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1.2.3 - Aetiology And Risk Factors Postpartum Haemorrhage: 
 
1.2.3.1- Aetiology: 
 
The main causes of primary postpartum haemorrhage are failure of the 
uterus to contract effectively (atonic uterus), retention of placenta and 
membranes in the uterus and trauma to the genital tract. Les common 
causes include placenta accreta, uterine inversion and coagulation 
disorders. It is not uncommon for more than one of these causes to be 
present in the same woman with postpartum haemorrhage(18).   
 
Uterine atony or failure of the uterus to contract effectively will result in 
incomplete separation of the placenta, and inhibition of contractibility of 
the uterine muscle to constrict the vascular channels in the placental bed 
with consequent excessive bleeding. Failure of expulsion of the placenta 
and membranes can also lead to excessive haemorrhage from the 
placental vascular bed and commonly coexists with uterine atony. Even 
the retention of a fragment of placental tissue or its membranes may be 
sufficient to cause postpartum haemorrhage(18).  
 
1.2.3.2- Risk factor for postpartum haemorrhage  
 
Although, active management of the third stage of labour is considered as 
effective in reducing incidence of postpartum haemorrhage; the 
identification of the main risk factors for major obstetric bleeding by 
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antenatal screening is significant. This aspect of antenatal care is of 
relevance in developing countries where a great proportion of deliveries 
occurs at home and in some cases may lead to unexpected complications.  
 
A case control study conducted by Combs et al on a hospital based 
population, found that the significant association with postpartum 
haemorrhage were: prolonged third stage of labour (≥ 30 minutes); pre-
eclampsia, mediolateral episiotomy, previous postpartum haemorrhage, 
twins pregnancy, soft tissue lacerations, forceps or vacuum extractions, 
nullipartity, and augmented labour(26). A population-based case-control 
study restricted to women with singleton, vertex birth, and spontaneous 
onset of labour without oxytocics or instrumental intervention was 
conducted in Zimbabwe. It showed that the predictor variables 
significantly associated with postpartum haemorrhage were: advanced 
maternal age, malposition of foetal head, prolonged first stage (> 10 
hours) and prolonged second stage (> 20 minutes) (27). Contrary to 
widespread belief, grand multiparity is not a risk factor in either developed 
or developing countries (28). 
 
Nevertheless, risk factors are relevant to discussion about the place of 
delivery and the need for increased vigilance but the rate of postpartum 
haemorrhage in most of the cases is unpredictable and occurs in low risk 
women. Furthermore, bloss loss can be rapid and there is simply not 
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enough time to seek treatment for PPH. Therefore, research in prevention 
should be focussed on routine measures to be taken in all labours. Hence, 
active management in the third stage of labour helps prevent PPH. 
 
1.2.4- Maternal mortality due to haemorrhage: the magnitude 
of the problem: 
 
1.2.4.1- Maternal mortality due to postpartum haemorrhage: 
The last two decades have witnessed an increasing awareness of gender-
related medical problems in the world. Maternal mortality figures have 
become increasingly an emotive political issue. The lack of improvement 
in these figures in the developing world reflects the complex nature of the 
problems these societies face. In some cases, calls were made to exert 
political pressure on governments to tackle the problems. Linking certain 
aspects of foreign aid to advances in reproductive health was portrayed as 
an effective leverage to implement change. In some cases where 
improvement was reported, it is difficult to ascertain how much of this 
improvement is a political dressing and how much is a real improvement. 
The fact remains however that the figures are far too high, reflecting in 
their distribution the socio-economic divisions around the globe (29). 
 
Data from observational studies suggests that the incidence of primary 
postpartum haemorrhage in developed countries is between 3.7% and 
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8.6% (30). Major postpartum haemorrhage defined as blood loss in excess 
of 1000 mL occurs following 1.3% of all deliveries in the UK (28).  
 
In the UK, the number of maternal deaths from postpartum haemorrhage 
has remained relatively unchanged from 1979 to 1993 (31). Maternal 
mortality from postpartum haemorrhage is a much greater problem in 
developing countries, WHO estimates that approximately 500.000 women 
die each year from pregnancy related causes and at least 98% of these 
deaths occur in developing countries. Postpartum haemorrhage a leading 
cause of morbidity and mortality occurs in 4-8% of vaginal delivery and 
may be responsible for up to 28% of maternal death (32). Death due to PPH 
is reported to represent between 17 and 40% of maternal mortality in 
some parts of the world (33, 34).  
 
Obstetric haemorrhage is one of the first two major causes of maternal 
deaths in all regions except Middle South Asia where postpartum sepsis is 
the major killer. However, the highest maternal mortality from 
haemorrhage is in East Africa (233 haemorrhage deaths / 100.000 live 
births). 
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Table 1: Rate of maternal death due to postpartum haemorrhage in 
different communities 
 
Authors Year Countries Percentage 
Bavadra et al (35) 1978 Fiji 31  
Linpainter (30) 1982 Bangladesh 22  
Mola & Aitken (36) 1984 Papua New Guinea 33  
Fortney et al (37) 1986 Manoufia, Egypt 54  
Walter  (38) 1986 Jamaica 23  
Kwast et al  (39) 1986 Addis Ababa 12  
Mohamed H(3) 1999 N’djamena  28  
 
In Khartoum Teaching Hospital (Sudan: 1978-1982) 16% of all maternal 
deaths were due to PPH, (WHO, Maternal Mortality a Global Fact Book, 
1st edition; 1999). It was observed that it is not only countries with high 
maternal mortality rate, which show a large proportion of haemorrhagic 
deaths. In China, a recent study of 21 provinces found that 44% of all 
maternal deaths were from haemorrhage giving an overall maternal 
mortality rate of 49/100.000 live births (40).  
 
1.2.4.2- Maternal morbidity due to postpartum haemorrhage: 
 
The third stage of labour is potentially the most hazardous part of labour 
for the mother. Irrespective of its definition, postpartum haemorrhage is 
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the commonest serious maternal complication of childbirth. Subsequent 
morbidity can be considerable, particularly when medical services are 
limited. 
 
As a condition, it is usually associated with meaningful implication to 
patient. Even the mild self-limiting case has consequence for the patient 
puerperium in the form of fatigue, failure to breast-feed and possible need 
for haematinics or blood transfusion. Postpartum haemorrhage can 
transform a normal woman in labour to a critically ill patient within 
minutes. While a mild haemorrhage of 500 - 800 mL may not be serious 
for a healthy well nourished women; a mild haemorrhage can lead to 
disastrous consequences among women with chronic anaemia due to iron 
deficiency malaria or others parasites.   
 
1.2.5- Pharmacology of uterotonic drugs: 
 
Primary prevention of PPH through active management of the third stage 
of labour by the judicious use of oxytocics can prevent a considerable 
proportion of maternal deaths. Pharmacological manipulation of 
myometrial contractility is an intervention with benefit in the prevention 
of PPH. Hence, it is an essential component of medical education and 
training for all involved in maternity care. Myometrial contractility in 
pregnancy is mediated via two main hormonal groups: oxytocin and 
prostaglandins. The use of hormone oxytocin and its subsequent 
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pharmacological synthetic forms preceded that of prostaglandins by 
several decades. The original studies examining oxytocin did not address 
its link with any other hormonal group. It is now established that oxytocin 
and prostaglandins are interlinked and the final step in the role of 
oxytocin – induced uterine contractility involves a prostaglandin cascade.   
 
Three types of oxytocics are currently used in the management of third 
stage of labour; they are: oxytocin, ergometrine and the E & F type 
prostaglandins. 
 
1.2.5.1 –Ergometrine:  
The discovery of ergometrine and its subsequent use in the treatment of 
postpartum haemorrhage was a landmark in the history of obstetric care. 
In the 1920s, postpartum haemorrhage (PPH) was a common cause of 
maternal death in Ireland and the UK, accounting for 22% and 14% 
respectively, of those countries maternal mortality rates. This problem 
extended worldwide and in the years 1931-1934, 8% of total maternal 
deaths in one area of the USA were still caused by PPH (41). 
 
Chassar Moir carried out the initial studies on crude ergot and found, 
with Dudley (1935), that ergometrine was the substance responsible for 
the oxytocics effect of ergot (42). The introduction of this drug as a 
therapeutic agent to control haemorrhage was hailed as a major break-
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through in the obstetric field. Deaths from haemorrhage fell in Ireland 
from 23 in 1936, to none in 1983. During this period, there were of 
course, other factors such as increased availability of blood transfusions, 
improved antenatal care, and the improved state of nutrition and general 
health of the women, which may have contributed to the reduction in the 
mortality rate due to PPH. For example, the incidence of anaemia in the 
study hospital had fallen from 75% to 14.5% in the period 1955-1957 
following the introduction of oral iron supplements to all pregnant women 
and it has remained at a level of between 4% and 7% over the past decade 
1978-1987 (43, 44). 
 
Few obstetric practitioners would dispute that oxytocics drugs have 
played the greatest part in treating haemorrhage and reducing the 
mortality rate.  
 
However, once ergometrine was established as a useful drug in the 
treatment of PPH, it was gradually introduced as a method of prevention 
and many studies were carried out in the 1940s and early 1950s to 
ascertain the effects of prophylactic administration of the drug (45, 46, 47, 48). 
    
Mechanism of action:  
 
Two chemically different, although similar obstetric ergot were available: 
ergonovine maleate (ergometrine) and methylergonovine maleate 
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(methylergometrine). These agents are α1 adrenergic agonist that acts on 
the uterine smooth muscle through α adrenergic receptors. In contrast, to 
oxytocin the half-life is approximately 32 minutes and ergots are known 
for producing long sustained uterine contractions. Given intravenously its 
action starts within 30 seconds to 1 minute, given intramuscularly, effects 
are seen after 1-4 minutes.   
 
Unwanted effects:  
Ergometrine may produce nausea and vomiting. A rather more serious 
effect is an increase in blood pressure, which may continue for several 
hours. The unpleasant and occasionally dangerous effects of ergometrine 
have been documented in many studies. Nausea has been noted in 20% of 
women who had 0.25 mg of ergonovine and 13% and 32% respectively 
have had retching or vomiting following ergometrine 0.2 mg i.v. (49, 50, 51). 
Nausea and vomiting are especially severe when women have had 
epidural analgesia (52). Hypertension has frequently been noted following 
the administration of Ergometrine i.v. (49) i.m. Syntometrine causes less 
severe changes, due perhaps to a combination of the slower uptake of the 
intramuscular drug and the hypotensive effect of oxytocin (53, 54).  
 
Johnston studied the cardio-vascular effects of oxytocics drugs and found 
that ergometrine constricted the alpha and beta blood vessels (55). He 
suggested that this widespread vasoconstriction might precipitate 
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postpartum hypertension or pulmonary oedema in obstetric patients at 
risk (i.e those with toxaemia, chronic anaemia, cardiovascular or renal 
disease). This view was shared by Browing, Dommisse, McFdyen and 
Abouleish who separately presented evidence that use of ergometrine may 
contribute to postpartum eclampsia (56, 57, 58, 59). Intracerebral haemorrhage 
resulting in death had also been reported Ringros60). Ergot alkaloids can 
cause coronary artery spasm in susceptible people and pulmonary oedema 
has been seen in cardiac patients (61, 62). Cases of cardiac arrest following 
i.v injection of ergometrine have been described, possibly due to the 
depression of the sinoatrial node, which has been demonstrated following 
i.v. injection of 0.5 mg of ergometrine (56, 63, 64). 
 
1.2.5.2 – Oxytocin: 
The knowledge and work on the role of oxytocin date back a century. In 
1906, Sir Henry Dale noted that posterior pituitary extract could induce 
uterine contractions and in 1909, Blair Bell showed that this extract could 
be used to treat the PPH in women with uterine atony. In 1953, Du 
Vigneaud, was able to synthesize an octapeptide containing the hormonal 
activity of oxytocin(65). 
 
Oxytocin increases free intracellular calcium in the myometrial cell and 
thereby promotes myometrial contractions. The half-life is relatively short 
approximately 3 - 5 minutes and the agent is metabolized primarily 
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through the renal system. Oxytocin in closely related to antidiuretic 
hormone and may produce water intoxication. Oxytocin should not be 
given intravenously as a large bolus because it has been shown to be 
associated with transient but significant fall in blood pressure by decrease 
in cardiac output. 
 
Embrey et al, subsequently, reported the advantages of combining this 
with ergometrine as syntometrine, the value of which was claimed to 
combine the rapid effect of oxytocin and the sustained effect of 
ergometrine (66). A few years after introduction of syntometrine in the UK, 
it became routine practice to administer this combined preparation 
prophylactically, usually in association with controlled cord traction to 
deliver the placenta. 
 
1.2.5.3- Prostaglandins: 
There are was substantial work done to characterize the cascades of 
hormonal events in the third stage of labour. Essential to this task was the 
development of sensitive prostaglandins assays. The very low serum 
concentration and short half-life of the prostaglandins have led to the use 
of surrogate measures such as prostaglandins metabolites to understand 
some of the changes that characterize this stage of labour.  
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Prostaglandins rise gradually in the first stage of labour, steeply in the 
second stage of labour and reach a peak immediately before and after the 
delivery of the placenta. With frequent serum sampling, Noort et al 
showed that the plasma prostaglandins F metabolite levels at placental 
separation were significantly higher than at full cervical dilatation and 
that the levels were highest 5 minutes after placental separation. 
Thereafter, the levels rapidly declined to full dilatation levels by 30 
minutes and were significantly below early labour levels by 3 hours 
postpartum67. 
 
The changes in oxytocin levels appear to run parallel to those of the 
prostaglandins, although there are minor differences. Within minutes of 
crowning of the foetal head, endogenous oxytocin levels reach a peak and 
plateau until the delivery of the placenta when they starts to decrease. It is 
established that there is an interaction between oxytocin and 
prostaglandins at this time, but the exact mechanism of this is unknown 
(68).  
 
Prostaglandins (PG) augment oxytocin-induced myometrial contractions 
in both humans and animals (69). This synergism forms the basis of current 
clinical practice in the induction of labour. Their role in induction of 
labour and treatment of PPH is now well established. 
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Prostaglandins, another class of uterotonics encompass one branch of a 
large family of agents that are bases of 20 carbons polyunsaturated fatty 
acids their basic mechanism of action is to increase free intracellular 
calcium thus promoting uterine contraction The endogenous 
prostaglandins tends to have short half-life; synthetic agents have a longer 
half-life.  
 
The prostaglandins used in obstetrics are dinoprostone (PGE2), dinoprost 
(PGF2α), sulprostone, and PGE1 analogue known as misoprostol. They 
can be administered intravenously, orally or in a form of pessaries per 
vagina. The use of prostaglandins in the third stage of labour was a logical 
extension of its success in the induction of abortion and initiation of 
labour.  
 
The sustained myometrial contractility associated with prostaglandins is 
well suited for the management of the third stage of labour and its 
complication.   
 
Karim et al were the first to confirm the important role of prostaglandins 
in the induction of regular uterine contractility 70. In 1969, 
Bygdemannsuggested that prostaglandins had potential in the 
management of uterine atony 71). Subsequently a randomized study by 
Takagi et al compared the effect of intra-myometrial injection of PGF2α 
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to its systemic administration in the treatment of postpartum haemorrhage 
and shown that the intra-myometrial route of administration was more 
efficient although unsuitable for routine use in the management of third 
stage of labour (72). However, the short duration of action of natural 
prostaglandins, and thus the need for repeated injection, coupled with a 
high incidence of side effects, prompted the development of methylated 
prostaglandins derivatives.  
 
The success of prostaglandins derivatives PGF2 15 methylester 
tromethamine salt in the treatment of postpartum haemorrhage reported 
in the observational trials has formed the basis of prostaglandins 
analogues in the treatment of PPH secondary to uterine atony. This was 
soon followed by other PG analogue investigated in the treatment of PPH 
including the E2 and E1 analogues. 
 
1.2.6- Misoprostol a new oxytocic:  
Over the last few years, a PGE1 analogue, misoprostol, has transformed 
the medical management of postpartum haemorrhage. The discovery of 
misoprostol was in the early 1970S as synthetic analogues of PGE1 (73). 
This drug marketed as a tablet has a gastric anti-ulcer activity that 
provides significant protection against gastric lesions. It was found to be 
free of side effects other than those on the gastrointestinal tract if given in 
a reasonable dose. Misoprostol is an uterotonic that can increase the 
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amplitude and frequency of uterine contractions and has been studied for 
both prevention and treatment of postpartum haemorrhage. This drug is 
an appealing agent that does not requires especial storage and has a long 
shelf life of several years. Unlike other uterotonic agent, it can be used in 
tropical countries where the majority of maternal death is secondary to 
postpartum haemorrhage.  
 
Misoprostol is given by one of three routes: orally, vaginally, or rectally 
when used in obstetric practice. The pharmacokinetic of the three 
modalities of administration of misoprostol were studied and defined. 
    
Misoprostol after oral administration is rapidly absorbed and deesterified 
to its acid. Miriam Zieman et al conducted study to characterise the 
pharmacokinetic of misoprostol after oral administration in a group of 20 
women: 10 women were pregnant and 10 non-pregnant. In all subjects 
receiving oral misoprostol, the plasma concentration of the drug rose 
quickly, peaked between 12.5 and 60 minutes (34±17 minutes) after 
administration, fell steeply by 120 minutes 74. 
 
Administration of misoprostol by the rectal route in the third stage of 
labour may allow the drug to be absorbed without being washed away 
and may avoid the adverse effects associated with the oral route. Rehan-
Uddin et al had conducted a study to characterise the pharmacokinetic of 
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rectally administered misoprostol in the group of 20 women. The studied 
subjects were pregnant women (20) randomly allocate to receive rectal 
misoprostol (10 women) or oral misoprostol (10 women) after delivery. In 
all subjects receiving rectal misoprostol, the serum concentration of 
misoprostol acid rose gradually reached a maximum level between 15 and 
60 minutes (mean = 40.5 minutes), decline slowly and by 240 minutes 
after administration reached its lowest level. In contrast, after 
administration of misoprostol orally; serum concentration of misoprostol 
acid rose quickly, peaked between 7.5 and 30 minutes (mean = 18 
minutes) after administration, fell steeply by 60 minutes and then 
remained low. In this study, the researcher had found that rectal 
misoprostol has a lower peaked serum concentration and longer half-life 
than oral misoprostol. The longer half-life of rectally administered 
misoprostol could prolong uterine contraction thus preventing a delayed 
haemorrhage, and may be more important than the peaked concentration 
levels. The bioavailability of the drug via the two routes is similar. The 
authors had reported that the levels of misoprostol free acid in the 
circulation at 7.5 minutes, as well as peak misoprostol free acid levels, 
were much higher in the oral group, and the duration to maximum drug 
concentration was longer in the rectal arm 75.  
 
These two findings might indicate a potential advantage for oral 
administration, but because the threshold serum level leading to clinical 
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effects is unknown and may be low, the absolute serum levels may not 
necessarily be associated with quantifiable clinical superiority. 
 
The postpartum intrauterine pressure of the uterotonic effects of oral 
misoprostol was compared with the effect of intramuscular syntometrine.  
A small study by El-Refaey in 199identified the very rapid change in 
uterine contractility in response to oral and vaginal misoprostol. The 
study showed that misoprostol administered by these routes is not only 
absorbed promptly but can also have a considerable impact on uterine 
contractility in minutes. El-Refaey et al later considered its use in the third 
stage of labour(11).   
 
Chong et al has conducted a study to investigate the effect of oral 
misoprostol in dosage varying from 200 to 800 µg on postpartum uterine 
contractility following normal vaginal delivery and compared these with 
the effect of intramuscular syntometrine 1 mL (76). They used a calibrated 
Gaeltec cathether, with an intrauterine pressure transducer at its tip 
inserted transcervical into the uterine cavity until the tip of the cathether 
could be felt to impinge on the fundus of the uterus. The catheter was then 
secured in place and connected to a Sonicaid; and uterine activity. 
Contraction was recorded automatically. However, the use of Cathether-
tip pressure transducers have been used to measure uterine activity in the 
third stage of labour reliably and safely in various studies. 
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The researchers after testing oral misoprostol at different dose (200, 400, 
500, 600 and 800 µg) compared to syntometrine had concluded that no 
difference was observed of the uterotonic effect of these drugs on the 
postpartum uterus. Oral misoprostol at a dose 200 and 400 µg had definite 
uterotonic effect that is not statistically different to intramuscular 
syntometrine; and less side effects than higher dose of misoprostol. 
Therefore, the safe oral dose of misoprostol would seem to be at 200 to 
400 µg. The authors had reported a slower onset action for oral 
misoprostol than that of syntometrine; but the duration of action of both 
drugs is similar. The critical period in the occurrence of PPH following 
uterine atony is within the first 10 min to delivery of the neonate. 
Therefore, oral misoprostol may effectively induce uterine contractions 
strong enough to prevent PPH as effectively as syntometrine.  
  
 1.2.6.1- Side effects and complications of the oral misoprostol : 
Shivering in association with normal delivery is well known by all 
obstetricians. A certain number of parturient present a shivering 
phenomenon during or, more often immediately after childbirth. 
Bruniquel had considered several possible explanations for this; and 
finally, came out with the conclusion that the most plausible pathogenic 
factor would be the penetration of amniotic fluid into the maternal 
circulation during labour (77). Several authors have reported this 
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phenomenon during the use of misoprostol in the management in the 
third stage labour. El-Refaey et al first reported shivering in association 
with the use of misoprostol in the third stage12. This was a prospective 
observational study including 237 consecutive women, who received 600 
µg of oral misoprostol and 60% of them had experienced shivering.  
 
Hofmeyr et al in a randomized placebo controlled trial of 400 µg oral 
misoprostol including 500 women indicated that shivering was the only 
significant side effect of misoprostol(78). 
 
In the pilot dose-finding trial conducted by Lumbganon et al before the 
initiation of the main WHO trial, shivering was found to be a dose related 
side effects of oral misoprostol79. Shivering was observed in 28% and 19% 
of women who received 600 µg and 400 µg of oral misoprostol 
respectively during the first hour after delivery. The relative risk of 
shivering with 600 µg misoprostol was 1.5 (95% CI 1.0 to 2.1) when 
compared with 400 µg misoprostol.  
 
Subsequently, the WHO trial that constitute the largest multicentre trial 
that tested 600 µg of oral misoprostol to oxytocin had confirmed that 
misoprostol was associated with a significantly higher incidence of 
shivering (RR 3.48 95% CI [3.15-3.84]) (13). Similarly, shivering was 
reported in almost all clinical trials that tested oral misoprostol to 
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conventional oxytocics or to placebo (12, 79). Detection and grading of 
shivering is to a large extent, subjective. However, shivering is more of a 
nuisance than a clinically serious morbidity. For same authors, this could 
adversely affect the use and acceptability of misoprostol. It is reassuring 
that despite the high incidence of observed shivering with misoprostol; 
this is dose related and mostly mild shivering. Only, very small number of 
parturient had necessitated treatment for the shivering (79). 
 
Body temperature regulatory mechanism: 
The reflex and semireflex thermoregulatory response in human include 
autonomic, somatic, endocrine and behavioural changes. This 
thermoregulatory adjustment involves local response as well as more 
general reflex responses. One group of responses include increase heat 
loss and decrease heat production. 
 
*     Pyrexia  
Pyrexia, defined as body temperature between 38°C and 40°C, appear 
most significantly with the use of oral misoprostol. In clinical studies, the 
temperature increase following misoprostol administration is relatively 
common (80). Creinin et al reported fever or chills in 31% of women 
undergoing first trimester abortion after vaginal misoprostol (81). 
Herabutya and O-Prasersawat reported pyrexia in 28% of women with 
600 µg, 2% with 400 µg and none with 200-µg misoprostol, in a trial of 
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second trimester abortion (82). Pyrexia after administration of misoprostol 
for induction of labour has been reported in a small proportion of women 
(< 3%) in some studies and not reported in others (83, 84).   
 
Pyrexia has been identified as adverse effects associated with the use of 
oral misoprostol for the third stage labour (12). The reported incidence of 
fever ranged between 3.8% (85) to 22% (86) and 34% (87) Misoprostol induced 
fever is of the interest in terms of possible prostaglandins related 
mechanism and the relevance to thermoregulatory physiology. Stobie-
Hayes KM et al reported that pyrexia is a centrally mediated 
prostaglandins E1 effect(88). For the same authors, these side effects may 
constitute a handicap to the use of misoprostol in the third stage of labour. 
However, Çaliskan et al 85report that these side effects were well tolerated 
and seemed to be dose related consistent with the original finding of El-
Refeay et al 12. These fever were accentuated while parturient were on 
epidural anaesthesia. Temperature rise recorded was usually of 0.5° C. 
However, in a randomized clinical trial, Lumbiganon et al reported 2 
cases of temperature above 39°C and none above 40°Camong 189 
parturient who received 600 µg oral misoprostol 87. 
 
1.2.6.2- Others side effects associated the use of oral misoprostol: 
In most of the trial of misoprostol for the third stage, side effects other 
than shivering and pyrexia were not reported because information were 
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collected within 1 hour after delivery. In the study of Lumbiganon et al, 
where the period of observation was extended to 24 hours after 
administration of oral misoprostol: nausea, vomiting and diarrhoea were 
reported in addition to shivering and pyrexia. In this study, about 5% of 
the women treated with misoprostol reported diarrhoea in the interval 2 - 
6 hours. This diarrhoea was not severe and all ceased by 12 hours 89.   
 
 1.2.6.3- Side effects and complications of rectal misoprostol:  
Shivering and pyrexia occur more frequently in women who were treated 
with misoprostol either oral or rectal when compared with women who 
were treated with parenteral oxytocics. Bamigboye et al in earlier trial of 
rectal misoprostol versus no treatment had reported 2.9% of shivering in 
the group of misoprostol90.  
 
For Diab et al in a comparative study of rectal misoprostol (400 µg) versus 
Oxytocin – Ergometrine, the quoted incidence of shivering was 7.21% and 
11.4% for vomiting, nausea and diarrhoea in the misoprostol 
group91.Meanwhile, in the control group no such side effects were 
reported. Subsequently, Çaliskan et al (2002) had reported an incidence of 
shivering: 11.8%, hyperthermia: 4.4% and diarrhoea: 2.7% in a group of 
subject treated with rectal misoprostol 400 µg92 
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1.2.7- Management of the third stage of labour: 
 
Postpartum haemorrhage is known as the most common cause of 
maternal mortality and serious morbidity especially in the developing 
world, accounting for approximately half of the 600.000 maternal deaths 
per year (93). Effects on maternal morbidity are less well documented but 
are likely to include such inter-related outcome as anaemia, fatigue and 
depression. 
 
Postpartum haemorrhage is a true obstetric emergency. A study in Egypt 
found that 88% of deaths from PPH occur within four hours of delivery 
(94Therefore, fast and vigorous treatment and proactive preventive 
management strategies are essential to face case fatalities from PPH. 
Concept of active management of the third stage of labour has been 
introduced with the aim of reducing the risk of PPH and its consequences. 
Active management of the third stage of labour, when performed 
routinely have been shown to reduce the risk of postpartum haemorrhage 
(maternal blood loss >500 mL and severe maternal blood loss >1000 mL) 
(95). 
 
However not all maternity units practice this active approach for 
reduction of PPH. Hence, as an alternative to active management some 
clinicians advocate using the expectant management of the third stage of 
labour. Most research of the third stage of labour has centred on 
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identifying which approach is superior: active or expectant management. 
Advocacy of active management is based on the assumption that a 
shortened third stage is associated with less overall postpartum blood loss.  
Advocacy for expectant management has a paradigm that considers 
normal physiology as best and is cautious about iatrogenic pitfalls. The 
debate is not a simple debate between two interventions but about two 
approaches, each composed of several interventions. 
 
1.2.7.1- Expectant management of third stage of labour: 
Expectant management of the third stage of labour is a passive or a 
physiologic approach that involves waiting for signs of placental 
separation and allowing the placenta to deliver spontaneously or aided by 
gravity or nipple stimulation. This approach is popular in some northern 
European countries and in some units in the USA and Canada. It is also 
the usual practice in domiciliary confinements in the developing world. 
 
 1.2.7.2- Active management of third stage of labour : 
All the strategies to prevent excessive blood loss after delivery revolve 
around enhancing the natural contractions of the postpartum uterus, and 
shortening the duration of the third stage. The principle behind active 
management is to hasten and augment uterine contraction and retraction 
at and after delivery of the baby and the placenta, in order to reduce 
postpartum blood loss due to uterine atony. 
 36
 
Active management of third stage of labour was defined as a package of 
interventions comprising: (i) administration of prophylactic oxytocics 
drug during or after delivery of the baby; (ii) early cord clamping and 
cutting; (iii) deliver of the placenta by controlled cord traction (96). 
 
In 1988, W. Prendiville and Elbourne (97) analysed data derived from eight 
prospective controlled trials in which a policy of routinely administered 
oxytocic drugs prophylactically to reduce the risk of postpartum 
haemorrhage has been compared with either placebo group or non routine 
prophylactic. They had also assessed whether routine use of oxytocics 
administration reduces the need for further oxytocics administration and 
whether it increases the incidence of retained placenta and need for 
manual removal. They had also considered the extent of side effects 
resulting from the use of oxytocics. Their analysis supported the 
hypothesis that routine use of oxytocis in association with management of 
the third stage of labour reduces the risk of postpartum haemorrhage and 
the need for administration of oxytocics later, but it increases the risk of 
increased blood pressure (97). 
 
Prendiville et al summarized five major trials exploring active versus 
expectant management in the Cochrane Database of Systematic Reviews-
2000 (98). The five trials were named according to their geographic sites, 
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namely Abu Dhabi, Brighton, Bristol, Dublin, and Hinchingbrooke. In 
general, the results were very similar among all the five trials. When 
active management techniques were used, maternal blood loss was 
reduced by an average of 79.33 mL (95% CI – 94.29 - 64.37), and the 
length of third stage was decreased by an average of 9.8 minutes (95% CI 
10.00 – 9.52). Among the other findings were a consistent decreases in the 
risk of postpartum haemorrhage, postpartum anaemia, and need for 
therapeutic oxytocics. 
 
Studies had also been conducted in low-resource settings to test this 
evidence, in these parts of the world where women die in large numbers 
from postpartum haemorrhage. A retrospective study from Ghana 
compared active versus expectant management in a rural setting at Holy 
Family Hospital in Berekum(99). They performed a chart review of 5088 
birth records from women who delivered between 1992 and 1993 when 
expectant management was routine, compared with 3840 records from 
women who delivered from 1996 to 1998 after the introduction of active 
management as the standard of care. The study found that PPH (blood 
loss ≥ 500 mL) occurred less often in the actively managed group (odds 
ratio, 0.8; 95% confidence interval (0.7-0.9). This study yields a number 
needed to treat of 27, which means that 27 women would have to be 
actively managed to avoid one case of PPH. They recommended active 
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management as a strategy to reduce PPH in rural hospital in developing 
countries. 
 
McCormick et al published a systematic review of study that assessed the 
effect of active management of the third stage of labour in low-resources 
setting. Active management reduces the incidence of PPH; decrease the 
need for blood transfusion, reduces the incidence of prolonged third stage 
of labour (< 30 minutes), and decreases the need for additional uterotonic 
drugs100. The study concluded that active management of the third stage 
of labour should be expanded to developing countries, as an effective, 
inexpensive intervention to prevent postpartum haemorrhage.  
 
Festin MR et al in an international survey on variation in practices of the 
management of the third stage of labour had concluded on the benefits of 
this policy. This had been disseminated through various sources, 
including the Cochrane Collaboration and the WHO Reproductive 
Health Library (93).  
 
Recently, the International Confederation of Midwives (ICM), and the 
FIGO, who are key partners in global Safe Motherhood efforts had given 
an international joint policy statement, “that active management of the 
third stage of labour should be offered to women since it reduces the 
incidence of PPH due to the uterine atony. That every attendant at birth 
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need to have the knowledge skills, and critical judgment to carry out 
active management of the third stage of labour as well as access to 
required supplies and equipment”(101). 
 
One of the key components of active management is the use of oxytocics 
agents, which have been shown to be particularly effective in reducing 
maternal blood loss associated of PPH.  
 
1.2.7.2.1- Comparison of oxytocic: Ergometrine versus syntometrine: 
In 1963, Embrey et al (66) compared the use of i.m. ergometrine with i.m. 
syntometrine (ergometrine combined with oxytocin), both given on 
delivery of the baby’s anterior shoulder. They reported a decrease in the 
PPH rate using syntometrine, with no increase in the rate of retained 
placenta. This rapidly became the drug of choice in the UK and to some 
extent in Ireland also. The majority of midwifery and obstetric textbooks 
recommend the routine use of an oxytocics drug, given with the anterior 
shoulder or during the third stage of labour, and syntometrine is especially 
mentioned in some of these (102, 103).  
 
A recent overview (104) of controlled trials comparing combination of 
ergometrine and oxytocin concluded that the unwanted side effects of 
ergometrine were such that it was no longer justifiable to use ergometrine 
routinely in the management of the third stage. They further suggested 
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that the prophylactic use of syntometrine is as effective as ergometrine, 
with reduced side effects, and more effective than oxytocin in reducing 
PPH.  This emphasise the need for further controlled studies in their area. 
 
Prendiville reported that the advantage of the routine oxytocics policy 
must be considered together with the rare but serious morbidity, which 
has sometimes been attributed to oxytocics administration. Maternal 
deaths from cardiac arrest and intracerebral haemorrhage have been 
attributed to ergometrine as have non-fatal instances of cardiac arrest and 
myocardial infarction, postpartum eclampsia and pulmonary oedema in 
cardiac patients as a result of the venous vasoconstriction, which is known 
to occur with ergometrine. On balance, the known benefits of routine 
oxytocics administration outweigh the likely risks in women who are not 
at increased cardiovascular risk. 
 
1.2.7.2.2- Comparison of oxytocics: oxytocin versus Syntometrine:   
The two most commonly used parenteral oxytocics agents for the third 
stage of labour are syntometrine and oxytocin.  
Elbourne et al (1988) analysed six papers comparing the choices of 
oxytocics preparations with each other in term of effect on postpartum 
haemorrhage and on unwanted effects such as hypertension (104).  
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When syntometrine was compared with oxytocin alone, it was found that 
syntometrine is superior in reducing the risk of postpartum haemorrhage. 
In contrast, Docherty et al found a higher mean blood loss in the 
syntometrine groups than in the oxytocin group 184 mL versus 99 mL 
(105). The length of the third stage was only considered in one trial. The 
risks of prolonged third stage (> 30 minutes) were reduced with 
syntometrine, although retained placentas were more common after using 
this preparation. Dumoulin reported that the incidence of manual 
removal of the placenta did not differ significantly between the two 
experimental groups (106). More recently, Pong Mo Yuen et al had 
conducted in Prince of Wales Hospital (Hong Kong) a randomized 
double blind study where 1000 women allocated to receive either 10 IU of 
oxytocin or syntometrine. The researchers had confirmed through this 
study, that syntometrine is associated with a significantly lower blood loss 
when used during the third stage of labour (107).  
 
Again, the risk of primary PPH was significantly decreased by 40% with 
syntometrine joining similar figure reported by Nieminen and Jarvinen 
(108) and Dumoulin (106). There was no difference in incidence of blood 
transfusion and drop in haemoglobin level. The need for additional 
oxytocics was reduced by 40% in the syntometrine group. No difference 
in the incidence of high blood pressure was observed in the both groups. 
The authors suggested that syntometrine constitute a better choice than 
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oxytocin in the management of the third stage of labour. On going studies 
at that time were carried on as which parenteral oxytocics (oxytocin 
versus syntometrine) constitute a better prophylaxis in the management in 
the third stage of labour.  
 
Hence, Quadir Khan et al in the Abu Dhabi third stage trial have 
compared the effect of oxytocin and syntometrine when used as part of 
active management of third stage of labour on PPH, hypertension, 
nausea, vomiting, and retention of placenta. A total of 2040 women were 
randomly allocated either to oxytocin (n=1017) or syntometrine 
(n=1023). The main outcome of this study is that oxytocin is as 
efficacious as syntometrine in preventing PPH both moderate (≥ 500 mL) 
and severe (> 1000 mL). Postnatal haemoglobin, haematocrit, and the 
need for blood transfusion were similar in both groups. However, 
syntometrine had shown three-fold increase in nausea, vomiting and 
headache. Both mean systolic and diastolic pressure were higher in the 
syntometrine group. These authors had deduced the efficacy of oxytocin 
10 IU in preventing PPH, without the ergometrine side effect of nausea, 
vomiting or headache (109).  
 
Suzan McDonald et al have compared intramuscular oxytocin alone and 
intramuscular ergometrine plus oxytocin (syntometrine) for their effects in 
reducing the risk of PPH. The setting was two metropolitan teaching 
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hospital in Perth, Western Australia and the study was double blind 
randomised controlled trials concerning 3693 women (oxytocin n = 
1953); syntometrine (n=1730). The primary outcome, the rate of PPH (≥ 
500 mL or ≥ 1000 mL) was reported to be similarly distributed in both 
arms. However, nausea, vomiting and increase in blood pressure were 
prominent side effect of oxytocin – ergometrine making few advantages 
but several disadvantages for the routine use oxytocin – ergometrine as 
prophylaxis in active management of third stage of labour (110).  
 
Most of the clinical trials had tested intramuscular syntometrine versus 
oxytocin 10 IU intramuscular. Nevertheless, few trials had compared 
intramuscular syntometrine with intravenous oxytocin. Hence, Choy et al 
had conducted randomized trials of oxytocin IV (10 IU) versus 
syntometrine and a total number of 991 women with singleton pregnancy 
were reported. There was no difference in the incidence of PPH, need for 
repeat oxytocics injection or delayed haemorrhage. Mean haemoglobin 
change in the second day postpartum, need for blood transfusion and 
manual removal of placenta were similar in both groups. However, also 
the incidence of nausea, vomiting, and headache were similar in both 
groups, more subjects who receive syntometrine had experienced 
hypertension (111).  
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The authors claimed a superior prophylactic effect of intravenous over 
intramuscular oxytocin, related to early onset of action of intravenous 
administration; as suggested by Soriano et al (112). One of disadvantages of 
using oxytocin intravenously in the management of the third stage of 
labour is the requirement of an intravenous access that may not always be 
available especially in the developing countries. According to these 
authors, intravenous oxytocin is particularity beneficial in patients with 
hypertensive disorder as it is less likely to cause hypertension. 
 
The therapeutic choice between the two oxytocics agents to be used in the 
third stage of labour therefore rest on the trade- off between the benefits 
against the disadvantages. Since the prevention of a maternal death from 
postpartum haemorrhage is considered a fair price to pay for experiencing 
nausea, vomiting and hypertension, syntometrine is now routinely used in 
most developed countries (113). 
 
 However, when syntometrine is stored for prolonged periods of time, it 
must be kept at between 2° and 8° C and protected from light. The 
ergometrine component of syntometrine has been found to be susceptible 
to 21-27% loss in potency after 1 month when stored under conditions 
simulated to those similar to tropical countries in the developing word. 
Conversely, oxytocin has been found to be more stable when stored under 
such similar conditions. There was little difference in cost between theses 
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two oxytocics. The better stability and equal cost of oxytocin over 
syntometrine has therefore limited the more wide spread use of the later 
drug for the third stage of labour in developing countries. 
 
1.2.8- Others uterotonics agents used for prevention of 
primary postpartum haemorrhage: 
 
Beside the injectable oxytocics and ergot alkaloids and misoprostol, used 
by proponents of the active management of the third stage of labour, other 
pharmacological alternatives have been tried with varying degrees of 
success. 
 
1.2.8.1- Intraumbilical uterotonic agents: 
 
In 1987, the first report of a randomized, double blind placebo-controlled 
trial was published on the influence of umbilical vein administration of 
oxytocin on the third stage of labour (114). Two placebo-controlled trials 
showed that intraumbilical oxytocin was effective in decreasing the length 
of the third stage of labour but not the blood loss (115).  Nonetheless, from 
the existing evidence it would appear that the routine use to intraumbilical 
oxytocin for the prevention postpartum haemorrhage is questionable, 
although its use for the management of retained placenta may be 
promising (116). 
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1.2.8.2- Injectable prostaglandins: 
The uterotronic activity of prostaglandins is well known. In a randomized 
controlled study, the prophylactic use of intramuscular prostaglandins 16- 
methyl F2α in the active management of the third stage of labour gave 
similar results to prophylactic intramuscular syntometrine in terms of 
length of the third stage of labour, incidence of PPH and total blood loss 
after delivery. It had the disadvantage however, of higher cost, as well as a 
statistically significant increase in the incidence of profuse diarrhoea (117). 
Gülmezoglu in Cochrane reviews in 2000 (118) had analysed 7 RCT that 
used prostaglandins as prophylaxis for PPH. The result included a 
number of statistically significant findings. When the use of any 
prostaglandins was compared to use of any others uterotonics, there was 
statistically significant decrease in blood loss : 69.7 mL (95% CI -92.5-
67.0) and when a group receiving any prostaglandins was compared to a 
group lacking any uterotonics the blood loss averaged a decrease of 224 
mL (95% CI -27.6-420.3). But, when compared to any others uterotonics 
there were more side effect in the group of prostaglandins, particularly 
vomiting, diarrhoea and abdominal pain. Gülmezoglu concluded that 
risks and benefits should be considered. Subsequently, in another 
Cochrane reviews in 2002, these authors had analysed 17 misoprostol and 
8 intramuscular prostaglandins trial; and shivering and elevated body 
temperature (> 38°C) were reported as the main side effects of 
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misoprostol and was dose related.  Compared to oxytocin, the RR of any 
shivering with 600 µg oral misoprostol is 6.76 (95% CI 5.95-8.57) (119).    
 
Injectable prostaglandins are associated with reduced blood loss in the 
third stage when compared to conventional uterotonic. The safety and the 
current cost of PGF2α and PGE2 may limit suitability for routine 
prophylactic management of the third stage of labour. Prostaglandins 
should continue to be used for treatment for postpartum haemorrhage 
when others measure fails.  
 
1.2.8.3- Carbetocin: 
The uterotonic activity of carbetocin, a long-acting oxytocin receptor 
agonist, was first described in 1987 (120). Carbetocin has shown a more 
prolonged uterine activity compared to oxytocin; that constituted 
advantages in the management of the third stage of labour. Its innocuous 
side-effect profile may also prove to be advantageous when compared to 
syntometrine. In a Canadian multicentre double blind, randomized 
clinical trial of patients undergoing elective caesarean section a single 100-
µg intravenous injection of carbetocin appeared to be more effective than 
a continuous infusion of oxytocin in maintaining adequate uterine tone 
and preventing excessive intraoperative blood loss during caesarean 
section (121). Carbetocin was well tolerated with a similar safety profile to 
oxytocin. Boucher M. et al had assessed the efficacy of carbetocin single 
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dose 100µg im compared to 10 IU oxytocin intravenous infusion in 
reducing of PPH in women at low risk (122).  
 
A single im carbetocin was found to be more effective in preventing PPH 
than continuous oxytocin infusion. Because of its relative lack of adverse 
effects, carbetocin may offer advantages when compared to syntometrine 
and others alkaloids. Its cost appears to be the limiting factor for its use in 
the prevention of PPH.  
 
1.2.8.4- Oral ergometrine and methylergometrine: 
Oral ergometrine and methylergometrine were considered as possible 
alternatives to conventional oxytocics as they are easy to administer. Both 
these oral drugs are known for their strong uterotonic effects, and for their 
relatively slight vasoconstrictive properties. Unfortunately, both are 
unstable even when stored under refrigerated conditions. Their 
pharmacokinetic and dynamic properties are unpredictable and no clinical 
effect on reduction of blood loss after childbirth has yet been shown (123). 
In a comprehensive review by de Groot et al, it was suggested that because 
of their unreliability, they had no place as routine prophylactic uterotonic 
agents (124). 
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1.2.8.5- Sublingual oxytocin: 
The bioavailability and pharmacokinetics of sublingual oxytocin were 
assessed by De Groot et al in a small number of patients. The study 
showed great inter-individual variability in bioavailability. It was 
concluded that the sublingual route of administration of oxytocin, with its 
long lag time and absorption half-life, did not seem a reliable route for the 
routine prevention of postpartum haemorrhage (125). 
 
In summary, the quest for the best uterotonics continues. It is not simply 
an academic exercise especially in areas of limited resources (10). In the 
USA today, oxytocin is generally chosen instead of syntometrine while in 
UK, syntometrine is preferred for prophylaxis in the third stage of labour. 
Ultimately, prostaglandins may displace them both, especially if future 
evidence finds that a stable, inexpensive agent is the most effective and 
safe. 
 
1.2.9- Misoprostol a novel prostaglandin for prevention of 
PPH :  
 
? Use of oral misoprostol in the prevention of PPH: 
The first report of misoprostol for prevention of postpartum haemorrhage 
was a prospective observational study conducted by El-Refaey et al that 
evaluated the incidence of PPH in 237 consecutives women undergoing 
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vaginal delivery (12). Postpartum haemorrhage was defined as an estimated 
blood loss of ≥ 500 mL. After receiving oral misoprostol 600 µg, 6% of the 
women had an estimated blood loss ≥ 500 mL. No participant had blood 
loss > 1000 mL.  
 
Surbek et al in a double blind placebo controlled trial had evaluated 600 µg 
of oral misoprostol for efficacy in the prevention of PPH in 65 participants 
(126). Blood loss estimated by attending physician was significantly reduced 
in the misoprostol group compared with placebo (345 ±19.5 mL versus 
417±25.9 mL, p= 0.31). However, the rate of PPH was not significantly 
different between the two groups (p=0.43) in addition more women in the 
placebo group require oxytocics therapy.  
 
The mean drop of haemoglobin concentration and haematocrit was 
smaller in the group in misoprostol. Only, shivering was reported in 
higher percentage in the group of women treated with misoprostol 22% 
compared with 3% of those randomized to placebo (p=0.023). 
 
Amant et al had examined the efficacy of orally administered misoprostol 
600 µg with intravenous methylergometrine 200 µg in 200 women (87). The 
main outcome in the study included rate of PPH, need for additional 
oxytocics and incidence of adverse effects within 1 hour to delivery. There 
was not statistically significant difference between subjects who received 
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methylergometrine or misoprostol with regard to estimated blood loss > 
500 mL (4.3% versus 8.3% respectively, p= 0.57). However, misoprostol 
treated subjects needed more additional oxytocics than those randomized 
to methylergometrine (12.8% versus 4.4% respectively, p= 0.65). 
Interestingly, there was no significant difference between treatment group 
in terms of mean haemoglobin concentration and haematocrit on the third 
day postpartum. Shivering and pyrexia had occurred more in the group of 
misoprostol compared to methylergometrine (40% versus 8.2% and 34% 
versus 3%, p=0.0001) for these investigators, misoprostol may be effective 
in prevention of PPH when used in combination with conventional 
oxytocics.  
 
In a multicentre clinical trial, Cook et al compared the efficacy of 
misoprostol with conventional uterotonic; the study consisted of 863 
women assigned to either oral misoprostol 400 µg or to conventional 
oxytocics. This study was not blind and was not restrictive to women at 
low risk of PPH (127).  
 
Blood loss was both estimated and measured and postpartum 
haemorrhage (blood loss > 500 mL) had occurred more in the group of 
misoprostol compared to oxytocics (15% versus 6% RR=2.72, 95% CI 
1.73-4.27). However, the incidence of severe PPH (blood loss >1000 mL) 
was similar in both groups. Shivering was the main side effects reported in 
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the group of misoprostol (19% versus 7%, RR 2.64, 95% CI (1.78-3.91). 
These authors concluded that misoprostol is not as efficacious as 
conventional therapy in the prevention on the PPH.  
 
In a subsequent trial conducted by El-Refeay et al to evaluate the efficacy 
and safety of misoprostol compared with conventional therapy, 1000 
participants were enrolled (128). Participants were randomized either to oral 
misoprostol 500 µg or to conventional oxytocics (syntometrine 80% of 
participants, oxytocin 18% and ergometrine 2%). The attending midwife 
or obstetrician estimated blood loss to occur in 12% of women given 
misoprostol and 11% of women given standard oxytocics (RR 1; 95% CI 
0.79-1.55). Blood loss of 1000 or more occurred in 2% in each group. The 
main side effects were shivering and rise in temperature. Others reported 
side effects were nausea, headache, dizziness that occurred more with 
syntometrine. For these authors, misoprostol and standard oxytocics were 
equally efficacious in prevention of PPH, but side effects of fever and 
shivering occurred more frequently with misoprostol (128). 
 
In a double blind prospective controlled trial designed by Walley et al in 
Ghana, 400 µg of oral misoprostol were compared with oxytocics 10 IU 
IM. The study population consisted of 400 low risk women the primary 
endpoint was change in haemoglobin from base line to 12 hours 
postpartum.  
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Secondary endpoints included estimated blood loss, need for additional 
oxytocics and the occurrence of adverse drug event. Change haemoglobin 
concentration was not significantly different between treatment groups: 
0.6 g/dl versus 0.55 g/dl in the group of misoprostol and oxytocin 
respectively. Similar results among treatment group were obtained in 
terms of estimated blood loss and additional oxytocics; no blood loss > 
1000 mL was recorded. Shivering was the main side effect that was 
recorded in the group of misoprostol 22% compared with 6% in the group 
oxytocin, (p<0.0001). The investigators concluded that, despite an 
increased incidence of shivering that had occurred with misoprostol; this 
agent constitutes an acceptable therapeutic alternative to oxytocin in the 
prevention of postpartum haemorrhage in low risk women (86). 
 
Ng et al had conducted a prospective multicentre randomized controlled 
trial to test misoprostol 600 µg orally or syntometrine in the prevention of 
PPH (129). The study population consisted of 2058 women at low risk of 
PPH. Blood loss was assessed by clinical estimation; there was no 
significant difference between the two groups with regard to mean blood 
loss incidence of PPH and fall in haemoglobin concentration. However, 
the use of misoprostol was associated with an increase in the need of 
additional oxytocics RR 1.62, 95% CI 1.34-1.96. Shivering and transient 
pyrexia were more common in the group of misoprostol. The authors 
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concluded that misoprostol is as effective as syntometrine for prevention 
of PPH and may be especially useful in situation were syntometrine is 
contraindicated, and facilities for storage and parenteral administration of 
oxytocics are limited. 
 
The WHO collaborative group of evaluation of misoprostol in the 
management of third stage of labour represented the largest trial. This 
multicentre randomized controlled trial is today the definitive equivalent 
study of oxytocin versus misoprostol. The trial included 18520 women 
from 9 countries and compared 600 µg of oral misoprostol with 10 IU of 
oxytocin given intramuscularly or intravenously. Misoprostol treated 
subjects had significantly higher incidence of blood loss ≥ 1000 mL (4% 
versus 3%, RR 1.39, 95% CI 1.19-1.63, p<0.0001). There was also a 
greater need for additional uterotonics in the group of misoprostol than in 
the oxytocin group 15% and 11% respectively (RR 1.40, 95% CI 1.29-
1.51; p<0.0001). Although statistically significant, this difference did not 
correlate with clinical outcome such as need for blood transfusion (13).  
 
In this study, fewer women given misoprostol needed blood transfusion 
than women given oxytocin; but statistically the difference was not 
significant (p=0.6). Higher rate of transient shivering and pyrexia was 
reported in the group of misoprostol compared to oxytocin but no long-
term harm was documented as result or these side effects. WHO group 
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concluded that in setting where active management of the third stage is 
standard, oxytocin is more efficacious compared with misoprostol. 
However, this study has been criticized in published commentaries (130). 
Some argued that, given the vast heterogeneity between the 9 study sites 
on the bases of the problem with this large influential RCT, many 
researchers and practitioners argued that there is ‘’still room’’ for 
discussion of the role of misoprostol in the active management of third 
stage in low resources setting (131).  
 
Mategrano et al had commented that in situations where conventional 
oxytocics are not readily available, storage requirements for oxytocics 
cannot be met, or the equipment for parental administration is not 
obtainable, misoprostol may be an acceptable prophylactic option (132). 
 
1.2.10- Use of rectal misoprostol in the third stage of labour:  
The first report of the rectal misoprostol for prevention of postpartum 
haemorrhage was a prospective RCT conducted by Bamigboye et al (14). 
These investigators had tested 400-µg rectal misoprostol compared to 
syntometrine in 491 women using estimated blood loss 1 hour after 
delivery as the primary endpoint. The two groups showed no significant 
difference in the mean blood loss (p=0.7). The percentage of postpartum 
haemorrhage (Blood loss ≥ 500 mL) was comparable in the two groups 
(0.9% versus 0.4%, p=0.6). However, the sample size was too small to 
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detect a difference in the incidence of PPH if one existed. A rise in both 
systolic and diastolic blood pressure had occurred in significantly higher 
rate in the group of syntometrine probably an adverse effect of 
ergometrine. 
 
 The same authors had tested the efficacy of rectal administered 
misoprostol 400 µg with a placebo in 550 women (90). In this study, blood 
loss was measured rather than estimated. The percentage of blood loss > 
1000 mL was not significantly different between the two groups (4.8 % for 
misoprostol versus 7% for placebo, p=0.37). Fewer women treated with 
misoprostol had needed additional oxytocics (3.3% versus 4.7% 
respectively, p=0.30). More women in the group misoprostol had 
experienced shivering compared to women randomized to placebo (2.9% 
versus 1% respectively).  
 
Diab et al had evaluated rectal misoprostol to combined intramuscular 
oxytocin and ergometrine (O-E) in the management in the third stage (91). 
Low risk women in the third stage of labour were allocated to receive 
either rectal misoprostol [200 µg n=25, 400 µg n= 45] or 5 unit oxytocin 
and 0.2 mg ergometrine IM n=75. Both group were well matched and had 
similar duration in the third stage of labour. Subjects in the group of 
misoprostol had lower estimated blood loss and needed less oxytocics 
compared to Oxytocin - Ergometrine group. Postpartum difference in 
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haemoglobin and haematocrit were significantly lower in misoprostol 
than Oxytocin - Ergometrine (-0.78 ± 0.08 versus -1.3 ±0.13 and -2.4±2.7 
versus 3.67±0.4 respectively). Postpartum hypertension had occurred 
more in Oxytocin - Ergometrine group while more shivering was reported 
in misoprostol group. The authors concluded that rectal misoprostol may 
be used safely in the management of the third stage.  
 
Gerstenfeld et al who evaluated 325 women in a study that compared  
misoprostol 400 µg rectally to oxytocin 20 units intravenously failed to 
demonstrate an efficacy of misoprostol in the prevention of postpartum 
haemorrhage (133).  
 
? Recent modalities for administration of misoprostol: Sublingual 
misoprostol versus parenteral oxytocics:   
 
In the last two years, the route of administration of misoprostol was 
further extended to the sublingual route. Sublingual misoprostol may offer 
a good alternative for women as it can avoid the first-pass effect in the 
liver and an uncomfortable rectal administration. 
 
Vimala et al were the first authors who tested misoprostol in the sublingual 
route of administration versus conventional oxytocics (134). These 
researchers in a comparative study of sublingual misoprostol 400 µg 
(n=60) versus methylergometrine (n=60) found no difference in the two 
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groups with regard to the incidence of PPH, additional need of oxytocics 
and mean haemoglobin change. In the misoprostol group 6.6% of women 
had experienced fever and 21.6% had shivering while no subjects in the 
group of methylergometrine had experienced side effects. For these 
authors, the advantages of misoprostol make it an attractive alternative for 
active management of the third stage of labour especially in rural setting 
in developing countries. However, larger randomized studies were needed 
to advocate its routine use. 
 
Lam et al in which sublingual misoprostol 600 µg was compared to 
intravenous syntometrine (135) conducted a similar study. The study 
population consists of 30 women at low risk of PPH in each group. There 
was no significant difference in the estimated mean blood loss (155 versus 
200 mL, p=ns) and the measured mean blood loss (226 versus 280 mL, 
p=ns). The change in haemoglobin was comparable between the two 
groups (0.85 g/dl versus 0.5 g/dl). More women in the misoprostol group 
required additional oxytocics (10 versus 0) but the difference was not of 
statistical significance. Shivering and pyrexia had occurred in women in 
the group of misoprostol. In conclusion, sublingual misoprostol was 
comparable to intravenous syntometrine in the measured blood loss. 
These authors had suggested that a larger trial was necessary to assess the 
clinical effectiveness of misoprostol sublingually in the management of the 
third stage. 
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1.2.11- Misoprostol in the prevention of postpartum haemorrhage at caesarean 
section: 
 
Although many delivery units use oxytocin as a first line agent at 
caesarean section, there is a need to evaluate others agents that could be 
used, thereby expanding the therapeutic options available to clinicians. 
Misoprostol had been investigated in several RCT for its role in the third 
stage of labour at vaginal delivery. So, it seemed logical that these 
investigations should be extended from vaginal delivery to caesarean 
section by RCT. Therefore, two randomized controlled trials were 
conducted; one by Acharyia et al (136) and the other by Lokugamage et al 
(137). 
 
In the study of Acharyia et al, 60 pregnant women were randomized either 
to receive misoprostol 400 µg orally or oxytocin 10 IU intravenously 
during caesarean section. The primary outcome measured was intra-
operative blood loss as estimated by physicians, and by values of 
preoperative and postoperative haemoglobin concentration and 
haematocrit. The estimated blood loss was 545 mL (95% CI 476-614) in 
misoprostol group and 533 mL (95% CI 427-639) in oxytocin group 
(p=0.85). Differences in preoperative and postoperative haemoglobin and 
haematocrit values were also similar in both groups. No serious side 
effects were noted in either group. The authors conclude that oral 
misoprostol appears to be safe and as effective as intravenous oxytocin in 
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reduction of intra-operative blood loss during elective caesarean section 
under regional anaesthesia and merits further investigation.  
 
Similarly, in the study of Lokugamage et al 40 women undergoing elective 
or emergency caesarean section were randomly allocated to receive 500 µg 
misoprostol orally or to receive oxytocin  10 IU as an intravenous bolus. 
These authors reported no significant difference in estimated blood loss, 
decrease in haemoglobin, use of additional oxytocics, need for blood 
transfusion, or the degree of shivering between the two groups. They 
concluded that oral misoprostol could be used as an alternative oxytocics 
agent for the third stage at caesarean section. However, there is a need for 
a larger randomized controlled trial to be undertaken. Zhao et al in the 
clinical study on reduction of postpartum bleeding in caesarean section 
had reported that misoprostol was more effective in reducing bleeding 
than oxytocin (138).  
 
1.2.12- Community based studies of misoprostol for prevention of PPH: 
 
Most of the studies to test for efficacy of misoprostol in the prevention in 
the PPH were RCT conducted in hospital. Recently, research on the 
efficacy of misoprostol had extended to the level of the community. 
Hence, two RCT of community based use of misoprostol for prevention 
of PPH are now in progress. In the Gambia, Walraven and colleagues are 
conducting a double-blind randomized study of 1200 women to determine 
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which preparation, 0.5 mg ergometrine or 600 µg misoprostol given 
orally, will be more effective at preventing PPH (> 500 mL) severe PPH 
(> 1000 mL) and postpartum anaemia (< 9 g/dl). Trained birth attendant 
are using the protocol in homebirth in rural areas(139). The results has 
come out in 2005 with oral misoprostol showing lower incidence of 
measured blood loss ≥ 500 mL (140).     
 
Similarly, the India site of the Global Network for Women and Children 
in research together with the University of Missouri - United States is 
conducting a collaborative randomized placebo controlled clinical trial in 
four primary health centre areas of Belgaum - district Karnataca. The 
primary goal of the trial is to assess the effectiveness of misoprostol 600 µg 
oral in reducing the incidence of acute PPH (≥ 500 mL) in women 
delivering at home or in neighbouring subcentre. Data collection is 
ongoing in this study and results not yet ready (141).  
 
A USAID funded project of the JHPIEGO Corporation and the Ministry 
of health of Indonesia and the Obstetric and Gynaecological Society of 
Indonesia had conducted a field demonstration project in two areas of 
Java, Bandung (intervention site) and Subang (control site) (142). The study 
was developed to demonstrate that antenatal, community based 
distribution of misoprostol and subsequent self administration of the drug 
immediately after home birth could lower the incidence of PPH among 
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women living in areas where skilled medical providers do not attend a 
high proportion of births. Nearly 4% of women in the comparison areas 
were referred for PPH compared to only 2.1% of women in the 
intervention areas. The authors used statistical model in the data analysis 
to conclude that women in the intervention areas were 25% less likely to 
perceive excessive bleeding, 30% to need an emergency reference to a 
health facility, and 45% less likely to need an emergency reference for 
PPH.  
 
It is important however to await the results of in-progress community 
bases studies before recommending widespread use of these medications 
at the community level (143) . 
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2.1- OBJECTIVES 
 
 
The objectives of the research: 
 
2.1.1- General objective: 
To study efficacy, safety, maternal tolerance, cost of the drug, best route 
of administration, duration of hospitalization, doctors and midwives and 
parturient satisfaction of misoprostol for the prevention of postpartum 
haemorrhage. 
2.1.2- Specific objectives: 
• Evaluate the effects of oral misoprostol in prevention of atonic 
postpartum haemorrhage; 
• Evaluate the effects of rectal misoprostol in prevention of atonic 
postpartum haemorrhage; 
• Determine the safety and side effects for each route of 
administration; 
• Identify the most efficient mode of administration that show the 
least side effects; 
• Compare the efficacy of the misoprostol versus syntometrine in the 
prevention of atonic postpartum haemorrhage; 
• Determine the cost for prevention of postpartum haemorrhage using 
the misoprostol.  
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2.2- METHODOLOGY 
 
The misoprostol versus syntometrine trial was a randomized controlled 
clinical trial. The main goal was to assess the efficacy of misoprostol in 
reducing the incidence of acute postpartum haemorrhage (> 500 mL) and 
acute severe postpartum haemorrhage (> 1000 mL) in women delivering 
in the maternity department of N’Djaména. 
 
2.2.1- Setting of the study:  
The study was conducted in the maternity department of the ‘‘Hôpital 
Général de Référence Nationale de N’Djaména’’; with the function of a 
University Teaching Hospital. This maternity department is the main 
reference centre for the capital of Chad N’Djaména and the surrounding 
areas, and is the site of about 12000 deliveries per year. Its maternal 
mortality rate was 800 per 100.000 live births (years 1989-1998) with 
haemorrhage being the leading cause of maternal mortality (28% of all 
maternal deaths) (2).  
The maternity department has:  
Staff:  six obstetricians and gynaecologist, two medical officers and one 
consultant anaesthesiologist, 18 midwives in the labour ward (n = 40). 
Hospital beds:  A total number of 72 beds including antenatal unit, 
postnatal ward, post operative and intensive care.  
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Operation theatres: there are 3 theatres with facilities for general and spinal 
anaesthesia. 
Delivery room:  there are 3 labour rooms with 2 delivery beds each and suit 
with 20 beds. 
An outpatient service: for gynaecology, antenatal care and family 
planning. 
Hospital facilities:  The hospital has facilities for blood transfusion (Blood 
Bank) and a department of radiology including x-ray and ultra-
sonography and a laboratory (for measurement of haemoglobin 
hematocrit).  
Ethics: 
This study was approved by the Faculty of Health Sciences and the 
authorities of the General Reference Hospital of N’Djaména and 
consultant obstetrician and gynaecologist of the maternity department. 
 
2.2.2- Population: 
All women in the antenatal clinic and in the antenatal ward were invited 
to participate in the study for the prevention of postpartum haemorrhage. 
Informations explaining the aim of the study were clearly given to them 
on the important of the study and on the possible side effects of the 
uterotonics.  On admission to the labour ward, women were reminded 
about the trial and an informed consent was obtained from those who 
accept to be involved in the trial.  
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It was only when delivery was imminent (at head crowning) that they 
were randomly allocated to either misoprostol (Cytotec; Searle) or 
syntometrine (Novartis). Drugs were kept in sealed numbered opaque 
envelope and allocation was at random with the next available numbered 
envelope containing either drugs. 
 
2.2.2.1- Criteria for selection:  
Women were eligible to be included in this study when vaginal delivery 
was expected. Only women in labour with singleton live pregnancy at 
term were considered eligible. 
 
2.2.2.2- Criteria for exclusion: 
- Refusal to participate; 
- Those who are a high risk of postpartum haemorrhage: multiple 
pregnancy, previous history of postpartum haemorrhage, 
antepartum haemorrhage, intrauterine foetal death;  
- Gestational age less than 37 weeks; 
- Pregnancy induced hypertension or known hypertensive patients; 
- Previous caesarean section;  
- known cardiac patients; 
- Those who presented contraindications to the use of the 
prostaglandins: glaucoma, asthma, and allergy to prostaglandins.  
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From a total of 2474 women, who were eligible to participate in this 
study; 2400 had completed the trial. All had spontaneous single, vertex 
deliveries and all neonates were born at term and alive. 
 
2.2.3- Methods and Type of study: 
2.2.3.1- Type of study and period: 
 
The study consists of prospective open randomized controlled clinical 
trials for prevention of postpartum haemorrhage comparing two different 
pharmacological agents conducted in the period October 2003 – 
December 2004. 
 
Therefore, two protocols were used: protocol A (for women who had 
received syntometrine), protocol B (for women who had received 
misoprostol). For protocol B, two different routes of administration were 
used: protocol B.1 (misoprostol was administered orally for a single dose 
of 400 µg) and protocol B.2 (misoprostol was administered intra-rectally 
for a single dose of 400 µg). 
 
2.2.3.2- Technique 
 
Active Management of the third stage of labour was the standard method 
used in this study. Random allocation was to one of the three policies for 
the management of the third stage of labour. The randomization 
envelopes were prepared in advance. Allocation was by selection of the 
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next sequentially, numbered opaque sealed envelop, which included a 
paper indicating one of the three policies. Each eligible woman was given 
the next envelope. The parturient was included in the study, once the 
envelope was opened even if the indicated policy was not followed. The 
attending doctor or midwife were asked to carry out the randomly 
allocated protocol of management.  
 
Those women who were randomly allocated for misoprostol; immediately 
after the birth of the infant and clamping of the cord had received either 
misoprostol 400 µg orally or 400 µg intra-rectally. The placenta was then 
delivered by controlled cord traction after being sure that the uterus was 
well contracted. Those women who were randomly allocated for 
syntometrine had received one dose of intra-muscular syntometrine, 
immediately after the birth of the infant and clamping of the cord. The 
placenta was then delivered by controlled cord traction after being sure 
that the uterus was well contracted. If blood loss was estimated to be ≥ 
500 mL, the birth attendant was instructed to set an infusion of Ringer 
lactate 500 mL containing oxytocin 20 IU. 
 
2.2.3.3- Measurement of blood loss  
 
Blood loss was estimated by using different parameters in order to 
minimize any error. These parameters were:  
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a) collection of the blood loss in graduated jug plus the estimated 
blood loss in the gauzes used; 
Objective clinical measurement of the immediate blood loss was 
carried as follow: just after delivery, linen soiled with amniotic fluid 
was removed and a low profile wedge shaped plastic fracture 
bedpan was sled under the women’s buttocks. This was found to be 
a comfortable and efficient way of collecting the great majority of 
blood lost after delivery, and could be left in place without 
discomfort even during suturing of the perineum.  This period lasted 
up two one hour.  When active bleeding had stopped, any blood 
clots were expressed from the uterus, the bedpan was removed and 
a sanitary towel was applied.  
 
The blood in the bedpan was measured in a measuring jug. One 
hour after delivery, any bloodstained linen-savers and sanitary towels, 
were placed in plastic bag and weighed in grams. The known dry weight 
of the linen savers and sanitary towels was subtracted to give the 
approximate volume of blood in millilitres (1 mL of blood equal 1 g) (144). 
This was added to the measured blood volume to give the total measured 
blood loss in the first hour after delivery (14). In an event of persisting 
bleeding a new bed pan was placed and additional determination of blood 
lost was made at the end of two hours.  
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b) Other means to estimate blood loss:  
** Postpartum change in haemoglobin and haematocrit: For this, 
measurements of haemoglobin concentration and haematocrit were 
done before delivery and 10±8 hours after delivery. This was 
according to the convenience of the recent parturient who accept to 
stay few more hours after a normally completed labour.  
** Blood transfusion as an indicator of great loss: blood transfusion 
was indicated in case the subject had shown sign of significant 
blood loss such as acute anaemia or if retrospectively the 
haematocrit drop was > 20%. 
 
In this study, postpartum haemorrhage was defined as the loss of more 
than 500 mL of blood in the first 24 hours following delivery (19). Again, a 
clinically equally relevant definition of post partum haemorrhage was a 
haematocrit drop of 10%; haemoglobin drop of 1 g and haemorrhage that 
require blood transfusion (145). 
 
Role of the Researcher: 
The researcher has done a seminar at the beginning of the research to the 
midwives and medical doctors in the maternity department to explain the 
objective principles and technique of the active management of labour 
with special reference to the uterotonics to be used in the prevention of 
postpartum haemorrhage including the misoprostol. 
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The researcher has done most of the work by actually proper 
measurement of the blood loss in the third stage of labour, proper 
recording  of vital parameter: blood pressure, temperature, pulse; 
collection of blood specimen for laboratory investigations and this 
include: full blood count, haemoglobin, hematocrit, blood group and 
rhesus factor, and possible complications were checked and carried on.  
He has also selected high risk group patient and made sure of the proper 
randomization of subjects. 
He has also personally registered  information and data about the patient 
in the computer for analysis. 
 
2.2.4- Data Collection: 
 
The data collection form was completed by the medical house officer and 
midwifes caring for the women. These forms contained information on 
maternal demographic characteristics such as age, weight, parity, 
gestational age; obstetric history including history of PPH; essential or 
pregnancy induced hypertension. Variables concerning labour recorded 
were:  induction, augmentation, analgesia, length of 1st stage (minutes), 
length of 2nd stage (minutes). Variables concerning delivery: included 
mode of delivery, episiotomy, lacerations, duration of third stage of 
labour, fetal weight, placenta weight, measured blood loss, need of 
additional oxytocics and manual removal of placenta. Observed side 
effects recorded included shivering, fever, nausea, vomiting, and 
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diarrhoea. Blood pressure and temperature were recorded at 30 minutes 
and 60 minutes to delivery; together with the haemoglobin concentration 
and haematocrit before and after delivery. Assessment of shivering was 
made by either observation or indirect questioning (i.e. “Do you have any 
complaints?”). If shivering was detected, the woman was asked whether 
she would consider her experience as mild (+), moderate (++) or severe 
(+++). Any side effect necessitating treatment was marked as severe (the 
treatment was noramidopyrine or prodafalgan by intramuscular 
injection). 
 
The primary outcomes of the study were; the mean blood loss, blood loss 
> 500 mL (acute PPH); blood loss > 1 000 mL (acute severe PPH); need 
for additional oxytocics (oxytocin, ergometrine); mean drop in 
haemoglobin concentration and haematocrit. Secondary outcomes 
included the length of third stage of labour; rate of manual removal of 
placenta; need for blood transfusion, severe maternal morbidity 
consequent to severe haemorrhage (such as exploration under 
anaesthesia, hysterectomy), maternal death and side effects (shivering, 
fever, nausea, vomiting, diarrhoea, and headache) and complications 
(hypertension). 
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2.2.5- Statistical methods: 
 
The main outcome of the study was the incidence of postpartum 
haemorrhage (defined as blood loss ≥ 500 mL). The incidence of 
postpartum haemorrhage estimated in our hospital when using standard 
oxytocics is 5% and we judged that an increase of twofold would be 
clinically unacceptable. We therefore based our study on a sample size of 
2400 women, which would allow us to detect a difference in the incidence 
of postpartum haemorrhage (from 5% to 8%) with a power of 80% at two-
sided significance level of 5%. 
 
Statistical analysis was performed using software SPSS for windows. Data 
for categorical variables were presented as numbers and percentages, and 
associations were assessed using the χ² test. Relative risk of misoprostol 
compared with the other oxytocics and their corresponding 95% 
confidence intervals were estimated for the primary and secondary 
outcomes. Data for continuous variables were presented as means and 
standard deviations. Comparisons of means were by student’s t-test and 
Anova (F test). A p <0.05 was considered statistically significant. 
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3- RESULTS 
 
ANALYSIS: 
 
 Maternal characteristics at trial entry:  
• Age; 
• Parity; 
• Weight; 
• Predelivery haemoglobin and haematocrit; 
• Predelivery body temperature; 
• Blood pressure. 
 
 Labour  outcome 
• mean duration of first stage of labour ;  
• mean duration of second stage of labour ; 
• mean duration of third stage of labour ; 
• episiotomy; 
• perineal tear;  
• mean  baby weight ; 
• mean placenta weight. 
 
 Outcome of treatment group 
•  primary outcome measures 
 75
o mean blood loss; 
o blood loss ≥ 500 mL; 
o blood loss > 1000 mL; 
o post delivery haemoglobin; 
o post delivery haematocrit; 
o mean haemoglobin change; 
o mean  haematocrit change; 
o number of additional oxytocics; 
 
• secondary outcome measures :  
o number of transfusion; 
o side effects and complications; 
? shivering; 
? pyrexia; 
? diarrhoea; 
? vomiting; 
? nausea; 
? headache; 
 
  others outcome of the study: 
• satisfaction: 
o women; 
o caregiver. 
• cost of drugs. 
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Two thousand and four hundred women had completed the trial. They 
were randomly distributed between the three groups, 800 (33.33%) in the 
group of syntometrine; 800 in the group of misoprostol orally, 800 in the 
group of misoprostol per rectum (Figure 1). All outcomes were analyzed 
in the allocated group. 
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Figure 1:  Trial profile  
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Misoprostol per 
oral
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rectum
33,33%
Syntometrine
33,33%
 
 
 
Figure 2: Distribution of the study population in the different groups of 
oxytocics. 
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Age  
 
Table 2 and fig. 3 show the age distribution of the study population. The 
majority of subjects were aged between 20-30 years (59.67%). The subjects 
in the age group < 20 years and those > 30 years represent 27.28% and 
12.75% respectively. The youngest parturient was 15 years and the eldest 
was 44 years. 
 
Table 2: Age distribution of the study population  
 
Age group  
(in years) 
No. of cases Percentage  
< 20 662 27.28% 
20-30 1432 59.67% 
> 30 306 12.75% 
Total 2400 100% 
 
 
 
 
 
 
 80
 
 
 
 
 
 
 
0
200
400
600
800
1000
1200
1400
1600
No. Of cases 662 1432 306
<20 20-30 >30
 
 
Figure 3: Age distribution of the study population 
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From table 3, it can be see that there was minimal variation in the mean 
age in the three groups, p=o.80. 
 
 
Table 3: Mean age in the three treatment groups (M ± SD) 
 
 
Age syntometrine misoprostol  
per oral 
misoprostol 
per rectum 
p 
 
 
Mean age 
 
 
24.07 ± 5.94 
 
24.10 ±6.44 
 
24.04±6.25 
 
 
 
0.80 
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Table 4 and fig. 4 show similar distribution with regard to age group 
among treated group. The majority of subjects were in the age group [20-
30] 59.12% versus 60% versus 59.87% respectively in the three treated 
groups.   
 
Table 4: Age distribution of the parturient in each treatment group 
 
Age group  
(in years) 
syntometrine misoprostol  
per oral 
misoprostol  
per rectum 
<20 224 (28%) 220 (27.5%) 218 (27.25%) 
20-30 473 (59.12%) 480 (60%) 479 (59.87%) 
>30 103 (12.87%) 100 (12.5%) 103 (12.87%) 
Total 800 800 800 
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Figure 4: Age distribution of parturient in each group of treatment 
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Parity: 
 
From table 5, it can be see that there was minimal variation in the mean 
parity in the three groups, p=0.52. 
 
 
Table 5: Mean parity in the three treatment groups (M ± SD) 
 
 
Parity syntometrine misoprostol  
per oral 
misoprostol 
per rectum 
p 
 
 
Mean parity 
 
 
2.44 ± 2.11 
 
2.37 ±2.21 
 
2.48±2.32 
 
 
 
0.52 
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Table 6 and figure 5 show that most of the subjects of the study 
population were multipara (57.75%) followed by the nullipara (24.50%) 
and the grandmultipara (17.75%). 
 
 
Table 6: Distribution of the total study population according to parity  
 
Parity No. of cases Percentage 
Nullipara (0) 588 24.50% 
Multipara (1 -4) 1386 57.75% 
Grandmultipara ≥ 5 426 17.75% 
Total 2400 100% 
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Figure 5: Parity of the total study population 
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This table 7 and figure 6 shows that the distribution of parity was similar 
in the three groups of treatment.  
 
 
Table 7: Distribution of the study population according to parity and 
treatment group 
 
Parity Syntometrine Misoprostol 
per oral 
Misoprostol 
per rectum 
Nullipara 194 
 (24.25%) 
202  
(25.25%) 
192 
 (24%) 
Multipara (2 -4) 466  
(58.25%) 
460  
(57.5%) 
460  
(57.5%) 
Grandmultipara ≥ 5 140 
(17.5%) 
138  
(17.25%) 
148  
(18.5%) 
Total 800 800 800 
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Most of the subjects in the group of syntometrine were multipara 58.25% 
followed by the nullipara 24.25% and the grandmultipara 17.50% (Table 8 
and figure 6). 
 
Table 8: Distribution of the parity in the group of syntometrine 
 
Parity No. of cases Percentage 
Nullipara (0) 194 24.25% 
Multipara (1 -4) 466 58.25% 
Grandmultipara ≥ 5 140 17.50% 
Total 800 100% 
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Figure 6 : Parity of the subjects who received syntometrine 
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Most of the subjects treated misoprostol per oral were multipara 57.50% 
followed by the nullipara 25.25% and the grandmultipara 17.25% (table 9 
and figure 7). 
 
Table 9: Distribution of the parity in the group of misoprostol per oral 
 
Parity No. of cases Percentage 
Nullipara (0) 202 25.25% 
Multipara (1 -4) 460 57.50% 
Grandmultipara ≥ 5 138 17.25% 
Total 800 100% 
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Figure 7: Parity in the group of misoprostol per oral 
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Table 10 and figure 9 shows that the majority of the subjects in the group 
of misoprostol per rectum were multipara 57.5% followed by the nullipara 
24% and the grandmultipara 18.5%. 
 
Table 10: Distribution of the parity in the group of misoprostol per rectum   
 
Parity No. of cases Percentage 
Nullipara (0) 192 24% 
Multipara (1 -4) 460 57.5% 
Grandmultipara ≥ 5 148 18.5% 
Total 800 100% 
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Figure 8: Parity in the group of Misoprostol per rectum 
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Maternal body weight: 
 
From table 11, it can be seen that the three groups of subjects were 
comparable with regard to the mean maternal body weight, p=0.06. 
 
 
Table 11: Distribution according to the mean weight of the parturient in 
the three groups (M±SD) 
 
 Syntometrine Misoprostol 
per oral 
Misoprostol 
per rectum 
p 
 
mean 
maternal 
weight(kg) 
 
 
 
62.28±9.84 
 
 
61.25 ±9.04 
 
 
61.32±9.74 
 
 
 
0.06 
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Duration of the first stage of labour: 
 
The mean duration of first stage of labour was not significantly different 
in the three treatment groups, p=0.26 (table 12).   
 
Table 12: Mean duration of first stage of labour in the different groups in 
minutes (M±SD) 
 
 Syntometrine Misoprostol 
per oral 
Misoprostol 
per rectum 
p 
 
Mean 
duration 
 
 
563±174 
 
 
577±180 
 
 
571±180 
 
 
 
 
0.26 
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Duration of the second stage of labour: 
 
Table 13 shows no significant difference in the mean duration of the 
second stage of labour between the three groups of treatment, p=0.091.   
 
Table 13: Mean duration of second stage of labour in the different groups 
in minutes (M±SD) 
 
 Syntometrine Misoprostol 
per oral 
Misoprostol 
per rectum 
p 
 
Mean 
duration 
 
 
 
47.26 ± 11.44 
 
 
48.52 ± 11.63 
 
 
48.02±11.62 
 
 
0.091 
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Episiotomy: 
 
The rate of episiotomy was similarly distributed between the three groups 
of subjects, p=0.9. 
 
 
Table 14: Episiotomy performance in the three-treatment groups 
 
Episiotomy Syntometrine Misoprostol 
per oral 
Misoprostol 
per rectum 
P 
 
Episiotomy 
 
 
20 
(2.5%) 
 
20 
(2.5%) 
 
21 
(2.6%) 
 
 
0.9 
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Perineal tear: 
 
 
Table 15 shows that the occurrence of perineal tear (1st and 2nd degree 
tear) was comparable among the treatment groups, p=0.28.  
 
 
 
Table 15: Occurrence of perineal tear in the treatment groups 
 
 Syntometrine Misoprostol 
per oral 
Misoprostol 
per rectum 
P 
 
Perineal 
tear 
 
 
 
 
33 (4.13%) 
 
 
30 (3.75%) 
 
 
34 (4.25%) 
 
 
 
0.28 
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Fetal birth weight: 
 
Table 16 shows that the mean fetal birth weight was not significantly 
different in the three groups of subjects, p=0.37.  
 
Table 16: Mean fetal birth weight in the three groups (M±SD) 
 
 
 Syntometrine Misoprostol  
per oral 
Misoprostol 
per rectum 
p 
 
mean fetal  
birth weight (kg) 
 
 
 
 
3.09 ± 0.40 
 
 
3.08 ± 0.35 
 
 
3.03 ± 0.34 
 
 
0.37 
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Primary outcome measures: 
 
a) mean blood loss : 
 
The mean blood loss was not significantly different between the treatment 
groups, p=0.44 (table 17 and figure 9). 
 
Table 17: Mean blood loss according to the treatment groups (M±SD)  
 
 Syntometrine Misoprostol  
per oral 
Misoprostol  
per rectum 
 
p 
 
mean blood 
loss (mL) 
 
 
 
223±142 
 
 
233±144 
 
 
232±146 
 
 
 
 
0.44 
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Figure 9: Mean blood loss according to the oxytocics used 
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b) Range of blood loss: 
 
The effect of syntometrine on postpartum blood loss was illustrated in 
table 18 and figure 10. It appeared that more women (39.50%) had blood 
loss in the range of [201-300] mL. The incidence of PPH and severe PPH 
were 4.88% and 0.75% respectively. However, 5.25% of treated subjects 
had blood loss < 100 mL.  
 
 
Table 18: Distribution according to the range of blood loss in the group of 
syntometrine 
 
Range of blood loss No. of cases Percentage 
< 100 42 5.25% 
100-200 300 37.50% 
201-300 316 39.50% 
301-400 54 6.75% 
401-500 46 5.75% 
501-1000 36 4.88% 
> 1000 6 0.75% 
Total  800 100% 
Mean blood loss = 223±142 mL 
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Figure 10: Range of blood loss in the group of syntometrine 
 100
 
 
Table 19 and figure 11 summarized the effect of oral misopostol on 
postpartum blood loss. Most of the subjects (42.38%) had a blood loss in 
the range of [200-300] mL. The occurrence of PPH and severe PPH 
represented 4.50% and 0.75% of cases respectively. However, 5.88% of 
treated subjects had blood loss < 100 mL.  
 
Table 19: Distribution according to the range of blood loss in the group of 
misoprostol per oral 
 
Range of blood loss No. of cases Percentage 
< 100 47 5.88% 
100-200 229 28.63% 
201-300 338 42.38% 
301-400 86 10.75% 
401-500 57 7.13% 
501-1000 37 4.50% 
≥  1000 6 0.75% 
Total 800 100% 
Mean blood loss 233 ± 144 mL 
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Figure 11 : Range of blood loss in the group of misoprostol per oral 
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Table 20 and figure 12 show the effect of rectal misoprostol on 
postpartum blood loss. The majority of subjects (39.63%) had a blood loss 
in the range of [200-300] mL, while parturient with blood loss in the range 
[100-200] mL represented 31.63%. The incidence of PPH and severe PPH 
represented 5.88% and 0.88% respectively, meanwhile, 5.50% of treated 
subject had blood loss < 100 mL.  
 
Table 20: Distribution according to the range of blood loss in the group of 
misoprostol per rectum 
 
Range of blood loss No. of cases Percentage 
< 100 44 5.50% 
100-200 253 31.63% 
201-300 317 39.63% 
301-400 92 11.50% 
401-500 47 5.88% 
501-1000 40 5.00% 
≥  1000 7 0.88% 
Total 800 100% 
Mean blood loss 232 ± 146 mL 
 103
 
 
 
 
 
0
50
100
150
200
250
300
350
No. of cases 44 253 317 92 47 40 7
< 100 101-200 201-300 301-400 401-500 501-1000 > 1000
 
 
Figure 12: Range of blood loss in the group of misoprostol per rectum 
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Postpartum haemorrhage: 
 
The incidence of postpartum haemorrhage was 4.62% in the syntometrine 
group compared to 4.75% and 4.75% in the two groups of misoprostol 
(oral and rectal). The differences were of no statistical significance, 
p=0.99 (table 21 and figure 13).  
 
 
Table 21: Incidence of postpartum haemorrhage in the treatment groups 
 
 Syntometrine Misoprostol  
per os 
Misoprostol  
per rectum 
 
P 
 
PPH (blood loss 
> 500 mL) 
 
 
 
 
37 
(4.62%) 
 
 
38 
(4.75%) 
 
 
38 
(4.75%) 
 
  
0.99 
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Figure 13: Incidence of postpartum haemorrhage in the treatment groups 
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Incidence of severe postpartum haemorrhage: 
 
 
Table 22 and figure 14 did not show significant difference with respect to 
the incidence of severe postpartum haemorrhage among treatment groups, 
p=0.94.   
Table 22: Incidence of severe postpartum haemorrhage in the three 
treatment groups  
 
 
Syntometrine Misoprostol 
per oral 
Misoprostol 
per rectum 
 
P 
 
blood loss > 
1000 mL 
 
 
 
 
6 (0.75%) 
 
 
6 (0.75%) 
 
 
7 (0.87%) 
 
 
0.94 
 
 
 
Maternal Mortality and Severe Morbidity: 
There was no case of maternal death.  Few women had severe maternal 
morbidity consequent to severe haemorrhage requiring exploration under 
anaesthesia. 
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Figure 14: Incidence of severe postpartum haemorrhage in the treatment 
groups 
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The risk estimates of primary outcome variables of treatment groups as 
compared to syntometrine are presented in table 23. 
 
Table 24: Relative risk estimates of treatment groups with regard to 
syntometrine group. 
 
 
Misoprostol per oral Misoprostol per rectum Variables 
RR (95% CI) p RR (95% CI) p 
blood loss > 
500 mL 
 
1.03 (0.66-1.60) 
 
0.1 
 
1.11 (0.72-1.72) 
 
0.6 
 
blood loss > 
1000 mL 
 
 
 
1(0.32-3.09) 
 
 
1 
 
 
1.17(0.39-3.46) 
 
 
0.78 
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Duration of third stage of labour: 
 
a) Mean duration 
 
The mean duration of third stage of labour was not significantly different 
in the three groups; although, it appears slightly longer in the group of 
syntometrine, p=0.21 (table 23 and figure 15).  
 
 
Table 23: Mean duration of third stage of labour in the different groups 
(M±SD) 
 
 
 
Syntometrine Misoprostol 
per oral 
Misoprostol 
per rectum 
 
P 
 
Mean duration 
(minutes) 
 
 
 
8.60 ± 2.20 
 
 
8.49 ± 2.18 
 
 
8.49 ± 2.12 
 
 
0.21 
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Fig 17: Mean duration of the third stage of labour in the different groups 
(in minutes) 
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b) Duration of the third stage of labour in the study population:  
 
The placenta was delivered within 10 minutes to delivery of the baby in 
most of the subjects in the treatment groups. More women in the group of 
syntometrine had delivery of the placenta within the interval ≥ 10 - 30 < 
compared to two groups of misoprostol (28.75% versus 22.63% versus 
24.63%). The duration of third stage of labour had exceeded 30 min for 
more subjects in the group for syntometrine (0.38% versus 0.13% versus 
0.13%) (Table 24 and figure 16 ). 
 
Table 24: Duration of the third stage of labour in the study population.  
 
Duration  
(in minute) 
Syntometrine 
 
Misoprostol 
per oral 
 
Misoprostol 
per rectum 
 
Total 
<10 570 (71.25%) 619 
(77.37%) 
603(75.37%) 1792 
≥ 10 - 30< 227(28.75%) 180(22.63%) 196(24.63%) 603 
>30 3(0.38%) 1(0.13%) 1(0.13%) 5 
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Figure 16: Duration of the third stage of labour in the different treatment 
groups 
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Additional oxytocics: 
 
The percentage of women requiring additional oxytocics was slightly 
higher for rectal misoprostol compared to others treatment group; but this 
difference was not statistically significant (11.38% versus 10.5% versus 
9.75%), p=0.52 (Table 25 and figure 17). 
 
 
Table 25: Need for further oxytocics in the different treatment groups 
 
 Syntometrine Misoprostol 
per os 
Misoprostol 
per rectum 
P 
 
Additional 
oxytocics 
 
 
 
 
85(10.62%) 
 
 
 
 
80(10%) 
 
 
94(11.75%) 
 
  
0.52 
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Figure 17: Need for further oxytocics in the different groups 
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Manual removal of placenta: 
 
The proportion of women requiring manual removal of placenta was 
higher in the group of syntometrine than in the group of oral and rectal 
misoprostol; although, the difference was statistically not significant, 
p=0.44 (Table 26 and figure 18). 
 
Table 26: Manual removal of the placenta in the different groups 
 
 Syntometrine Misoprostol 
per oral 
 
Misoprostol 
per rectum 
p 
 
 Manual 
removal of the 
placenta 
 
 
 
 
3 (0.37%) 
 
 
 
1(0.01%) 
 
 
 
1 (0.01%) 
 
 
 
 
0.44 
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Figure 18 : Manual removal of placenta in the three studied groups  
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Need for blood transfusion: 
 
The proportion of women requiring blood transfusion was comparable in 
the three treatment groups, p=0.94 (Table 27 and figure 19). 
 
 
Table 27: Need of blood transfusion in the different groups 
 
 Syntometrine Misoprostol 
per os 
 
Misoprostol 
per rectum 
p 
 
need of blood 
transfusion 
 
 
 
6(0.75%) 
 
 
6(0.75%) 
 
 
7(0.87%) 
 
 
 
0.94 
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Figure 19: Incidence of blood transfusion in the different study groups 
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The risk estimates of secondary outcome variables of treatment groups as 
compared to syntometrine are presented in table 28. 
 
 
Table 28: Relative risk estimates of secondary outcome variables of 
treatment groups with regard to syntometrine group. 
 
Misoprostol per oral Misoprostol per rectum Variables 
RR (95% CI) p RR (95% CI) p 
Additional 
oxytocics 
 
0.98(0.13-1.31) 
 
0.86 
 
1.12(0.85-1.49) 
 
0.42 
 
Manual 
removal of 
placenta 
 
 
0.33(0.03-3.20) 
 
 
0.31 
 
 
0.33(0.03-3.20) 
 
 
0.31 
 
Blood 
transfusion 
 
1(0.32-3.09) 
 
 
1 
 
1.17(0.39-3.46) 
 
0.78 
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Hospitalization: 
 
The proportion of women requiring hospitalization for blood transfusion 
was not significantly different between the treatment groups, p=0.94 
(Table 29). 
 
 
 
Table 29: Subjects needing hospitalization for blood transfusion in the 
different groups 
 
 Syntometrine Misoprostol 
per oral 
 
Misoprostol 
per rectum 
p 
Women 
requiring 
hospitalization 
 
 
 
6 (0.75%) 
 
 
6 (0.75%) 
 
 
7 (0.87%) 
 
 
 
 
0.94 
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Laboratory criteria: 
 
Table 32 shows that the mean pre-delivery haemoglobin level was similar 
in the three treatment groups, p=0.89. 
 
 
Table 30: Mean pre-delivery haemoglobin level of the treatment groups 
(M ± SD) 
 
 
 
 
Syntometrine Misoprostol 
per oral 
Misoprostol 
per rectum 
p 
 
Mean  
pre-delivery 
haemoglobin 
(g/dl) 
 
 
 
11.17±0.92 
 
 
 
 
11.19±1.11  
 
 
11.17±1.03 
 
 
 
0.89 
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The mean post-delivery haemoglobin level is not significantly different in 
the three studied groups, p=0.60 (Table 31). 
 
 
Table 31: Mean post-delivery haemoglobin level in the three groups 
(M±SD) 
 
 Syntometrine Misoprostol 
per oral 
Misoprostol 
per rectum 
 
p 
 
Mean  
post-delivery 
haemoglobin 
(g/dl) 
 
 
 
 
10.61±0.89 
 
 
 
10.59± 1.05 
 
 
 
10.56±1.01 
 
 
 
 
 
0.60 
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No significant differences were detected among the three groups regarding 
the mean drop in haemoglobin level after treatment, p= 0.06 (Table 32 
and figure 20). 
 
Table 32: Mean drop in haemoglobin level of the three groups (M±SD) 
 
 
 Syntometrine Misoprostol 
per os 
 
Misoprostol 
per rectum 
p 
 
Mean drop in 
haemoglobin 
(g/dl) 
 
 
 
0.55±0.38 
 
 
 
 
0.59±0.49 
 
 
0.60±0.33 
 
 
 
 
 
0.06 
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Figure 20: Mean drop in haemoglobin level of the three different groups 
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The three groups were comparable as to the mean pre-delivery 
hematocrit, p=0.71 (Table 33) 
 
 
Table 33: Mean pre-delivery hematocrit level in the three groups (M±SD) 
 
 Syntometrine Misoprostol 
per oral 
Misoprostol 
per rectum 
 
p 
 
Mean  
pre-delivery 
haematocrit (%) 
 
 
 
33.60±2.70 
 
 
 
 
 
33.70±3.14 
 
 
 
 
33.59±3.07 
 
 
 
 
0.71 
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The mean post-delivery haematocrit was comparable in the three groups, 
p= 0.57 (Table 34). 
 
 
Table 34: Mean post-delivery haematocrit level of the three groups 
(M±SD) 
 
 Syntometrine Misoprostol 
per oral 
Misoprostol 
per rectum 
 
p 
 
Mean  
post-delivery 
haematocrit (%) 
 
 
 
31.91 ± 2.62 
 
 
 
 
31.86 ± 3.17 
 
 
 
 
 
31.75 ± 3.01 
 
 
 
0.57 
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No significant differences were detected among the three groups regarding 
the mean post delivery drop in the level of haematocrit, p= 0.08 (table 35 
and figure 21). 
 
 
Table 35: Mean drop of haematocrit in the studied groups (M± SD) 
 
 
 Syntometrine Misoprostol 
per oral 
 
Misoprostol 
per rectum 
p 
 
Mean drop of 
haematocrit (%) 
 
 
 
1.70 ± 1.17 
 
 
1.83 ± 1.07 
 
 
 
1.83 ± 1.03 
 
 
 
 
0.08 
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Misoprostol 
per rectum; 
1,83
Syntometrine; 
1,7
Misoprostol 
per oral; 1,83
 
 
 
Figure 21: Mean post–delivery drop in haematocrit level in the three 
groups of subjects. 
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Table 36 describes no significant difference among the three groups with 
regard to the number of subjects with post-delivery drop in haematocrit 
level of more than 10%, p=0.84. 
 
 
Table 36: Number of subjects with post-delivery drop in haematocrit level 
of more than 10% in the three groups 
 
 Syntometrine Misoprostol 
per oral 
Misoprostol 
per rectum 
 
p 
 
Haematocrit  
drop > 10% 
 
 
 
42 
 
 
 
 
43 
 
 
47 
 
 
0.84 
 
 
 
 
 
 130
 
 
From table 37, it can be seen that the level of pre-delivery maternal 
anaemia was comparable in the three groups, p=0.95. 
 
 
Table 37: Distribution according to the pre-delivery maternal anaemia in 
the three groups (Hb <10.5 g/dl). 
 
Pre-delivery 
maternal 
anaemia 
(Hg<10.5 g/dl) 
Syntometrine Misoprostol 
per oral 
Misoprostol 
per rectum 
P 
  
 
No. of cases 
 
 
 
200/800 
 
 
203/800 
 
 
205/800 
 
 
0.95 
Percentage 25% 25,37% 25.62% 
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Table 38 shows that the percentage of post-delivery maternal haemoglobin 
level < 9 g/dl was not significantly different between the three groups of 
subjects (p=0.36). Although less women in the group of syntometrine had 
haemoglobin level < 9 g/dl. 
 
 
Table 38: Post-delivery maternal haemoglobin <9 g/dl in the three groups 
 
Post-delivery 
maternal 
Hg<9 g/dl 
Syntometrine Misoprostol 
per oral 
Misoprostol 
per rectum 
P 
 
No. of cases 
 
13 /800 
 
21/800 
 
16/800 
 
0.36 
 
Percentage  0.01% 0.02% 0.02% 
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Side effects  
 
The rate of shivering and fever were significantly higher in the two groups 
of misoprostol compared to syntometrine group. However, fewer subjects 
in the group of rectal misoprostol had experienced shivering and fever 
compared to those who received misoprostol orally (table 39). 
 
Table 39: Observed side effects of syntometrine and misoprostol oral or 
rectal 
 
Side effects Syntometrine misoprostol per 
oral 
 
misoprostol 
per rectum 
Shivering 
 
32(4%) 118(14.75%) 70(8.75%) 
Fever 
 
10(1.25%) 63(7.87%) 52(6.56%) 
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Subjects in the groups of misoprostol were more likely to experience 
shivering and fever than those in the group of syntometrine (table 44). 
 
Table 40: Relative risk estimates of observed side effects of misoprostol 
with regard to syntometrine 
 
misoprostol per oral misoprostol per rectum Variables 
RR (95% CI) p RR (95% CI) P 
 
Shivering 4.1 (2.73-6.35) <0.0000 2.30 (1.47-3.6) <0.0000 
 
Fever 6.7 (3.35-14.11) <0.0000 5.49 (2.67-11.59) <0.0000 
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From table 41 and figure 22, it can be seen that subject who received 
misoprostol per oral were more likely to experience shivering and pyrexia 
compared to those who received misoprostol per rectum. 
 
Table 41: Adverse effects of oral misoprostol compared to rectal 
misoprostol 
 
Side 
effects 
Misoprostol 
per oral 
 
Misoprostol 
per rectum 
RR (95% CI) P 
 
 
Shivering 
 
118(14.75%) 
 
70(8.75%) 
 
 
1.69(1.25-2.23) 
 
0.0001 
 
Fever 
 
63(7.87%) 
 
52(6.56%) 
 
 
1.21(0.85-1.73) 
 
0.28 
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Figure 22: Incidence of shivering and pyrexia in the group misoprostol per 
oral compared to misoprostol per rectum 
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More women in the group of oral misoprostol had severe pyrexia 
compared to rectal misoprostol and syntometrine group; although it was 
statistically not significant. None of participants had temperature above 
40°C (table 42).   
 
 
Table 42: Incidence of temperature higher then 39°C in the studied 
population 
 
Pyrexia Syntometrine Misoprostol 
per oral 
Misoprostol 
per rectum 
 
p 
 > 39°C < 40°C 1(0.13%) 5(0.63%) 3(0.38%) 0.26 
>40°C 0 0 0 1 
Requiring 
treatment 
 
1(0.13%) 
 
5(0.63%) 
 
3(0.38%) 
 
0.26 
  
 
 137
 
 
Adverse effects: 
 
 
Headache, nausea, and vomiting were reported more often in the group of 
syntometrine alone when compared with both groups of misoprostol, 
p=0.0000. The incidence of diarrhoea was comparable in the three 
groups, p=0.47 (table 47 and figure 23).   
 
Table 43: Observed side effects among subjects in the different treatment 
groups 
 
Side Effect Syntometrine Misoprostol 
per oral 
Misoprostol 
per rectum 
p 
Headache 57 (7.12%) 2 (0.25%) 4 (0.5%) 0.0000 
Nausea 64 (8%) 4 (0.5%) 5 (0.6%) 0.0000 
Vomiting 25 (3.1%) 3 (0.37%) 3 (0.37%) 0.0000 
Diarrhoea 3 (0.37%) 6 (0.75%) 3 (0.37%) 0.47 
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Figure 23: Observed side effects among subjects in the different treatment 
groups. 
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 Subjects in the groups of misoprostol were less likely to experience 
nausea, vomiting and headache when compared to the group of 
syntometrine (table 44). 
 
 
Table 44: Relative risk estimates of the secondary outcome variables of 
treatment groups with regard to group of syntometrine 
 
misoprostol per oral misoprostol per rectum Variables 
RR (95% CI) p RR (95% CI) P 
 
Nausea 0.06(0.02-0.17) 0.0000 0.08(0.03-0.19) 0.000 
 
Vomiting 0.13(0.04-0.43) 0.0000 0.13(0.04-0.43) 0.0000 
 
Diarrhoea 2(0.4-10.1) 0.31 1 (0.16-0.62) =1 
 
Headache 0.04(0.01-0.14) 0.0000 0.07(0.03-0.19) 0.0000 
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Table 45 and figure 24 show higher rate of hypertension in the group of 
syntometrine when compared to the two groups of misoprostol. 
 
 
Table 45: Incidence of hypertension in the three groups of treated subjects 
at one hour after delivery 
 
Hypertension Syntometrine Misoprostol per 
oral 
Misoprostol 
per rectum 
 
SBP ≥ 140 69 (8,62%) 16 ( 2%) 19 (2.37%) 
 
DBP ≥ 90 74 (9,25%) 25 ( 3.13 %) 27 (3.37%) 
 
SBP : systolic blood pressure       
DBP : diastolic blood pressure 
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Figure 24: Incidence of hypertension in the three groups of treated subject 
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Women in the groups of misoprostol were less likely to suffer 
hypertension compared to the group of syntometrine, p=0.000 (table 46). 
 
 
Table 46: Relative risk estimates of hypertension in the two groups of 
misoprostol with regard to the group of syntometrine 
 
misoprostol per oral misoprostol per rectum Variables 
RR (95% CI) P RR (95% CI) P 
 
SBP ≥ 140 0.23(0.14-0.40) 0.0000 0.28(0.17-0.45) 0.0000 
 
DBP ≥ 90 0.34(0.22-0.53) 0.0000 0.36(0.24-0.56 0.0000 
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Satisfaction of midwives, doctors and parturient: 
 
Table 47 and figure 25 show that most of the women were satisfied with 
the use of oral misoprostol and rectal misoprostol; while syntometrine 
was less favoured by the parturient.   
 
Table 47: Distribution according to the satisfaction of the parturient in the 
three groups 
 
Satisfaction 
of the parturient 
 
Syntometrine Misoprostol 
per oral 
Misoprostol 
per rectum 
p 
Very good 
 
184 (23%) 624 (78%) 575(71.87%) 0.0000 
Good  
 
416 (52%) 128(16%) 168(21%) 0.0000 
Poor  
 
200(25%) 48 (6%) 67(8.37%) 0.0000 
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Figure 25:  Satisfaction of the parturient in the three groups 
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Table 48 and figure 26 show that most of the caregivers were satisfied 
with the use of oral or rectal misoprostol compared to the use of 
syntometrine. 
 
Table 48: Distribution according to satisfaction of the caregiver in the 
three groups 
 
Satisfaction 
of the 
caregiver 
Syntometrine Misoprostol 
per oral 
Misoprostol 
per rectum 
 
P 
Very good 146 (18.25%) 640(80%) 560 (70%) 0.0000 
 
Good  454 (56.75%) 120 (15%) 184 (23%) 0.0000 
 
Poor  
 
200(25%) 40 (5%) 56 (7%) 0.0000 
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Figure 26:  Satisfaction of midwives and doctors in the three groups 
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Cost of oxytocics: 
 
The unit cost of syntometrine was significantly greater than this of 
misoprostol for a cost ratio of 1 to 4.  
 
 
Table 49: Cost of the different oxytocics used for prevention for PPH (in 
USD) 
 
 
Oxytocics Cost of drug 
Syntometrine (1 vial) + needle and 
syringe  
Oxytocin 
 
4 USD 
½ USD 
misoprostol per oral (2 tbts) 1 USD 
misoprostol per rectum (2 tbts) 1 USD 
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4- DISCUSSION 
 
The practice of prophylactic administration of parenteral oxytocics in the 
active management of the third stage of labour had led to a 30% to 40% 
reduction in the incidence postpartum haemorrhage. Despite this fact, 
postpartum haemorrhage is still a major cause of maternal death in the 
developing countries. The third stage of labour is often viewed as an after 
thought. However, it is an integral component of the birth process and 
deserves as much attention as either of the others stages and prevention of 
excessive blood loss is the critical objective (146). 
Maternal mortality and morbidity due to postpartum haemorrhage are 50 
times more common in countries underdeveloped than in the U.K.  
Contributing factors to this situation are numerous: inadequacy in 
supervised deliveries, blood transfusion, and anaesthetic services. 
However, the most important factor is the unavailability or ineffectiveness 
of routine oxytocics used in the third stage. The most commonly 
oxytocics agents used for this purpose are parenteral drugs (oxytocin, 
ergometrine, syntometrine). These drugs require sterile needles and 
syringes for administration as well as storage in cold condition (2°c to 8° 
C), and away from light. The potency of injectable oxytocics in tropical 
climate had been questioned in some studies. Despite the widespread use 
of oxytocics, the choice of preparation varies. Syntometrine, a 
 149
combination of oxytocin and ergometrine, is the most popular oxytocics 
preparation used in Britain (147). It has the theoretical advantage of 
combining the rapid effect of oxytocin and the sustained effect of 
ergometrine(66).  However, the use of ergometrine increases the risk of 
hypertension, deaths from cardiac arrest and intracerebral haemorrhage(61, 
62,148). In Canada and in some European countries oxytocin alone is the 
preferred medication.  The use of oxytocin alone is free from these side 
effects, but whether it is better than syntometrine in controlling 
haemorrhage remains controversial(105,106). 
In Denmark and the some African countries, ergometrine is solely used. 
Paradoxically in a same country, the oxytocic used in the active 
management of the third stage of labour differs from one institution to 
another. Therefore, there is no standard oxytocic for the third stage of 
labour throughout the world.  
The quest for the best uterotonic continues. It is not simply an academic 
exercise especially in areas of limited resources. In the developing 
countries, the choice is for an oxytocic that is cheap, simple to use, 
efficient, and with minimal side effects and complications.In the strategies 
to reduce the incidence of postpartum haemorrhage the ideal oxytocic is 
the one, which can be administer orally and which do not required special 
storage condition . 
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This prospective, three arms, randomised controlled clinical trial has the 
objective to address the present concern of which oxytocic is better: 
syntometrine or oral misoprostol or per rectum. 
 
In the present research, the studied population was comparable in its 
demographic characteristics. A total number of 2400 women were 
randomly allocated to receive: misoprostol orally 400 µg (n=800) or 
misoprostol rectally 400 µg (n=800) or syntometrine 1 mL IM (n=800). 
The main outcomes of the study were the incidence of postpartum 
haemorrhage (blood loss > 500 mL), severe postpartum haemorrhage 
(blood loss >1000 mL), need of therapeutic oxytocics, change in 
haemoglobin and haematocrit concentration (drop of 1 g/dl or 10% in 
haematocrit). The secondary outcomes were: need for blood transfusion, 
duration of the third stage, manual removal of placenta, severe maternal 
morbidity, adverse side effects and complications (shivering, fever, 
nausea, vomiting, diarrhoea, headache and hypertension). 
 
Blood loss in the third stage of labour 
 
Meanwhile, clinical trails have relied on assessment of blood loss as an 
endpoint to interpret the efficacy of different medications in the third stage 
of labour. Methods that are easy to handle and reproducible, are preferred 
by most of the researchers. Hence, assessment of blood loss is usually 
done visually, or by collecting blood spilled into a bedpan in the third 
 151
stage of labour while also weighing any blood-soaked bed linen and 
gauzes. The former is widely called a subjective assessment and is 
recognized to underestimate blood loss (149). The latter is referred to as an 
objective method although it is also recognized to overestimate blood loss.  
 
Objective clinical measurements of blood loss were found to be an 
acceptable method in previous randomised trial (14). Measurement of 
change in haemoglobin and haematocrit before and after delivery appears 
to be a reliable method to estimate blood loss in the third stage of labour; 
most authors consider it as the gold standard in clinical studies in this 
field. Change in haemoglobin has also been used as a guide for estimation 
of blood loss. The American College of Obstetrician and Gynaecologist 
suggest that the definition of postpartum haemorrhage may be based on 
change in laboratory finding in the postpartum period. Hence, a drop of 
Hb of 1 g/dl or Hte of 10% between the time of administration of 
uterotonic and after delivery is used to define the occurrence of PPH (150 ). 
 
In the present study, blood loss in the third stage of labour was objectively 
determined by direct measurement and two laboratory criteria, namely 
changes in haemoglobin concentration and haematocrit. In our study, Hb 
and Hte were estimated by taking two samples of blood; before 
administration of oxytocics and within 8±6 hours of delivery. This is 
because of limitation of available beds in the postnatal ward, also because 
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most of parturient are reluctant to stay more in hospital after a normal 
delivery. In two comparatives studies of misoprostol versus conventional 
therapy for prevention of postpartum haemorrhage, the researchers had 
taken the second sample of blood within 12±4 hours to delivery (86, 151).  
 
In our study, blood loss during the third stage of labour was expressed as 
mean blood loss; blood loss > 500 mL (acute PPH) and blood loss > 1000 
mL (acute severe PPH).   
 
4.1- Effects of oral misoprostol compared to syntometrine in 
the third stage of labour:  
 
4.1.1- Mean blood loss:   
In this study, the mean blood loss was not significantly different between 
treatment groups: 233 ± 144 mL for oral misoprostol versus 223 ± 142 
mL for syntometrine. This is in agreement with the different authors who 
found no significant difference in the mean blood loss between oral 
misoprostol and syntometrine (85, 128, 129).  
 
Similar to our study, El-Refeay et al (128) have conducted a randomized trial 
to evaluate efficacy of misoprostol compared with conventional 
uterotonic. 2000 women were randomly allocated to 500 µg oral 
misoprostol or to others uterotonic including syntometrine (80% of 
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participant), oxytocin (18%), or ergometrine (2%). The mean blood loss 
recorded was comparable for misoprostol and syntometrine: 256 mL (244-
268) and 251 mL (239-263) respectively (p=0.59). Subsequently, in 
another prospective multicentre randomized controlled trial designed by 
Ng et al. 2058 women at low risk of PPH received either misoprostol 
orally (600 µg, n= 1026) or syntometrine (n = 1032). There was no 
significant difference in the mean blood loss between the two groups: 296 
mL for misoprostol versus 254 mL for syntometrine (129). 
 
Several randomized trial compared oral Misoprostol with others 
uterotonic agents such as ergometrine or oxytocin. Garg et al in a 
comparative study of oral misoprostol 600 µg versus injectable 
ergometrine did not found difference in the mean blood loss between 
treatment groups (124.1 mL versus 124.1 mL) (152). 
 
In a study conducted by Oboro et al in a Teaching Hospital in Nigeria, 
586 women at low risk of PPH were randomly allocated to misoprostol 
400 µg orally or to oxytocics 10 IU im. The measured blood loss was not 
significantly different in the two groups (341 mL versus 339 mL for 
misoprostol and oxytocin respectively) (151). Similarly, misoprostol 600 µg 
orally was compared to oxytocin 10 IU im in a study conducted by 
Dassouki et al in an Indonesian teaching hospital. The mean blood loss in 
the third stage of labour was comparable in both groups 144.23 mL versus 
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131.02 mL respectively mean difference of 13.26 mL. For these authors, 
the effectiveness of oral misoprostol in the prevention in PPH is not 
significantly different than when oxytocin is used (153).  
 
In a recent prospective randomized controlled study conducted by 
Zachariah et al, at Christian Medical College Hospital, Vellore in India 
oral misoprostol (400 µg, n=730) was compared to ergometrine (2 mg 
intravenous, n=617) and oxytocin (10 IU intramuscular, n= 676) for 
efficacy in the management of the third stage of the labour . The mean 
blood loss in the third stage of labour was comparable in the three groups 
195.5 mL, 183 mL and 188 mL respectively (154). 
 
4.1.2 - Incidence of PPH and use of additional oxytocics and blood 
transfusions: 
 
In most of the clinical trial design to test the efficacy of misoprostol versus 
conventional oxytocics in preventing PPH, the primary endpoints were 
the incidence of acute PPH (blood loss > 500 mL), and acute severe PPH 
(blood loss > 1000 mL). Secondary outcomes included the need for 
additional oxytocics and postpartum blood transfusion.  
 
In our study, the percentage of blood loss > 500 mL was not statistically 
different between treatment groups 4.75% versus 4.62% in the group 
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misoprostol and syntometrine (p=0.1, R =1.1, 95% CI=0.72-1.72). Blood 
loss > 1000 mL occurred in 0.75% of women who received oral 
misoprostol; and 0.75% those who received syntometrine (p= 1, RR= 1, 
95% CI=0.32-3.9). The early active management of excessive bleeding 
with additional oxytocics have reduced the incidence of acute severe PPH 
and protect against severe blood loss which is difficult to compensate for 
in our set up. However, there was no significant difference between the 
two groups in the need for additional oxytocics 10.0% versus 10.63%, 
p=0.17, RR=0.94, 95% CI=0.70-1.26 and the need of blood transfusion 
RR=1, 95%CI= 0.32-3.9, p=1. 
 
The results that came out from our study were in accordance with the 
result of previous studies. Hence, Ng et al had reported similar figures, 
with an incidence of acute PPH (5.8% versus 4.8%), and severe acute 
PPH (0.5% versus 0.4%) in the treatment groups of oral misoprostol 600 
µg compared to syntometrine (129).  
 
However, these authors reported higher rate in the need for additional 
oxytocics in the misoprostol group 22.6% versus 14% in the group of 
syntometrine. 
 
Higher figures were reported by El Refeay et al in a similar study testing 
oral misoprostol compared to conventional oxytocics. The incidence of 
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blood loss ≥ 500 mL was 12% in the group of subjects treated with oral 
misoprostol compared to 11% in those treated with conventional 
oxytocics (p=57, RR, 95% CI= 1.1 [0.79-1.55]). Blood loss > 1000 mL or 
more occurred in 2% of women in each group (p=0.81, RR 0.89 (0.37-
2.19)). In this trial, blood loss was subjectively estimated by attending 
midwife and it was not restricted to subject at low risk of postpartum 
haemorrhage. This could explain the higher rate of postpartum 
haemorrhage in this study compared to our results, although, the 
difference between the treatment groups were not statistically significant. 
More women treated with misoprostol required additional oxytocics but 
this did not reach statistically significant difference (14% versus 10%, p= 
0.08) (128). 
 
Caliskan et al reported higher incidence of PPH and severe PPH in a 
group of women treated by oral misoprostol (400 µg, n= 388) compared to 
another group treated with oxytocin - ergometrine (n=398) with 9% 
versus 3% and 3.6% versus 1.2% respectively. More women in the 
misoprostol group required additional oxytocics compared to Oxytocin - 
Ergometrine with 5.9% versus 2.2% (85). These authors did not use 
extensive selection criteria for inclusion in the study, and the enrolled 
participant were not restricted to low risk of PPH. 
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In previous RCT, oral misoprostol was found to be as effective as 
conventional oxytocics in reducing the rate of acute PPH and severe acute 
PPH. In their study, Oboro et al (151) had shown that oral misoprostol 
could replace intramuscular oxytocics in reducing PPH in low risk 
women in developing countries.  
 
Walraven et al in a very recent study for the use of Misoprostol in the 
management of the third stage of labour in home delivery setting in rural 
Gambia had concluded on the efficiency of oral Misoprostol. A total 
number of 2229 women delivering at home under the guidance of trained 
traditional birth attendants were randomized to either 600 µg of oral 
misoprostol or 0.5 mg ergometrine tablet. The misoprostol group 
experience lower incidence of measured blood loss ≥ 500 mL. For these 
authors, misoprostol is a promising drug to prevent life-threatening PPH 
in this setting (140).  
 
Similarly, Kundodyiwa et al in their study conducted in Zimbabwe, had 
shown that misoprostol 400 µg orally was as effective as intramuscular 
oxytocics in the prevention of PPH. The rate of blood loss > 500 mL was 
15.2% versus 13.3% and blood loss > 1000 mL, 3.7% versus 2% for 
misoprostol and oxytocin respectively; the difference was no statistically 
significant (p=0.53 and 0.23) (155). These authors concluded that 
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misoprostol has potential in reducing the high incidence of PPH in 
developing countries.  
The WHO study have shown that oral misoprostol was associated with a 
higher rate of measured blood loss of 1000 mL or more and the use of 
additional oxytocics compared to oxytocin 10 IU. 
 
In a recent study, Garp et al did not found significant difference in the 
incidence of postpartum haemorrhage and need of additional oxytocic 
between subjects treated by oral misoprostol and methylergometrine (8% 
versus 6 %, and 10% versus 7%) (152).  
Similarly, in an other recent study, Zachariah et al had shown that 
misoprostol taken orally was as efficacious as oxytocin or ergometrine in 
the routine management in the third stage of the labour. Theses authors 
did not found statistically significant difference in the proportion of 
women with blood loss greater than 500 mL or greater than 1000 mL 
between the three groups [(2,6% versus 2.1% versus 3%, p=0.62) and 
(0.1% versus 0.65% versus 0.89%, p=0.14) respectively].  The need for 
additional oxytocic was also similar (8.6% versus 6.2% versus 7.5%, 
p=0.23 respectively). For theses authors, misoprostol can be 
recommended for routine use in home deliveries and peripheral centres in 
low resource settings where both refrigeration facilities and skilled 
personnel continue to be scarce (154).  
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In previous RCT, oral misoprostol was found to be more effective than 
placebo in reducing the rate of acute PPH and severe acute PPH.  
For Surbeck et al, the mean blood loss (307 versus 347 mL) and the rate of 
PPH (7% versus 15%) were significantly lower with the use 600 µg oral 
misoprostol compared to no treatment respectively (156).  
 
In a recent trial in India conducted by Chandhiok et al oral misoprostol 
was used for prevention of PPH by paramedical workers. Cluster 
randomization was used to enrol a total number of 1200 women 
distributed in two groups of 600 women each to either 600-µg oral 
misoprostol or to no treatment. There was a significant reduction in the 
postpartum blood loss in the intervention group (157). For these authors, 
simple interventions can be easily implemented in rural health care 
settings to reduce the blood loss during labour. This finding has significant 
implications for developing countries, in which the prevalence of anaemia 
is high.  
 
A recent trial conducted by Bullar et al where 200 µg of buccal misoprostol 
was compared to placebo found no significant difference in the mean 
blood loss (377 mL versus 379 mL) and the incidence of PPH (3% versus 
5%) (158). Misoprostol at a dose 400 µg seems to confer additional benefits 
in term of reduction in the postpartum blood loss.  
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In conclusion, oral misoprostol has the potential to prevent postpartum 
haemorrhage as any conventional oxytocic. Misoprostol has therefore a 
value as a prophylactic uterotonic drug that prevents PPH and reduce 
maternal mortality in developing countries, where it is most needed.  
 
4.1.3- Duration of third stage of labour and manual removal of 
placenta: 
  
The average women lose less than 500 mL of blood during the third stage 
of labour. The actual amount of blood loss for any individual appears to 
depend on the time between placental separation and the contractions of 
the placental bed by uterine activity. Conventional wisdom acknowledges 
that a rapid and total expulsion of the placenta is associated with a modest 
reduction in the loss of blood.  
 
Combs and Laros studied the length of third stage of labour in more than 
12.000 women with vaginal births, none of whom had proactive manual 
removal of the placenta. The median length of the third stage of labour 
was 6 minutes, with only 3.3% lasting more than 30 minutes. The authors 
did found a relationship between the duration of third stage of labour and 
amount of blood loss. Hence, the blood loss increased more than three 
fold, for subject where the third stage of labour had lasted from 30 to 60 
minutes (24). 
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Dombrowski et al published similar results in their study of more than 
45.00 births. There was an association between postpartum haemorrhage 
and length of third stage of labour. These authors did found differences 
even within the first 30 minutes of the third stage of labour. The incidence 
of postpartum haemorrhage was 3.3%, if the placenta was delivered 
within 10 minutes, 4.8%, if it took between 11 and 20 minutes and 8.3% if 
it was delivered within 21 and 30 minutes and 21%, if the third stage 
lasted between 31 and 40 minutes. The shorter the duration of the third 
stage the less is the risk of haemorrhage (159).  
 
In efforts to understand the physiology of third stage, several studies 
monitored intrauterine pressure by inserting a catheter-tipped pressure 
transducer transcervically within 5 minutes of delivery of the neonate.  
 
In 1996, Chua et al conducted a study designed to compare uterine 
activity measured by catheter to blood loss as measured in a laboratory 
using absorbent paper and colorimetric measurement of haemoglobin 
content; in 1998, they showed reliability of the technique as a research 
methodology. The researchers found that increased activity in the third 
stage tended to be associated with an overall decrease in blood loss (160).  
 
 162
In the present study, the mean duration of the third stage of labour was 
not significantly different between treatment groups 8.49 minutes versus 
8.6 minutes for oral misoprostol and syntometrine respectively (p=0.21). 
For most of the subjects, the placenta was delivered within 10 minutes 
after delivery of the baby. The duration of third stage of labour was less 10 
minutes for 75.37% and 71.11% respectively (misoprostol versus 
syntometrine) and 22.63% versus 28.75% in the time between 10-30 
minutes. More subjects in the group of syntometrine had needed manual 
removal of placenta (3 cases versus 1 case); but the difference was not 
statistically significant.   
 
In another clinical trial by El Refaey et al comparing oral misoprostol with 
syntometrine, the reported mean duration of the third stage of labour were 
6.3 (6 - 6.7) minutes versus 6.4 (6 - 6.8) minutes respectively (128). The rate 
of manual removal placenta reported by El -Refaey et al was similar with 
2% for misoprostol and 3% for oxytocics.  
 
In the study of Ng et al (129) (oral misoprostol versus syntometrine) 79.5% 
versus 86.2% of subjects had a duration of third stage of labour less than 
10 minutes, 18.5% versus 11.9% a duration of third stage between 11-30 
minutes and only 1.4% versus 1.6% had a duration of third stage >30 
minutes. However, the rate of manual removal of placenta reported by Ng 
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et al was lower for misoprostol compared to syntometrine 0.4% versus 
1.4%.  
In the study of Vimala et al, the mean duration of the third stage of labour 
was 9.1±4.6 minutes for methylergometrine versus 8.6±4.2 minutes for 
sublingual misoprostol and the rate of manual removal of placenta 1.6% 
versus 0% (134). 
For Oboro et al, (misoprostol oral versus oxytocin im), the mean duration 
of third stage (8.1 versus 7.1 minutes) was comparable in both groups. 
More subjects in the group of misoprostol had needed manual removal of 
placenta although this was of no statistical significance, p=0.67 (151).  
 
Our study showed that the use of misoprostol in the active management 
of the third stage of labour reduce the duration of third stage of labour. It 
reduces maternal morbidity and mortality related to retention of placenta. 
The need for manual removal of placenta is conversely limited with less 
risk of septic endometritis. 
 
4.1.4- Laboratory criteria to define PPH: 
 
Change in laboratory criteria such as haemoglobin and hematocrit is a 
more objective measure than estimated blood loss. These objective 
laboratory measurements can be considered as a proxy for the clinical 
outcome for excessive blood loss.  
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In the present study, the pre-delivery and post-delivery haemoglobin 
concentration and haematocrit were comparable between treatment 
groups. The mean haemoglobin and haematocrit change were: 0.59 g/dl 
versus 0.55 g/dl and 1.83% versus 1.70% for misoprostol and 
syntometrine respectively, these differences were not statistically 
significant.  
 
Our results were in accordance with the result of previous studies.  Ng et 
al found no difference in the mean fall in haemoglobin concentration after 
delivery between treatment groups (misoprostol versus syntometrine) with 
1.34 g/dl versus 1.34 g/dl (129). Similarly, Çaliskan et al found no 
difference among group treated with oral misoprostol versus Oxytocin - 
Ergometrine in term of decrease in Hb and Hte at 24 hours after delivery 
with 1.4±1.1 versus 1.5±1.1 and 4.1±3.7 versus 4.6±3.6 respectively (85). 
Same findings were reported by El Refaey et al with mean change in Hb 
and Hte of 1 (1.2) versus 1 (1.6) and 0.03 (0.04) versus 0.03 (0.05) for oral 
misoprostol and oxytocics (128).  
 
Walley et al found no significant difference in mean Hb change (0.6(0.93) 
g/dl versus 0.55 (0.73) g/dl, p= 0.54) between subject treated with oral 
misoprostol compared to oxytocin (second sample of blood taken at 12±4 
hours) (86). For Oboro et al, the mean Hb and Hte drop in the postpartum 
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period (second sample of blood taken at 12±4 hours) were similar 
between treatment groups (misoprostol versus oxytocin) with 0.71 (0.94) 
g/dl versus 0.68 (0.78) g/dl and 3.21 (2.6) g/dl versus 2.8(3) g/dl 
respectively (151). 
 
Asok R, et al comparing oral misoprostol to methylergometrine im, 
reported lesser average fall in haemoglobin between treatments groups 
(0.5 g/dl versus 1.4 g/dl) (161). In the study of Garg et al, the number of 
patient with haemoglobin difference ≥ 1 g/dl and mean haematocrit 
difference ≥ 3% was similar between treatment groups (oral misoprostol 
versus syntometrine) (152). 
 
When misoprostol was compared to no treatment as in study of Amant et 
al the difference in Hb (1.6 ±0.3 versus 2.6±0.3) and in Hte (4.5±0.9 
versus 7.9 ± 1.2) were higher in the placebo group, denoting more efficacy 
of misoprostol in reducing the postpartum blood loss (87).  
 
In conclusion, oral misoprostol shows equal efficacy when compared to 
conventional oxytocics and better than no treatment (placebo) in the 
reduction of postpartum blood loss as reflected by change Hb and Hte. 
This is in accordance with our study and of particular clinical relevance in 
countries where many women present severe anaemia during pregnancy 
because of nutritional genetic or environmental factors. 
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4.1.5- Side effects and complications: 
4.1.5.1- Shivering and fever : 
 
Shivering and fever are all well-known side effects of oral misoprostol 
when it is used in the management of third stage (12, 86, 87). This adverse 
effect is dose dependant (79). Fever is another side effect of oral misoprostol 
in the third stage (86, 87).  
 
In our study, assessment of shivering was made by either direct 
observation or indirect questioning about any complaints, and accordingly 
shivering was graded as mild (+) or moderate (++) or severe (+++ or 
necessitate treatment). Meanwhile, pyrexia was objectively measured by 
standard thermometer.  
 
In the present study, misoprostol was associated with fourfold increase in 
the incidence of shivering compared to syntometrine p<0.0000   RR, 95% 
CI 4.1 (2.73-6.35). Most cases of shivering were mild requiring no 
treatment. Severe shivering requiring active intervention had occurred in a 
few numbers of parturient in the group misoprostol. Misoprostol was also 
associated in three-fold increase in the incidence of pyrexia (t ≥ 38° ≤ 39°) 
when compared to syntometrine. p<0.0000, RR, 95% CI=6.7 (3.35-
14.11). Only 5 women had temperature > 39°C in the group of 
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misoprostol with 1 woman in the group of syntometrine. Shivering during 
the use of misoprostol for the third stage was regard generally as a 
nuisance rather than serious morbidity limiting its use (85). 
 
Our results were in accordance with those reported by Caliskan et al 4.3% 
for fever and 11.3% for shivering, when oral misoprostol 400 µg was 
compared to Oxytocin - Ergometrine 1.2 % versus 3.7% (85). Cook CM et 
al quoted a figure of 19% of shivering and 15% of fever among their 
parturient who received 400 µg misoprostol orally compared to those on 
syntometrine 19% and 10%; the difference was statistically significant. RR 
and 95% CI =2.64 (1.78-3.91) and 1.59 (1.08-2.34) (127). 
 
In others studies where misoprostol 400 µg orally was compared to 
methylergometrine or to oxytocin, the incidence of fever and shivering 
were much higher than in our study. Vimala et al had reported 21.6% and 
6.6% for shivering and pyrexia respectively in the group of misoprostol 
with no case for methylergometrine p< 0.05 (134). Shivering and fever were 
prominent side effects reported by Garg et al when oral misoprostol (600 
µg) was compared to methylergometrine (31% and 29% versus 10% and 
7%, p=0.000) (152). Similarly, Waley et al found that shivering was the main 
side effect of misoprostol 400 µg compared to oxytocin 10 IU im (RR, 
95% CI = 4.73 (2.31 - 9.68); p<0.0001) (86).  
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Hofmeyr et al in a study conducted in South Africa had shown an 
association of oral misoprostol 600 µg with shivering when compared to 
placebo 44% versus 11% (162).  
Chong et al observed a case on pyrexia of 41.9°C, which continued for 3 
hours after administration of 800µg oral misoprostol (163). 
  
In the studies where oral misoprostol was used at a dose higher than 400 
µg, it seems that the occurrence of shivering became a serious problem.  
El Refaey et al when using 600 µg of misoprostol orally reported a figure 
of 62% for shivering (128).  
Oboro et al had reported fourfold increase in shivering associated with the 
use of 600 µg oral misoprostol (57.1%) over oxytocin (14.1%), the 
difference was very significant (151).  
Ng et al quoted a figure of 30.2% for shivering and 8.5% for fever among 
their parturient who received 600 µg orally compared to those on 
syntometrine (9.9% and 1.3%); the difference was statistically significant 
(RR and 95% CI =3.06 (2.49-3.76) and 6.73 (3.78-11.98) p < 0.05) (129). 
 
Lumbiganon et al in a study designed to assess the misoprostol dose-
related shivering and pyrexia in the third stage of labour had reported 
figure of 28.28% and 7.5% for 600 µg and 19.19% and 2% for 400 µg 
respectively. The authors had confirmed that the incidence of shivering 
and pyrexia were dose dependant (89). 
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Our study had confirmed the association between the use of oral 
misoprostol and the occurrence of shivering when given for prevention of 
postpartum haemorrhage. However, most cases of shivering reported, 
were mild and require minimal or no-treatment. It appears therefore that 
shivering was a well tolerated side effect in our study and the dose 400 µg 
of oral misoprostol has shown less incidence of shivering than when 
higher dose were used as described in other trials. 
 
4.1.5.2- Diarrhoea : 
 
In the present study, diarrhoea was infrequently reported 6 cases (0.75%) 
for misoprostol and 3 cases (0.37%) for syntometrine. In most RCT, 
diarrhoea was not reported as a side effect of oral misoprostol, although it 
is a well known prostaglandins related effect. These reports did not detect 
this side effect because they collect information within 1 hour after 
delivery.  
 
In the study of Lumbiganon et al on the side effects of oral misoprostol in 
the first 24 hours after administration. Diarrhoea was not reported within 
1 hour after delivery. However, it became apparent after the first hour and 
was significantly higher in the misoprostol group in the intervals 2-6 and 
7-12 hours after delivery than in the group who received oxytocin (79). 
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4.1.5.3- Nausea, vomiting and headache:  
The use of oxytocin - Ergometrine was associated with significantly 
elevated blood pressure and higher rate of unpleasant maternal side effects 
including nausea and vomiting.  The high incidenc of side effects 
associated with the use of Oxytocin – Ergometrine preparation has been 
well recognised elsewhere (106,108,164). These side effects reduce the 
acceptability of oxytocics preparation containing ergometrine, and have 
been the major stimulus to obstetrician in the past three decades to search 
for alternative drugs.  In the present study, nausea, vomiting and 
headache are minimal side effects that appear, with the use for 
misoprostol orally compared to syntometrine: RR 95% CI = 0.06(0.02-
0.17), 0.13(0.04-0.43) and 0.04(0.01-0.14) respectively. Therefore, 
misoprostol orally had shown better tolerance than syntometrine. This 
finding was confirmed by El Refaey et al with almost double of the subject 
in their study having experienced nausea (31 cases versus 44 cases) and 
headache (10 cases versus 20 cases) (128). Ng et al did not find any 
significant difference between subjects who received misoprostol or 
syntometrine with regard to occurrence of nausea (1.9% versus 2.6%), 
vomiting (1.4% versus 2.2%) and headache (7.9% versus 8%) (129).   
Garg et al reported the same observation concerning the occurrence of 
diarrhoea (3% versus 3%). Meanwhile, more subjects treated with 
methylergometrine had nausea and vomiting compared to oral 
misoprostol (30% versus 20% and 30% versus 19%) (152).  
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In this study, we did not report any complaints of chest pain, shortness of 
breath, bradycardia that would give undue concern regarding their 
possible association with coronary artery spasm 61) and cardiovascular 
compromise (62 
 
It has been strongly suggested that in developing countries where 
postpartum haemorrhage remains an important causes of death, the use of 
the apparently more effective intramuscular agent theOxytocin - 
Ergometrine preparation, should be preferred despite the substantial 
incidence of unpleasant side effects (113, 165). Our study contribute to this 
debate only as far as showing that when misoprostol can be safely 
administered. It is probably the drug of choice. 
 
4.1.5.4- Hypertension: 
In the present study, both systolic and diastolic blood pressure levels (BP 
≥ 140/90 mm Hg) were significantly higher in the group of syntometrine 
compared to oral misoprostol [RR=0.23, 95% CI(0.14-0.40) and 95% CI 
0.34(0.22-0.53)  p=0.0000]. 
  
Ng et al made a similar observation; misoprostol did not cause 
hypertension and was associated with 55 to 65% reduction in the 
incidence of hypertension when compared with syntometrine (129).  
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Meanwhile, El Refaey et al did not report change in blood pressure in 
subject who received oral misoprostol 400 µg compared to oxytocics (128). 
In the study of Cook et al, the figures quoted for hypertension were not 
different between treatment groups (3% for misoprostol and 4% for 
syntometrine) (127). Again, Amant et al found no difference in the incidence 
of hypertension between parturient who were given misoprostol orally 
compared to methylergometrine (87). 
 
We conclude with the remark of Ng et al that misoprostol does not cause 
hypertension and may be used as an oxytocic in hypertensive and 
preeclamptic women undergoing vaginal delivery (129). Our study is 
consistent with the conclusion that oral misoprostol was as efficacious as 
standard oxytocics for prevention of PPH and without the hypertensive 
effect of drug that contain ergometrine (166). 
 
4.2 - Effects of rectal misoprostol compared to syntometrine in 
the third stage of labour: 
 
4.2.1- Mean blood loss: 
In the present study, there were no significant difference in the mean 
blood loss between the group of rectal misoprostol and the syntometrine 
group (232 ± 146 mL versus 223 ± 142 mL). This is in agreement with 
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several authors who reported no significant difference in the mean blood 
loss between subjects treated with rectal misoprostol (400 µg) versus 
syntometrine.  
 
Similarly, in an early study designed to compare the efficacy of rectal 
misoprostol versus syntometrine, Bamigboye et al had randomly allocated 
491 women a low risk of PPH to either 400-µg misoprostol per rectum or 
to syntometrine. The mean blood loss reported was not significantly 
different in both groups: 187 mL versus 183 mL (14). However, Diab et al in 
a randomized trial of rectal misoprostol (200-400 µg, n=70) compared to 
oxytocin - ergometrine (n=70) for prevention of PPH quoted lower mean 
blood loss for misoprostol (234±11 mL versus 273±12 mL) (91). 
 
Rectal misoprostol was also tested in other studies for efficacy in reducing 
PPH compared to uterotonics others than syntometrine.  
Bughalo et al testing rectal misoprostol 400 µg (n= 324) compared to 
oxytocin 10 IU given im (n= 339) had reported mean blood loss that was 
not different between the two groups (155±122 mL versus 157±138 mL) 
although these figures were lower than in our study (167). In a recent study 
conducted by Okan et al, rectal misoprostol has been tested against 
vaginal misoprostol in the prevention of the PPH and the mean blood loss 
was similar in both groups (171.1 mL versus 171.4 mL) (168). 
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4.2.2- Incidence of PPH, use of additional oxytocics and blood 
transfusion 
 
In most of the clinical trial design to test the efficacy of misoprostol versus 
conventional oxytocics to prevent PPH, the primary end point were 
incidence of acute PPH (blood loss ≥ 500 mL) acute severe PPH (blood 
loss ≥ 100 mL) and secondary outcomes including need for additional 
oxytocics and postpartum blood transfusion.  
 
In our study, there was no significant difference in the incidence of acute 
PPH, and acute severe PPH between treatment groups. Blood loss was 
estimated to be > 500 mL for 4.75% of women who received rectal 
misoprostol; and 4.62% who received syntometrine (RR 95% CI= 1.1 
(0.72-1.72), p= 0.6). Blood loss > 1000 mL occurred in 0.87% of women 
who received oral misoprostol; and 0.75% in those who received 
syntometrine (RR 95% CI=1.17 (0.39-3.46), p=0.78). There was no 
significant difference between the two groups for the need of additional 
oxytocics 11.75% versus 10.62%, (RR 95% CI= 1.11 (0.84-1.4), p=0.51) 
and blood transfusion 0.88% versus 0.75%.  
 
Bamigboye et al had conducted a comparative study of rectal misoprostol 
400 µg versus syntometrine of 491 women at low risk in labour for 
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prevention of PPH. They reported blood loss > 500 mL in 0.9% and 0.4% 
respectively for syntometrine and misoprostol (14).  
 
Caliskan et al in comparative study of rectal misoprostol 400 µg (n=396) 
with Oxytocin - Ergometrine (n=402) had reported higher incidence of 
postpartum haemorrhage (9.8% versus 3.5%) and severe PPH (4.2% 
versus 1.7%). These authors have found that the use of rectal misoprostol 
was associated with a tendency toward an increased need for additional 
oxytocics 12.8% versus 3.6% (92). 
 
For Diab et al, the incidence of blood loss > 500 mL was not different in 
both groups (2 versus 3). However, more subjects in the Oxytocin - 
Ergometrine needed therapeutic uterotonic (15 versus 4, p<0.01). The 
authors concluded that rectal misoprostol is safe and effective in the 
management of the third stage of labour (91). 
 
These different findings may be attributed to the extensive exclusion 
criteria used in certain studies that resulted in a low risk population and to 
the small sample size in others studies. The efficacy of rectal misoprostol 
had been also evaluated in few studies compared to uterotonic other than 
syntometrine or to placebo. 
In the study of Bughalo et al (167), the need for additional oxytocics and 
blood transfusion was evenly distributed in both groups (misoprostol 400 
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µg versus oxytocin 10 IU im: 2.2% versus 2.1% and 1.2% versus 0.6% 
respectively). 
 
In the study conducted by Gerstenfeld et al (133) in Los-Angelos /California 
comparing rectal misoprostol (400 µg) to intravenous oxytocin, no 
significant difference was noted in the percentage of PPH between groups. 
Secondary outcome such as the need for blood transfusion was also 
similar between groups; however more subjects required additional 
uterotonic in the group of misoprostol (23% versus 11%). 
 
When, rectal misoprostol (400 µg) was compared to no treatment as in the 
study of Bamigboye et al, the percentage of blood loss ≥ 1000 mL was 
higher in the placebo group than in the misoprostol group 4.8%  versus 
7% (RR 95% CI=0.69 (0.35-1.35), p=0.37). More subjects in the placebo 
group required additional oxytocics than in the group of misoprostol 4.7% 
versus 3.3%. These authors concluded that the postpartum use of 400 µg 
rectal misoprostol was associated with less PPH (90). 
 
4.2.3 - Duration of the third stage of labour and manual removal of 
placenta 
  
In the present study, there was no significant difference in the mean 
duration of the third stage between the treatment groups of rectal 
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misoprostol and syntometrine (8.49 minutes versus 8.60 minutes). The 
duration of third stage of labour was less than 10 minutes for 75.37% and 
71.11% respectively (misoprostol versus syntometrine) and between 10-30 
minutes in 24.63% versus 28.75% respectively.  
 
Meanwhile, manual removal of the placenta was needed for more subjects 
in the group receiving syntometrine (3 cases compared to 1 case) than for 
rectal misoprostol; a statistically not significant observation. 
 
In two clinical trials comparing rectal misoprostol with syntometrine, the 
mean duration of the third stage of labour reported were consistent with 
our findings (9.3±4 versus 8.4±1.7 minutes) for Caliskan et al (92) (7.7 
minutes versus 7.9 minutes) for Bamigboye et al (14). However, the mean 
duration of the third stage was shorter in the study of Diab et al (2.97±0.14 
minutes versus 3.11±0.13 minutes) (91). 
  
In the study conducted by Karkanis et al comparing misoprostol to 
oxytocin, the mean duration of the third stage was similar in both groups 
(9.4 minutes versus 7.9 minutes). More women in the group of oxytocin 
had needed manual removal of placenta; although the difference was not 
statistically significant (6 cases versus 1 case, RR 95% CI = 0.17 (0.02-
1.40), p= 0.06) (169). 
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In conclusion, rectal misoprostol (400 µg) as a major component of active 
management significantly shorten the duration of third stage of labour. 
This beneficial effect is crucial in terms of reduction of maternal mortality 
and morbidity. 
  
4.2.4- Laboratory criteria to define PPH:  
 
In the present study, the pre-delivery and post-delivery haemoglobin 
concentration and haematocrit were comparable in both groups. The 
mean haemoglobin and haematocrit change were: 0.60 g/dl versus 0.55 
g/dl and 1.83% versus 1.70% for rectal misoprostol and syntometrine 
respectively, these differences were not statistically significant. 
 
Our results were in accordance with the result of previous studies. Hence, 
Çaliskan et al found no difference in the mean fall in haemoglobin 
concentration after delivery between subjects who received rectal 
misoprostol compared to Oxytocin - Ergometrine (1.5 g/dl versus 1.5 
g/dl) and drop in haematocrit level (4.7 ± 4.3% versus 4.6±3.6%) (92).  
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However, in the study of Diab et al, there was a significant decrease in 
postpartum haemoglobin and haematocrit levels in Oxytocin - 
Ergometrine group compared to misoprostol group (1.3±0.13 versus -
0.78±0.08 versus and -3.67±0.4 versus -2.4±0.27) (91). 
 
In randomized trial comparing rectal misoprostol (400 µg) with oxytocin 
(10 IU im), the haemoglobin and hematocrit drop between treatment 
groups were not significantly different. Bughalo et al quoted no significant 
difference in mean haemoglobin and hematocrit change after treatment in 
subjects who received rectal misoprostol compared oxytocin (0.9 versus 
0.7 g/dl and 2.3% versus 2%) (167).  
 
For Karkanis et al, the mean Hb and Hte drop were similar between the 
misoprostol group compared to oxytocin group (1.4 versus 1.6, p=0.35 
and 0.04 versus 0.05, p= 0.11) (169). 
  
It seems that when compared to conventional oxytocics, rectal 
misoprostol 400 µg shows equal efficacy in reducing the postpartum blood 
loss as reflected by change in haemoglobin and haematocrit. In 
conclusion, rectal misoprostol might be used safely in the treatment of the 
third stage of labour.  
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4.2.5- Side Effects and Complications: 
 
4.2.5.1- Shivering and pyrexia: 
Shivering and pyrexia have been identified as adverse effects that are 
associated with the use of misoprostol in the third stage of labour (12). 
However, most existent data concerned orally administered misoprostol. 
Little is known about the occurrence of these side effects with the use of 
rectal misoprostol.  
 
In present study, we reported significantly higher rates of shivering, in 
women who received rectal misoprostol compared to syntometrine 
(8.75% versus 4%. RR 95% CI=2.30(1.47-3.6), p<0.0000). Most cases of 
shivering were mild requiring no treatment. The rate of hyperthermia (> 
38°C) was also higher among subjects treated with rectal misoprostol than 
those who received syntometrine [6.56% versus 1.25%, RR 95% 
CI=5.49(2.67-1.59), p<0.0000]. Very few cases of severe hyperthermia 
(>39°C < 40°C) were reported in the studied population and no case of 
temperature > 40°C. More subjects in the group of rectal misoprostol had 
temperature > 39°C < 40°C when compared to syntometrine group: 3 
cases versus 1 case.   
 
Our findings were consistent with the results of Çaliskan et al. These 
authors reported more shivering (11.8% versus 4.7%) and hyperthermia 
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(4% versus 4%) in subjects who received rectal misoprostol 400 µg than 
among those who received Oxytocin - Ergometrine (92). 
 
Similarly, Diab et al have reported more shivering in subjects who 
received misoprostol 400 µg rectally (5 cases versus no case) for Oxytocin 
- Ergometrine group. Shivering and hyperthermia were reported to be 
high in studies where rectal misoprostol was compared to oxytocin or to 
placebo (91).  
 
For Karkanis et al, the incidence of shivering was higher in the group of 
rectal misoprostol compared to oxytocin RR 95% CI = 1.82(1.02-3.23), 
p=0.04 (169). For Bughalo et al, shivering had occurred more in women 
who received rectal misoprostol compared to oxytocin (38.1% versus 
15.1%, p=0.01) (167).  
 
Our study had confirmed the association between the use of rectal 
misoprostol and the occurrence of shivering and hyperthermia in its use 
for reducing postpartum blood loss. 
   
In conclusion, the use of rectal misoprostol 400 µg seem to be associated 
with less shivering and pyrexia compared to oral misoprostol; a strong 
point in its favour as a possible interesting alternative to conventional 
oxytocics in the prevention of postpartum haemorrhage.  
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4.2.5.2- Diarrhoea: 
 
Diarrhoea, in the present study is a minimal side effect that occurred with 
the use of rectal misoprostol: 0.37% [RR 95% CI=1 (0.16-0.62), p=1].  
 
Çaliskan et al had quoted no difference in the gastrointestinal side effects 
of misoprostol per rectum compared with Oxytocin - Ergometrine. 
Vomiting and diarrhoea had occurred in 0.5% and 2.7% in the group of 
rectal misoprostol 400 µg compared to 0.2% and 2.4% in the Oxytocin - 
Ergometrine group (92).  
 
4.2.5.3- Nausea, vomiting and headache: 
In this study, nausea, vomiting and headache were minimal side effects 
that had occurred with the use of rectal misoprostol when compared to 
syntometrine. The relative risk estimated of these three variables were 
0.6% [RR 95% CI=0.08(0.03-0.19), p = 0.000]; 0.37% [RR 95% 
CI=0.13(0.04-0.43) p=0.0000]; and 0.5% [RR 95% CI=0.07(0.03-0.19), p 
= 0.0000] respectively.  
 
For Diab et al, nausea vomiting and diarrhoea had occurred more in the 
misoprostol group with 8 cases and no case for Oxytocin - Ergometrine  
group, p=0.01 (91). 
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In the study of Karkanis (misoprostol versus oxytocin), no statistically 
significant difference was reported in the incidence of nausea, vomiting 
and headache between treatment groups (169). 
 
4.2.5.4- Hypertension: 
 
In our study significantly more women in the group of syntometrine had 
both systolic and diastolic hypertension (SBP and DBP) when compared 
to rectal misoprostol: 69 cases versus 19 cases [RR 95% CI= 0.28 (0.17-
0.45), p=0.0000] and 74 cases versus 27 cases [RR 95% CI=0.36(0.24-
0.56), p=0.0000] respectively. Similar results were obtained by Diab et al 
with more cases of systolic and diastolic hypertension (11 cases and 10 
cases respectively) in the group of Oxytocin - Ergometrine meanwhile no 
case of hypertension in the group of misoprostol or rectum (91).  
 
For Bamigboye et al, diastolic hypertension after delivery was more 
common in the group of syntometrine compared to the group of 
misoprostol (13% versus 4.6% p=0.04) (14).  
 
In the study where misoprostol was compared to oxytocin, the incidence 
of systolic hypertension was similar between treatment groups. Bughalo et 
al did not report significant difference between subjects treated with 
misoprostol or with oxytocin (167).  
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4.3 - Effects of Misoprostol Oral Compared to Misoprostol 
Rectal in The Third Stage of Labour: 
 
One of main advantages of this three arm study is that oral misoprostol 
was compared to rectal misoprostol. The aim was to detect differences in 
primary and secondary outcome measure; side effect and complications, 
of these two modalities in the use of misoprostol for prevention for 
postpartum haemorrhage.  
 
The primary outcomes measure of the two treatment modalities that was 
clinically measured blood loss had showed no difference. The mean blood 
loss was estimated to be 233 ± 144 mL versus 232 ± 146 mL; blood loss > 
500 mL (38 cases versus 38 cases); blood loss > 1000 mL (6 cases versus 7 
cases). The need of additional oxytocics is similarly distributed in both 
treatment groups (10% versus 11.75%). The mean change in haemoglobin 
and haematocrit, after treatment, was not significantly different in the two 
groups: 0.59 ±0.49 g/dl versus 0.60 ± 0.33 g/dl and 1.83% ± 1.07% 
versus 1.83% ± 1.03% respectively. There are no significant differences 
between groups in the duration of third stage of labour (8.49 ± 2.18 
minutes versus 8.49 ± 2.12 minutes) or in the proportion of women that 
required manual removal of the placenta (1 case versus 1 case) and blood 
transfusion (0.75% versus 0.87%). 
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Shivering (14.75% versus 8.75%) and pyrexia (7.87% versus 6.56%) had 
occurred in a greater proportion of women in the group of oral 
misoprostol compared to the group of rectal misoprostol. Khan et al had 
shown that rectal misoprostol was associated with 27% relative risk 
reduction in the incidence of shivering and 72% in the incidence of the 
severe shivering when rectal misoprostol was compared to oral 
misoprostol.  
 
Pyrexia was also less likely with rectal misoprostol. The lack of sharp 
absorption peak may be responsible for the lower incidence of shivering 
and pyrexia observed when misoprostol is administered rectally (75). 
 
The incidence of nausea (0.5% versus 0.6%), vomiting (0.37% versus 
0.37%), diarrhoea (0.75% versus 0.36%) and headache (0.25% versus 
0.5%) was similar in both groups. Systolic (2% versus 2.37%) and diastolic 
(3.13% versus 3.37%) hypertensions recorded were minimal among 
subjects in the two groups. 
  
In conclusion, oral and rectal misoprostol were equally efficacious in 
preventing PPH, but side effects of fever and shivering occurred more 
frequently with oral misoprostol. The use of misoprostol as a part of 
active management of third stage of labour has received a category A 
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recommendation (Good and consistent scientific evidence to support the 
recommendation)(170). In addition, the United States Pharmacopoeia has 
recently recommended that prevention of PPH is an acceptable indication 
for misoprostol especially in setting were parenteral uterotonic drugs are 
not available (171) . 
 
4.4–  Satisfaction:  
 
Clark et al on their reports on the use of misoprostol in Obstetric and 
Gynaecology in Brazil, Jamaica and the USA had stated that for 
prevention of postpartum haemorrhage provider found that the drug is 
acceptable to more than 80% of women and they felt that vaginal 
administration is more effective than rectal administration (172). Our study 
is the first to address the question of satisfaction for both the users 
(midwives and doctors) and the receivers (parturient) in the orally or 
rectal administration misoprostol. The majority of parturient were 
satisfied because they were not subjected to an injection, therefore no risk 
of exposure to blood born diseases. This new management was non-
invasive, with minimal bleeding, and minimal after pain. 
The midwives and doctors were also satisfied because with this approach 
in the third stage of labour. There was substantial reduction in the amount 
of blood loss. The technique was easy to use, and with minimal exposure 
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to blood born disease during the manipulation and administration of this 
uterotonic. 
 
Our study is in agreement with Surbeck who stated that misoprostol 
might be useful in less developing countries because, this drug is equally 
effective in minimising blood loss but easier to use than standard 
oxytocics (173). 
 
4.5 - Cost of uterotonics: 
 
The cost of an uterotonic does not simply mean the price to purchase the 
drug but a lot of element should be taken into consideration and this; 
include its efficiency in different conditions of conservation. Therefore, 
the instability of injectables uterotonics in tropical climates had been the 
subject of much debates.  
Parenteral ergometrine is widely used for the prevention and treatment of 
excessive uterine bleeding following birth.  It is classified as an essential 
drug in the WHO Model list of Essential drugs. 
 
It is widely available and cheap.  In view of the potentially fatal 
complications of excessive bleeding, especially in developing countries 
where blood transfusions are difficult and dangerous, it has been 
 188
considered a vital drug that should always be available, and of good 
quality. 
However, in the late 1980s anecdotal reports emerged of occasional 
ineffectiveness of injectable ergometrine in tropical climates.  The first 
documented evidence published by WHO in the Lancet in 1988, was 
quite alarming.  Of 24 samples of injectable ergometrine taken from 20 
rural health facilities in Bangladesh, Yemen and Zimbabwe, only nine  
conformed to United States Pharmacopoeia and British Pharmacopoeia  
guidelines with a level of active ingredient between 90 and 110% of the 
stated amount: seven (29%) contained less than 20% active substance (174) 
 
These early finding were soon confirmed by a longitudinal study of the 
sstability of five essential drugs, including ergometrine, during transport 
between Sweden and rual Sudan(175). 
 
The simulation and the Zimbabwe study have clearly demonstrated that 
considerable differences may exist between products of different 
manufacturers.  Hence, this implies that careful supplier selection and 
frequent quality control measures are necessary(176).  However, high 
temperature and exposure to light leads to a rapid loss of active ingredient 
(probably at a rate of about 20% per month). 
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This constitures an enormous constraint in term of conservation of the 
drug and refrigeration as much as possible but this is rarely done in 
practices.  It is obvious therefore, that injectable ergometrine cannot be 
the drug of choice for the prevention of PPH at the scale of 
underdeveloped countries. 
 The question of other alternative drugs that are more stable as a 
replacement of ergometrine has been the object of a debate.  
Methylergometrine was proposed as more stable substitute than 
ergometrine and it can be used as an alternative in tropical climate.  
However, this hypothesis was tested in first simulation study and showed 
no difference in instability between specially and uniformly produced pair 
of injectable ergometrine and methylergometrine. 
 
In conclusion, as an active substance methylergometrine is not more 
stable than ergometrine. Parental oxytocin alone or in combination with 
ergometrine is effective in the prevention of PPH.  However, simulation 
study had shown that like ergometrine and methylergometrine, oxytocin 
has gradual loss of active ingredient over time, with faster decline at 
higher temperature.  Although, under tropical condition of temperature 
and light oxytocin is more stable than the last two drugs(177).  Some studies 
had shown that oral oxytocics (oral ergometrine, oral methylergometrine, 
buccal oxytocin) are even less stable than injectable(178,179). 
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Misoprostol has been used widely in obstetric and gynaecology because of 
its effectiveness, low cost, stability in light and hot climate conditions and 
ease of administration compared with its counterpart: dinoprostone and 
gemeprost (180)  
 
The consensus of the USP Expert Committee is that misoprostol can be 
an alternative agent in preventing PPH, especially in situation in which 
oxytocin and other uterotonic drugs are unavailable. They suggested a 
single dose of either 400 to 600 µg given orally or rectally immediately 
following delivery of the child.  Carpenter et al had stated that misoprostol 
is a practical option in developing countries because it is thermo/light 
stable, inexpensive, safe, widely available, in tablet form, and easily 
administered (181). For Daly et al (182), rectal misoprostol because of its cost 
and ease of administration may assume a greater role in preventing 
postpartum blood loss.  
 
For Lazarus et al, in low-income settings, the prostaglandin misoprostol 
should be considered as it is low-cost, stable at room temperature and 
easy to administer (183). 
 
For Prata et al who conducted a study in Tanzania to determine the safety 
of household management of postpartum haemorrhage, misoprostol is a 
 191
low cost, easy to use technology that can control PPH even without a 
medically trained attendant (184). 
 
Geller et al had emphasized that misoprostol have shown promise as 
potential solution to save the live of women during childbirths in resource-
poor settings (185). 
 
For Langenbach, continuing to weigh the benefits of one effective drug 
against another only delays the distribution of misoprostol in countries 
where it is the only feasible choice and must be measured against no 
treatment at all(186). 
 
An important consideration for less developed countries to maintain and 
administer uterotonic agents is financial burden. The WHO has 
recommended the use of oxytocin 10 IU im for the prevention of PPH. In 
several hospitals, syntometrine is the drug of choice in the active 
management of the third stage of labour.   
 
In this study, our result had shown that misoprostol has the potential to be 
the uterotonic of choice. In Chad, the unit cost of misoprostol (1 $ US) is 
less expensive than syntometrine (4 $US); although, it may be greater than 
oxytocin (1/2 US). Nevertheless, the total expense of parenteral 
uterotonic cannot be compared with misoprostol because it includes the 
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additional cost of refrigeration, sequestration from light and need for 
clean needles. This additional cost becomes a major problem in countries, 
with a high incidence of HIV where injection supplies may be 
unavailable. Interpreting this fact, misoprostol is a relatively affordable 
and cost/effective drug that appears to make a better choice for managing 
the third stage of labour.   
 
4.6 - Implication for Further Researchs:   
 
This study is the result of a cooperation between Faculty Medical Science 
University of N’Djaména and Faculty of Medicine University of 
Khartoum. The primary goal of this research was to test whether 
misoprostol is a safe and effective medication that can be administered in 
the management of the third stage of labour to reduce the incidence of 
acute PPH. However, this study had also tested the feasibility of utilizing 
misoprostol in a maternity of a developing country, underserved by 
midwives. The study had also the goal to train and improve midwifes in 
the health practices, for the care of parturient, thereby this will improve 
the health of the community. Although these were not intended primary 
outcome of the study they were anticipated as very important 
complementary benefit. Such a project can serve as a model applicable to 
rural maternities through Chad and for improving delivery practices in 
other developing countries. The research capability built during the 
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conduct of this joint collaboration between the two Faculties of Medicine 
can be maintained and utilized as basis for initiation of others studies on 
health issues related to women health. The importance of testing the 
efficacy and the feasibility of an innovative method to reduce maternal 
mortality and morbidity is critical to the developing nations of the world. 
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5.1  CONCLUSION 
 
 This study had the objective to address if misoprostol (oral or rectal) 
could replace syntometrine as an alternative drug in the management of 
the third stage of labour.  
 
Based on this present study, 400 µg of misoprostol is as effective as 
syntometrine in reducing postpartum blood loss and the incidence of 
postpartum haemorrhage in low risk women. The adverse side effects of 
misoprostol were minor and mild and did not reduce its acceptability in 
the prevention of postpartum haemorrhage. Misoprostol was not 
associated with hypertension; it can be used safely in hypertensive 
women. Rectal misoprostol was as efficacious as oral misoprostol and 
with fewer side effects. Both midwives and doctors and parturients who 
received oral or rectal misoprostol favoured its uses.  
 
Active management of the third stage of labour using misoprostol as an 
oxytocics agent is a relatively simple and inexpensive intervention, which 
can be applied to a variety of environments.  The better stability and cost 
may be added to clinical arguments that misoprosol (oral or rectal) is the 
drug of choice in the prevention of PPH.   It can be recommended for 
routine use in home deliveries and peripheral centres where both 
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refrigeration facilities and skilled personnel continue to be scarce.   This 
intervention could have a considerable impact on reducing postpartum 
haemorrhage in many resource-poor nations. 
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5.2   RECOMMENDATIONS 
 
? Based on the current evidences, we recommend that an active 
approach to the third stage should be adopted to decrease the risk of 
postpartum haemorrhage and to avoid manual removal of the 
placenta.  
 
? Misoprostol should be in the labour ward together with 
conventional uterotonic and used as standard active management of 
the third stage of labour at vaginal delivery in low risk patients. 
 
? It should be used in the prevention of postpartum haemorrhage, 
preferentially to parenteral uterotonic in situation where drug that 
contain ergometrine is contraindicated. 
 
? Its use should be promoted in most health centres, maternities, and 
setting in remote areas. 
 
? Support should be given to community base studies for the use of 
misoprostol in the developing countries. 
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? Drug manufacturer should make misoprostol affordable as rectal 
suppository for its use in the third stage for labour. 
 
? Clinical studies should be undertaken to assess efficacy of 
misoprostol in the prevention of postpartum haemorrhage in high 
risk parturient. 
 
? Clinical studies should be undertaken to investigate the effect of 
misoprostol in the treatment of atonic postpartum haemorrhage. 
 
? We encourage Universities in the developing countries to promote 
research in health reproduction for the benefit of the population as 
the example of this fruitful cooperation between the Faculty of 
Medical Science, University of N’djamena and Faculty of Medicine 
University of Khartoum.   
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